DecideAct Annual Report 2023: Optimized and right-sized with lean operations to ensure the path to profitability and future growth

In 2023, DecideAct has used the learning and experience gained in recent years to strengthen its focus and has optimized and streamlined the business to become a lean and efficient organization with a very clear focus on supporting selected market segments such as investment funds and their portfolios as well as large and complex organizations, including the public sector. The DecideAct Group has reached an ARR of DKK 8.9 million (consolidated for the Group) on 31 December 2023 and expects to increase ARR by 50% during 2024. The Group aims to reach profitability by 2025 and achieve a contracted ARR of DKK 18-20 million by the end of 2025, growing to more than DKK 50 million by 2030. To be profitable, the DecideAct Group needs to reach a revenue of DKK 15 million in 2025. It is expected that the contracted ARR will be doubled by the end of 2025, reaching a level of DKK 18-20 million. KEY FIGURES (DECIDEACT A/S) +------------------------------+-----------+-----------+----------+-----------+| | H1 2022| 2022| H1 2023| 2023|+------------------------------+-----------+-----------+----------+-----------+|Gross profit (DKK) | -7,191,520|-13,766,963|-4,025,222|-10,491.264|+------------------------------+-----------+-----------+----------+-----------+|Operating profit/loss (DKK) |-10,299,077|-20,640,037|-7,955,204|-18.708.192|+------------------------------+-----------+-----------+----------+-----------+|Profit/loss for the year (DKK)| -9,890,317|-20,164,088|-7,628,835|-19.191.829|+------------------------------+-----------+-----------+----------+-----------+ DecideAct A/S’ result of DKK -19.2 million for 2023 is as expected, influenced significantly by investments in further product development, sales and marketing, and customer success management.  The Parent Company’s equity amounts to DKK 12.7 million, and intangible assets are DKK 16.6 million. Given the current world market situation, the strong platform for growth, and profitability in reach, the management considers the Company’s economic performance to be acceptable. DecideAct A/S has come through 2023 well without losing focus on what is most important, namely keeping direction and momentum toward the long-term goals and driving breakthroughs despite the continued turbulence in the world. The product is still unparalleled, especially when it comes to the ability to handle the most complex business issues and customize solutions to customer needs. To ensure being in the best position to become a dominant player, DecideAct A/S must also be able to match the competition on the other critical parameters. It is therefore reassuring to note that investor support and confidence in DecideAct A/S’ long-term ambition remain high. Despite challenges externally with the decline in major customers' industries and internally with an intensified focus on adapting the organization, the DecideAct Group has managed to keep ARR at an acceptable level with the addition of new customers. Against this backdrop and with the current pipeline, management is confident that the DecideAct Group can achieve its overall goals and create great value for DecideAct A/S’ investors. About DecideAct A/S [ACT] DecideAct is a provider of SaaS software and solutions that move manual execution and follow-up of strategy to a cloud-based Strategy Execution Management platform. By rethinking the way strategy is executed, DecideAct has created a groundbreaking tool that is relevant to all companies and organizations, public or private, in all industries, geographies, functional roles, and their mission-critical priorities related to achieving strategic goals. DecideAct’s vision is to modernize strategic leadership through technology. Contact Information Company: Certified Advisor: CEO, Flemming Videriksen Keswick Global AG + 45 78756550 + 43 1 740 408045  E-mail: ir@decideact.net E-mail: info@keswickglobal.com DecideAct A/S Østre Kajgade 3, 3730 Nexø, Denmark

Peptonic Medical AB granted patent in the USA for treatment and prevention of yeast infections among women

The patent is based on Peptonic's clinically proven gel base which has been adapted to target candida albicans, the most common cause of vaginal yeast infections. The gel is designed to moisturize and balance the natural pH in the intimate area, while gently preserving the delicate vaginal flora. A clinical study on a limited population of women showed a good effect against Candida albicans, highlighting its potential to treat and prevent vaginal yeast infections. "The granted patent not only protects our unique formulation in treating yeast infections but also constitutes a fundamental part of our ambition to enabling women to independently self-diagnose, treat, and prevent common medical conditions in the intimate area," says Anna Linton, CEO of Peptonic. Vaginal yeast infections are a prevalent condition affecting up to three out of four women at some point in their lives, with many experiencing recurring infections. Globally, there are indications of and concerns about resistance development to available treatments, creating a need for new treatment options. For more information contact:Anna Linton, CEO Peptonic Medical ABEmail: anna.linton@peptonicmedical.sePhone:  +46 70-244 92 07 About Peptonic Medical AB                                                                                                      Peptonic Medical AB (publ) is an innovative Swedish biomedical company engaged in the development and sales of clinically proven self-care treatments and self-diagnostic rapid tests in intimate women's health. The portfolio is sold under the brands Vagivital and Vernivia. Peptonic Medical is a cutting-edge Swedish biomedical company, dedicated in the development and distribution of clinically proven self-care treatments and rapid self-diagnostic tests in intimate women's health. Under the esteemed brands Vagivital and Vernivia, the portfolio delivers tangible solutions. The company's vision is to revolutionize intimate health by empowering women to diagnose, treat, and prevent intimate medical conditions independently and effectively. The company continuously aims to broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio. Central to the growth strategy is the geographic expansion of VagiVital and Vernivia through local partners. The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense in the USA and Peptonic Medical in Israel. Peptonic Medical was founded in 2009, and the company's shares have been listed on the Spotlight Stock Market since 2014.

Kesko’s sales in March

”Kesko’s sales decreased by 8.9% in March. Sales decreased in all divisions. Due to the timing of Easter, the number of delivery days was down by 2-4 days year-on-year depending on the business, which had a marked impact on sales performance. One delivery day has an approximately 2-4 percentage point impact on Kesko’s wholesale, depending on the business,” says Jorma Rauhala, Kesko’s President and CEO. Sales in the grocery trade division totalled €543.7 million in March, down by 3.0%. Sales to K Group grocery stores decreased by 2.7%. Sales in K-Citymarket’s home and speciality goods (non-food) decreased by 0.8%. Kespro’s sales decreased by 4.8%. The number of delivery days in grocery trade was down by 2 year-on-year, and the number of delivery days for Kespro was down by 3 year-on-year. Sales in the building and technical trade division totalled €362.1 million in March, down by 13.8%, or by 21.7% in comparable terms. The number of delivery days in March was down by three year-on-year in Finland and Sweden, and by four in Norway. The calendar impact on sales was approximately 14 percentage points. Sales in building and home improvement trade decreased by 3.5%, or by 20.4% in comparable terms. Sales in technical trade decreased by 22.9% in comparable terms. In comparable terms, sales decreased by 22.9% in Finland, 20.0% in Sweden, and 24.0% in Norway. The sales figures of the Danish Davidsen have been consolidated into the figures of Kesko’s building and technical trade division from 1 February 2024 onwards. Sales in the car trade division totalled €98.8 million in March, a decrease of 19.3%. Car trade sales decreased by 17.0% in comparable terms, impacted by reduced delivery volumes for new cars, the lower number of sales days, and sales delayed until April due to strikes. Sports trade sales decreased by 23.7%. Kesko Group’s sales in March 2024 totalled €1,002.9 million, representing a decrease of 8.9%. Kesko Group sales in euros, excluding VAT, in March 2024: March 2024 Comparable € million Change, % change, %Grocery sales to K Group grocery 445.2 -2.6 -2.7stores and non-food sales, totalKespro 98.5 -4.8 -4.8Grocery trade, total 543.7 -3.0 -3.1Building and home improvement 187.3 -3.5 -20.4tradeTechnical trade 180.1 -22.8 -22.9Building and technical trade, 362.1 -13.8 -21.7totalCar trade 83.3 -18.4 -17.0Sports trade 15.5 -23.7 -23.7Car trade, total 98.8 -19.3 -18.2Common functions and -1.7eliminationsGrand total 1,002.9 -8.9 -11.8 Finland, total 812.4 -10.0 -9.9Other countries, total 190.6 -3.5 -20.3Grand total 1,002.9 -8.9 -11.8 Kesko Group sales in euros, excluding VAT, in January-March 2024: 1.1.-31.3.2024 Comparable € million Change, % change, %Grocery sales to K Group grocery 1,249.2 +1.8 +1.8stores and non-food sales, totalKespro 286.4 +0.4 +0.4Grocery trade, total 1,535.6 +1.5 +1.5Building and home improvement 472.4 -4.1 -15.9tradeTechnical trade 540.5 -7.4 -13.7Building and technical trade, 997.8 -5.7 -14.8totalCar trade 247.6 -7.0 -5.0Sports trade 41.3 -22.1 -22.1Car trade, total 288.9 -9.5 -7.9Common functions and -5.5eliminationsGrand total 2,816.8 -2.3 -5.4 Finland, total 2,289.3, -4.3 -4.1Other countries, total 527.5 +7.2 -12.1Grand total 2,816.8 -2.3 -5.4 Change % indicates the change when compared to the corresponding period of the previous year. The comparable change % has been calculated in local currencies and excluding the impact of acquisitions and divestments completed in 2023 and 2024. In addition, the calculation of comparable sales also takes into account the minor change in the business model of technical trade in Norway. The reported sales for Kesko Group include the acquisitions and divestments completed in 2023 and 2024 in accordance with the dates of completion. In 2023, Kesko completed the acquisition of Elektroskandia Norge AS in Norway in March, Zenitec Sweden AB in Sweden in April, and Geitanger Bygg AS in Norway in October. At the end of March 2023, Kesko completed the divestment of its MAN business (trucks and buses). In February 2024, the business operations of an individual Neste K service station were transferred to Kesko. As of 1 February 2024, Davidsen Koncernen A/S has been part of Kesko. Sports trade has been part of the car trade division from 1 April 2023 onwards. Prior to that, it was part of the building and technical trade division. In this release, sales for sports trade are included in the figures for the car trade division from the start of 2023. The number of delivery days in March 2024 was down by 2 year-on-year in Kesko’s grocery trade, by 3 in Kespro and in building and technical trade in Finland and Sweden, and by 4 in building and technical trade in Norway. In January-March, the number of delivery days was down by 1 year-on-year in grocery trade, in Kespro, and in building and technical trade in Finland and Sweden. Meanwhile, in Norway, the number of delivery days was down by 3 in January-March. Saturdays are wholesale delivery days in grocery trade but not in Kespro or in building and technical trade. Under normal circumstances, one delivery day has an approximately 2-4 percentage point impact on Kesko’s wholesale, depending on the division. Kesko publishes advance information on the retail sales of K Group stores quarterly in connection with interim reports. Further information is available from Hanna Jaakkola, Vice President, Investor Relations, tel. +358 105 323 540, and Eva Kaukinen, Vice President, Group Controller, tel. +358 105 322 338. Kesko Corporation DISTRIBUTIONMain news mediawww.kesko.fi

AFRY advices EnfraGen on award-winning renewables transaction in Latin America

EnfraGen is a leading company in grid stability and value-added renewable energy infrastructure in Latin America, jointly controlled by Glenfarne Energy Transition, LLC and the global private markets investment manager, Partners Group. The landmark acquisition of six operating renewable assets from Celsia S.A. by EnfraGen was recognised as the “Acquisition Deal of the Year” for the Americas by Project Finance International (PFI). This accolade highlights EnfraGen's success in adeptly managing the complex financing processes for both acquiring the renewable energy portfolio in Central America and refinancing a previous facility, while also underscoring their commitment to transitioning to zero-carbon emission electrical grids. AFRY conducted thorough technical due diligence on the renewable power assets to assess the operational efficiency and sustainability of the portfolio, and evaluated the potential of the assets, ensuring a seamless acquisition process. AFRY has been supporting EnfraGen since 2016 conducting technical due diligence services on several portfolios of assets across the Americas, and providing technical advisory in the renewable energy market. “Our competencies and focus on sustainable energy infrastructure have been instrumental in moving towards the closing of the deal. We are proud of our continued collaboration with EnfraGen and congratulate them on this prestigious award that recognises the commitment to advancing the renewable energy development and grid stability in the region”, says Angel Arancibia, Commercial Manager, AFRY Chile. For further information, please contact: Angel Arancibia, Commercial Manager, AFRY Chileangel.arancibia@afry.com Virginia Ferrari, Communications Manager, Energyvirginia.ferrari@afry.com

MEKO accelerates expansion of fast-growing brand in Sweden

Established in Sweden by MEKO in 2019 to challenge established retail and wholesale businesses and provide a strategic alternative to well-known brands such as MECA and Mekonomen, BilXtra has seen significant success in Sweden. The number of BilXtra facilities has soared from three to 27 during this time. The new collaboration with BILAM, the owner of five facilities in southern Sweden, translates into an 18 percent increase in connected facilities. These facilities, located in Halmstad, Hässleholm, Laholm, Osby, and Älmhult, have up until now been running as part of a different chain. Starting from April, they will be integrated into the BilXtra brand. “We are delighted to welcome BILAM and their operations to our family. Their addition not only underscores the appeal, resilience and strength of MEKO's concept, but also its capacity to enhance the success of our workshops. We look forward to a fruitful association with BILAM and our ongoing efforts to bolster our market share in Sweden,” says Petra Bendelin, Chief Operating Officer at MEKO and interim CEO for MEKO’s business in Sweden. In Sweden, MEKO runs 14 brands catering to the independent automotive aftermarket, including MECA, Mekonomen, BilXtra, Speedy, and Promeister. Each brand and concept is tailored to specific market segments, enabling MEKO to reach a broad spectrum of target groups concurrently. MEKO's revenue from its Swedish operations exceeded SEK 4.1 billion in 2023, constituting over 24 percent of MEKO's total worldwide revenue. For further information, please contact: Petra BendelinCOO, MEKOPhone: +46 (0)8-464 00 00Email: petra.bendelin@meko.com Anders OxelströmDirector of Communications, MEKOPhone: + 46 73 522 52 42Email: anders.oxelstrom@meko.com

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On April 11, 2024, BlackRock's holding in Metso’s shares exceeded the 5 percent threshold and amounted to 43,027,566 shares or 5.19 percent of total shares and votes. BlackRock's holding through financial instruments in Metso amounted to 1,195,330 shares, which corresponds to 0.14 percent of the total amount of Metso’s shares. On April 11, 2024, BlackRock's total position amounted to 44,222,896 or 5.33 percent of Metso’s shares and votes. Metso’s total number of shares and voting rights is 828,972,440.BlackRock, Inc.’s holdings according to the notification: % of % of shares and voting rights Total of both shares through financial instruments in % (7.A + and (total of 7.B) 7.B) voting rights (total of 7.A)Resulting 5.19% 0.14% 5.33%situation on thedate onwhich thresholdwas crossed orreachedPosition of 4.95% 0.15% 5.11%previousnotification A: Shares and votingrightsClass/type of Number of % ofshares shares and shares and voting voting rights rightsISIN code Direct(SMA Indirect(SMA Direct(SMA Indirect(SMA 9:5) 9:6 and 9:7) 9:5) 9:6 and 9:7)FI0009014575 43,027,566 5.19%SUBTOTAL A 43,027,566 5.19%B: FinancialInstruments accordingto SMA 9:6aType of financial Expiration Exercise/ Physical or Number of % of sharesinstrument date Conversion cash shares and and voting Period settlement voting rights rightsAmerican Depositary N/A N/A Physical 8,969 0.00%Receipt(US5926721094)Securities Lent N/A N/A Physical  1,186,361 0.14% SUBTOTAL B 1,195,330 0.14% Further information: Juha Rouhiainen, Vice President, Investor Relations, Metso Corporation, tel. +358 20 484 3253, email: juha.rouhiainen(a)metso.com   Distribution:  Nasdaq Helsinki Ltd Main media www.metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com, x.com/metsoofficial

Notice to Annual General Meeting in Bong AB

RIGHT TO ATTEND AND REGISTRATION MADE TO THE COMPANY Those who which to attend the annual general meeting shall firstly             be recorded in the share register kept by Euroclear Sweden AB as of Monday 6 May 2024, and secondly       no later than Wednesday 8 May 2024, notify the Company of their participation by sending a letter to Bong AB, att: “Annual General Meeting”, Box 516, 291 25 Kristianstad or via email to anmalan.arsstamma@bong.com, mark with "Annual General Meeting". When registering, the name/company name and ID.no/organization number, address, phone number and, where applicable, information about the representative and/or deputy must be stated. If the shareholder intends to bring one or two assistants to the meeting, such participation must be notified as stated above. Complete authorization documents such as registration certificate or equivalent should also be attached to the notification, where applicable, for example for a legal entity. Nominee-Registered SharesAnyone who has had their shares registered by a nominee must, in order to have the right to participate in the annual general meeting, have the shares registered in their own name, so that the person concerned is registered in the share register maintained by Euroclear Sweden AB on Monday 6 May 2024. Such registration can be temporary (so-called voting rights registration) and is requested from the nominee according to the nominee's routines at such a time in advance as the nominee determines. Voting rights registration that has been requested by shareholders in such a time that the registration has been made by the nominee no later than Wednesday 8 May 2024 will be taken into account when preparing the share register. ProxiesShareholders who are represented by a proxy must issue a written, signed and dated power of attorney for the proxy. If the power of attorney was issued by a legal entity, a certified copy of the registration certificate or equivalent authority document for the legal entity must be attached. The original power of attorney and any certificate of registration should be sent before the annual general meeting to the Company at the address above. Proxy forms are available on the Company's website, www.bong.com and are provided to the shareholder upon request. PROPOSED AGENDA 1. Opening of the annual general meeting 2. Election of chairperson of the annual general meeting 3. Preparation and approval of the voting list 4. Approval of the agenda 5. Election of one or two persons to adjust the minutes 6. Determination if the annual general meeting has been duly convened 7. Presentation of the annual report and the auditor’s report and the consolidated financial statements and the consolidated auditor’s report 8. Resolutions on: a. adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet, b. allocation of the Company’s result according to the adopted balance sheet, c. discharge from liability for the directors and the managing director 9. Approval of the board of directors' remuneration report10. Resolution on the number of board directors11. Determination of the remuneration to the board of directors12. Resolution on the board of directors and the chairperson of the board of directors13. Resolution on the number of auditors14. Determination of the remuneration to the auditor15. Resolution on the auditor16. Resolution on instructions for the nomination committee17. Resolution on guidelines for remuneration to senior executives18. Resolution to amend the articles of association19. Resolution on issue authorisation20. Closing of the meeting PROPOSALS FOR RESOLUTIONS Nomination Committee’s proposal (item 2 as well as items 10-16)The nomination committee, consisting of Stéphane Hamelin (representative of Holdham S.A), Christian Paulsson (representative of Paulsson Advisory AB), and Per Åhlgren (representative of GoMobile Nu AB) has proposed the following: item 2           Per Åhlgren shall be elected chairperson at the annual general meeting. item 10         The board shall consist of four ordinary members elected by the annual general meeting without deputies. item 11         Remuneration to the members of the board shall be SEK 300,000 to the chairperson of the board and SEK 150,000 to each of the other members elected by the annual general meeting who are not employees of the Company, and fees for work in the audit committee shall be paid with SEK 100,000 for the chairperson and with SEK 50,000 for a member. item 12        The members Christian Paulsson, Stéphane Hamelin, Eric Joan and Per Åhlgren shall be re-elected for the period until the end of the next annual general meeting in 2025. Per Åhlgren shall be appointed as the chairperson of the board. item 13          A registered auditing company shall be appointed as the auditor. item 14          The auditor shall receive compensation on an approved account. item 15        The auditing firm Grant Thornton Sweden AB shall be elected as the Company's auditor for a mandate period of one year, in accordance with the audit committee's recommendation, thus up until the end of the annual general meeting in 2025, whereby the auditing firm has informed that the authorized auditor Mia Rutenius will be appointed as principal auditor. item 16         The nomination committee shall consist of three (3) members. The Nomination committee appoints a chairperson from among its members. The members of the nomination committee shall be appointed by a procedure where the chairman of the board contacts the three biggest majority shareholders, in terms of votes, based on the statistics from the shareholders´ register maintained by Euroclear Sweden AB as of 30 September each year, the opportunity to each nominate a member to the nomination committee for the period until a new nomination committee has been appointed. If requested shareholder refrain from nominating a member to the nomination committee, the right to nominate a member to the nomination committee will be given to the next shareholder, through the above nomination procedure, has the majority shareholding in the Company, in terms of votes. If a member leaves the nomination committee before the end of the mandate period, and if the nomination committee deems it necessary, a replacement shall be appointed by the same shareholder who appointed the resigning member or, if this shareholder is no longer one of the three largest shareholders in terms of voting rights, by the new shareholder belonging to this group. The composition of the nomination committee shall be published on the company's website as soon as it has been appointed and no later than six months before the annual general meeting. In the event that a change in the ownership structure occurs after the nomination committee has been composed in such a way that one or more of the shareholders who have appointed members of the nomination committee are no longer among the three largest shareholders in terms of voting rights, the composition of the nomination committee may also be changed accordingly, if the nomination committee deems it necessary. The duties of the nomination committee shall be to prepare and present proposals for the annual general meeting regarding the chairman of the general meeting, chairman of the board and other board members to be elected by the meeting, remuneration to the board, election of auditors, remuneration to auditors, and if applicable, instructions for the nomination committee. The company shall be responsible for reasonable costs that the nomination committee deems necessary in order for the nomination committee to be able to fulfil its duties.                       These instruction for the nomination committee shall apply until further notice. The Board of Directors’ proposals (item 8(b) as well as items 17-19) Resolution regarding allocation of the Company’s result in accordance with the adopted balance sheet (item 8b)The board of directors proposes that no dividend shall be paid for the financial year 2023. The board's complete proposal for profit distribution will be reported in the Company's annual report. Resolution on guidelines for remuneration to senior executives (item 17)The board of directors proposes that the annual general meeting resolves on guidelines for remuneration to the CEO and the other senior executives as follows: Other senior executives are defined as members of the group management, at present consisting of the company´s CEO, also Business Unit Manager Central Europe, Chief Financial Officer (CFO), Business Unit Manager Nordic countries, Business Unit Managed United Kingdom and Business Unit Manager South Europe and North Africa, also Business Unit Manager Bong Retail Solutions. The guidelines are forward-looking, i.e. they are applicable to remuneration agreed, and amendments to remuneration already agreed, after adoption of the guidelines by the annual general meeting 2024. These guidelines do not apply to any remuneration decided or approved by the general meeting. The guidelines promotion of the company´s business strategy, long-term interest and sustainabilityIn short, the company´s business strategy is the following. Bong is one of the leading envelopes manufactures in Europe, offering a wide and flexible range of solutions for distribution and packaging of information, advertisement and lightweight goods. Important growth areas in the Group are packaging within retail and e-commerce and the envelope market within Eastern Europe. Bong conducts broad sustainability work aimed at low environmental impact, safe workplaces whereby employees are treated equally and high business ethics. A prerequisite for the successful implementation of the company’s business strategy and safeguarding of its long-term interests, including its sustainability, is that the company is able to recruit and retain qualified personnel. To this end, it is necessary that the company offers competitive remuneration. These guidelines enable the company to offer the executive management a competitive total remuneration. Variable cash remuneration covered by these guidelines shall aim at promoting the company’s business strategy and long-term interests, including its sustainability. Types of remuneration, etc.The remuneration shall be on market terms and may consist of the following components: fixed cash salary, variable cash remuneration, pension benefits and other benefits. Additionally, the general meeting may – irrespective of these guidelines – resolve on, among other things, share-related or share price-related remuneration. The satisfaction of criteria for awarding variable cash remuneration shall be measured over a period of one year. The variable cash remuneration may amount to not more than 60 per cent of the fixed annual cash salary. For the CEO, pension benefits, including health insurance (Sw. sjukförsäkring), shall be premium defined. Variable cash remuneration shall not qualify for pension benefits. The pension premiums for premium defined pension shall amount to not more than 30 per cent of the fixed annual cash salary. For other executives, pension benefits, including health insurance, shall be premium defined unless the individual concerned is subject to defined benefit pension under mandatory collective agreement provisions. Variable cash remuneration shall qualify for pension benefits to the extent required by mandatory collective agreement provisions. The pension premiums for premium defined pension shall amount to not more than 30 per cent of the fixed annual cash salary. Other benefits may include, for example, life insurance, medical insurance (Sw. sjukvårdsförsäkring) and company cars. Premiums and other costs relating to such benefits may amount to not more than 15 per cent of the fixed annual cash salary. For employments governed by rules other than Swedish, pension benefits and other benefits may be duly adjusted for compliance with mandatory rules or established local practice, taking into account, to the extent possible, the overall purpose of these guidelines. Termination of employmentThe notice period may not exceed twelve months if notice of termination of employment is made by the company. Fixed cash salary during the period of notice and severance pay may together not exceed an amount equivalent to the CEO’s fixed cash salary for two years, and one year for other executives. The period of notice may not to exceed six months without any right to severance pay when termination is made by the executive. For employments governed by rules other than Swedish, termination of employment may be duly adjusted for compliance with mandatory rules or established local practice, taking into account, to the extent possible, the overall purpose of these guidelines. Criteria for awarding variable cash renumeration, etc.The variable cash remuneration shall be linked to predetermined and measurable criteria which can be financial or non-financial. They may also be individualized, quantitative or qualitative objectives. The criteria shall be designed so as to contribute to the company’s business strategy and long-term interests, including its sustainability, by for example being clearly linked to the business strategy or promote the executive’s long-term development. The applied criteria are financial performance targets such as profit before tax and growth targets for Light Packaging, which both contribute to the Group’s business strategy, long term interests and sustainability. Bong conducts a broad sustainability work which aims at low environmental impact, safe workplaces where employees are treated equally and high business ethics. To which extent the criteria for awarding variable cash remuneration has been satisfied shall be evaluated/determined when the measurement period has ended. The remuneration committee is responsible for the evaluation so far as it concerns variable remuneration to the CEO. For variable cash remuneration to other executives, the CEO is responsible for the evaluation. For financial objectives, the evaluation shall be based on the latest financial information made public by the company. Salary and employment conditions for employeesIn the preparation of the board of directors’ proposal for these remuneration guidelines, salary and employment conditions for employees of the company have been taken into account by including information on the employees’ total income, the components of the remuneration and increase and growth rate over time, in the remuneration committee’s and the board of directors’ basis of decision when evaluating whether the guidelines and the limitations set out herein are reasonable. The decision-making process to determine, review and implement the guidelinesThe board of directors has established a remuneration committee. The committee’s tasks include preparing the board of directors’ decision to propose guidelines for executive remuneration. The board of directors shall prepare a proposal for new guidelines at least every fourth year and submit it to the general meeting. The guidelines shall be in force until new guidelines are adopted by the general meeting. The remuneration committee shall also monitor and evaluate programs for variable remuneration for the executive management, the application of the guidelines for executive remuneration as well as the current remuneration structures and compensation levels in the company. The CEO and other members of the executive management do not participate in the board of directors’ processing of and resolutions regarding remuneration-related matters in so far as they are affected by such matters. Derogation from guidelinesThe board of directors may temporarily resolve to derogate from the guidelines, in whole or in part, if in a specific case there is special cause for the derogation and a derogation is necessary to serve the company’s long-term interests, including its sustainability, or to ensure the company’s financial viability. As set out above, the remuneration committee’s tasks include preparing the board of directors’ resolutions in remuneration-related matters. This includes any resolutions to derogate from the guidelines. Resolution to amend the articles of association (item 18)The board of directors proposes that the annual general meeting resolves to amend the Company's articles of association to clarify the possibility for the Company to elect a registered accounting firm as the auditor as follows. Current wording: § 8 The general meeting shall appoint two (2) auditors and two (2) deputy auditors. A registered accounting firm may also be appointed as auditor or deputy auditor. Proposed wording: § 8 The meeting shall appoint two (2) auditors and two (2) deputy auditors or appoint a registered accounting firm as auditor. The board of directors, or the person appointed by the board of directors, shall be entitled to make such minor adjustments to the resolutions of the general meeting as may be required for registration with the Swedish Companies Registration Office. Resolution on issue authorisation (item 19)The board of directors proposes that the annual general meeting resolves to authorise the board to, on one or more occasions until the next annual general meeting, with or without regard of shareholders’ pre-emption rights, to resolve on issuance of shares, warrants and/or convertibles. The resolution also includes the right to resolve on issuance of shares, warrants or convertibles with provisions on contribution in kind, set-off issue and or in other ways subscribed in accordance with the Swedish Companies Act. The total number of shares issued in such share issue must be within the limits of the share capital according to the articles of association, in force from time to time, regarding the share capital and number of shares. The board of directors, or the person appointed by the board of directors, shall be entitled to make such minor adjustments to the resolutions of the general meeting as may be required for registration with the Swedish Companies Registration Office. DOCUMENTSComplete proposals as well as accounting documents and auditor's report for 2023 will be available at the Company, and on the Company's website www.bong.com, no later than three weeks before the general meeting and will be sent immediately and free of charge to the shareholders who request it and state their postal address. The documents will also be available at the general meeting. INFORMATION AT THE MEETINGThe board and the managing director must, if a shareholder requests it and the board considers that it can be done without significant damage to the Company, at the meeting provide information about conditions that may affect the assessment of a matter on the agenda, conditions that may affect the assessment of the Company's or subsidiary's financial situation, the consolidated accounts and the Company's relationship with other group companies. SHARES AND VOTES At the time of the notice, there are 211,205,058 shares and votes in the Company. The Company does not hold any own shares. PROCESSING OF PERSONAL DATA For information on how your personal data is processed, please see:https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf ____________ Kristianstad in April 2024 Bong AB (publ) For further information, please contact Carsten Grimmer, CFO of Bong AB (publ). Tel (switchboard) +46 44-20 70 00.

Wyld Networks launch new Wyld Connect satellite IoT product in L-band spectrum adding additional USD 1.1 billion to Wyld’s total addressable market

Wyld Networks L-band end to end satellite IoT service uses Swiss based Astrocast’s low earth orbiting satellite constellation. This new bidirectional and comprehensive satellite Internet of Things (IoT) service focusses on tackling global connectivity challenges for industries such as agriculture, energy, utilities, maritime and environmental monitoring. Wyld Networks’ L-band solutions enable connectivity for sensors and devices and are already being deployed in Europe, Middle East, Africa and Asia Pacific. L-band is the radio spectrum from 1 to 2 gigahertz (GHz). The new L-band product supports 2-way communications opening up multiple new use cases. Wyld Networks already supports satellite IoT in the ISM band and launched S-band products in early 2024 and now with the addition of L-band products the company solidifies its position as a full satellite IoT service provider for multiple spectrum and multiple industry sectors. Wyld Networks first deployment of L-band products is in Australia with PLF. This is already generating data for soil moisture applications. Further deployments with identified customers are scheduled for May in Africa and Europe. “We are delighted to be deploying the new Wyld Connect product in the L-band,” said Alastair Williamson, CEO Wyld Networks. “Our satellite partner Astrocast has already deployed 18 low earth orbiting satellites providing excellent global coverage for the Internet of Things. The L-band increases Wyld’s overall addressable market to approximately USD 5.4 billion and increases the number of use cases we can target specifically with the 2-way communications.” For further information, please contact: Alastair Williamson, CEO Wyld NetworksE-mail: alastair.williamson@wyldnetworks.com Tel: +44 7 824 997689 About Wyld Networks AB Wyld Networks develop and sell innovative wireless technology solutions that enable affordable connectivity anywhere in the World, addressing the problems for businesses and people regarding the lack of global mobile network coverage. The solutions are mainly targeted to wireless connectivity for the Internet of Things (IoT) and people. Wyld Networks Ltd was formed in Cambridge, UK in 2016 and is a wholly owned subsidiary of Wyld Networks AB. The Wyld Networks share (WYLD) is traded on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB (tel +46 8-5030 1550, email ca@mangold.se). Read more on www.wyldnetworks.com

Nordisk Bergteknik signs several new orders related to wind farm projects worth about SEK 140 million

- It is very pleasing that we have been entrusted to contribute to the establishment of more wind farms. Nordisk Bergteknik has a clear ambition to contribute to the development of the future sustainable society and play an active role in the green transition. Our ambition is to continue being a strategic and leading partner in the expansion of wind power, power lines, and other sources of renewable energy. With our modern machinery and broad expertise in rock handling and foundation solutions, we are often the most attractive partner, says Andreas Christoffersson, CEO Nordisk Bergteknik AB. ¨ The underlying need for increased production of renewable energy is based on the green transition of society where new and expanded fossil-free steel production is one of several driving factors. In northern Sweden, there is a large number of project developers driving renewable power projects in various phases towards permission and construction. The current assessment, according to new forecasts from the Swedish Energy Agency, is that after the last couple of years with a lower construction pace, the number of power projects entering the construction phase increases both in number and size. Thus, the need for services such as rock excavation, foundation reinforcement, transportation, and terracing for road networks increases. Services which the subsidiaries of Nordisk Bergteknik can offer throughout the country. For further information, contact: Andreas Christoffersson, CEO, +46 70-621 19 28, andreas.christoffersson@bergteknikgroup.com Johan Lundqvist, CFO, +46 76-392 71 21, johan.lundqvist@bergteknikgroup.com About Nordisk Bergteknik Nordisk Bergteknik has a clear growth strategy with the objective to contribute to the development of a future sustainable society. Our companies are specialists within rock handling and foundation solutions, and through compassion and skill they are able to combine demand with the surrounding natural conditions. To be involved at an early stage in building modern societal functions is our everyday life, our home ground and our future.

Addtech acquires Cell Pack Solutions Ltd

Addtech Electrification, a business area in the Addtech Group, has today signed an agreement to acquire 90 % of the shares outstanding in Cell Pack Solutions Ltd (”Cell Pack”). Cell Pack develops, manufactures and markets internationally battery solutions under its own brand to customers primarily in water treatment, safety and medical technology. The company has 30 employees and a turnover of approximately GBP 5.6 million with headquarters in South Shields, UK. Cell Pack complements and strengthens Addtech's existing operations in the area of battery solutions and will be part of the Battery Systems business unit. The closing will take place today. The acquisition is expected to have a marginally positive impact on Addtech's earnings per share during the current financial year. Stockholm, April 15, 2024 Addtech AB (publ) For further information, please contactNiklas Stenberg, President of Addtech AB, +46 470 49 00Per Lundblad, Business Area Manager, Electrification, +46 70 795 66 02 Addtech is a technical solutions group that provides technological and economic value added in the link between manufacturers and customers. Addtech operates in selected niches in the market for advanced technology products and solutions. Its customers primarily operate in the manufacturing industry and infrastructure. Addtech has about 3,900 employees in more than 150 subsidiaries that operate under their own brands. The Group has annual sales of more than SEK 18 billion. Addtech is listed on Nasdaq Stockholm. The information was submitted for publication, through the agency of the contact persons set out above, on April 15, 2024, at 9.00 a.m (CEST).

SmartCraft ASA (SMCRT) - SmartCraft acquires Swedish SaaS company Locka

15 April 2024: SmartCraft ASA has acquired Locka Group AB, adding software solutions within 3D visualization, customer interaction and after-sales service for the construction industry. “We have added 10 software companies into the SmartCraft family through acquisitions over the past seven years, integrating them successfully whilst simultaneously realizing synergies. We are excited to have the Locka team joining SmartCraft and to offer their effective and appealing SaaS based specialized software solutions for 3D visualization, customer interaction and after-sales service. Locka is a great match for us and adds a wonderful complement to our existing portfolio of software solutions for the construction industry,” said SmartCraft CEO Gustav Line. Locka offers powerful and practical tools for 3D visualization, option management, case management and customer interaction for construction companies and property developers. In 2023, Locka's revenue was SEK 37 million (excluding some discontinued operations) with an EBITDA margin of 10 percent. The company currently has 21 employees and in the first two months of 2024, Locka grew its revenue organically by 3 percent to SEK 6.2 million (YTD February) with a 16% EBITDA margin and 10% EBITDA-CAPEX (“cash EBITDA”) margin. At the end of 2023 approximately 50 percent of the revenue was recurring. “Locka has faced challenges but is now in a good position with organic growth and positive margins. We have a proven history of enhancing the performance, growth and margins of the companies we have acquired, and we see ample opportunities to do the same for Locka. SmartCraft will focus on value creation by applying our established methods to adapt Locka’s business model, boost the company’s recurring revenue and shift sales to ARR, like we have done with other acquisitions in the past” said Gustav Line. “We are eager to embark on a new chapter of profitable growth as part of the SmartCraft team. The SmartCraft culture, construction software competence and the strong track record in building successful SaaS companies for the construction industry feels like a natural and positive step for us at Locka,” said Johan Corke, CEO of Locka. The transaction is based on an enterprise value of SEK 24 million, which will be settled in cash. The transaction closed today, on 15 April 2024. ContactGustav Line, CEOEmail: gustav.line@smartcraft.comPhone: +47 952 67 104 About SmartCraftSmartCraft is the leading Nordic provider of mission-critical SaaS solutions to SME's in the construction sector. The company's business model is highly scalable, based on 97% recurring revenue and low churn. The construction sector is among the least digitalized industries and represents a NOK 10bn software market in the Nordics, growing at a double-digit rate. SmartCraft's solutions help customers to increase their productivity, margins, and resource efficiency.

The Board of Directors of Citycon Oyj decided on two new incentive plans and amendment to the Stock Option Plan 2024

The Board of Directors of Citycon Oyj has resolved to launch a new stock option plan and restricted share unit plan directed to the Chief Executive Officer. The aim is to align the objectives of the shareholders and the CEO in order to increase the long-term value of the company, to retain the CEO at Citycon, and to offer her a competitive reward plan.Stock Option Plan 2024A-CThe maximum total number of stock options to be issued is 1,591,848 and they entitle their owners to subscribe for up to an equivalent number of new shares in total in the company or existing shares held by the company. The stock options are issued gratuitously. Of the stock options, 530,616 are marked with the symbol 2024A, 530,616 are marked with the symbol 2024B and 530,616 are marked with the symbol 2024C.The shares subscribed for with the stock options to be issued will account for a total maximum of 0,85 per cent of all the company's shares and votes after possible share subscriptions if new shares are issued in the subscription. As a result of the share subscriptions made with the stock options, the number of shares in the company may increase by a total maximum of 1,591,848 shares if new shares are issued in the subscription.The share subscription price for stock options 2024A-C is 4,05 euros per share.The share subscription price will be credited to the company's reserve for invested unrestricted equity.The share subscription period for stock options is, · for stock options 2024A, 1 April 2024 – 1 April 2027 · for stock options 2024B, 1 April 2025 – 1 April 2027 · for stock options 2024C, 1 April 2026 – 1 April 2027 The theoretical market value of one stock option 2024A-C is approximately 0,19 euros. The theoretical market value of the stock options 2024A-C is approximately EUR 300,000 in total. The theoretical market value of a stock option has been calculated by using the Black & Scholes model taking into account the subscription price of the stock option and the following input factors: share price EUR 3,83, risk-free interest rate 2,79%, validity of stock options approximately 3 years, volatility approximately 21,02% and dividend yield approximately 8,68%.The Board of Directors decided on the new stock option plan based on the authorisation given by the Annual General Meeting of Shareholders on 19 March 2024. The Company has a weighty financial reason for the issue of stock options since the stock options are intended to form part of the incentive and commitment program for the Group key employees.Restricted Share Unit Plan 2024-2027The Board of Directors may allocate rewards from the plan during the financial year 2024. The value of the rewards to be paid on the basis of the plan corresponds to a maximum total of 75,000 shares of Citycon Oyj, including also the proportion to be paid in cash.The rewards will be paid in three instalments in April 2025, April 2026 and April 2027. The reward is based on a valid director contract and on the continuity of service.The reward will be paid partly in Citycon’s shares and partly in cash. The cash proportion of the reward is intended to cover taxes and statutory social security contributions arising from the reward. As a rule, no reward will be paid if the director’s contract terminates before the reward payment.Amendment to Stock Options 2024The Board resolved on stock options 2024 on 19 March 2024. The Board resolved to increase the maximum number of stock options distributed from the plan with 150,000 stock options, so the total maximum number of stock options will be 500,000 stock options.CITYCON OYJFor further information, please contact:Sakari JärveläChief Financial OfficerTelephone +358 50 387 8180sakari.jarvela@citycon.comCitycon is a leading owner, manager and developer of mixed-use real estate featuring modern, necessity-based retail with residential, office and municipal service spaces that enhance the communities in which they operate. Citycon is committed to sustainable property management in the Nordic region with assets that total approximately EUR 4.0 billion. Our centres are located in urban hubs in the heart of vibrant communities with direct connections to public transport and anchored by grocery, healthcare and other services that cater to the everyday needs of customers.Citycon has investment-grade credit rating from Standard & Poor's (BBB-). Citycon’s shares are listed on Nasdaq Helsinki Ltd.www.citycon.comATTACHMENTS                 Terms and conditions of the Citycon Oyj Stock Options 2024A-C             Terms and conditions of the Citycon Oyj Stock Options 2024

SmartCraft ASA (SMCRT) - SmartCraft acquires Swedish SaaS company Locka

15 April 2024: SmartCraft ASA has acquired Locka Group AB, adding software solutions within 3D visualization, customer interaction and after-sales service for the construction industry. “We have added 10 software companies into the SmartCraft family through acquisitions over the past seven years, integrating them successfully whilst simultaneously realizing synergies. We are excited to have the Locka team joining SmartCraft and to offer their effective and appealing SaaS based specialized software solutions for 3D visualization, customer interaction and after-sales service. Locka is a great match for us and adds a wonderful complement to our existing portfolio of software solutions for the construction industry,” said SmartCraft CEO Gustav Line. Locka offers powerful and practical tools for 3D visualization, option management, case management and customer interaction for construction companies and property developers. In 2023, Locka's revenue was SEK 37 million (excluding some discontinued operations) with an EBITDA margin of 10 percent. The company currently has 21 employees and in the first two months of 2024, Locka grew its revenue organically by 3 percent to SEK 6.2 million (YTD February) with a 16% EBITDA margin and 10% EBITDA-CAPEX (“cash EBITDA”) margin. At the end of 2023 approximately 50 percent of the revenue was recurring. “Locka has faced challenges but is now in a good position with organic growth and positive margins. We have a proven history of enhancing the performance, growth and margins of the companies we have acquired, and we see ample opportunities to do the same for Locka. SmartCraft will focus on value creation by applying our established methods to adapt Locka’s business model, boost the company’s recurring revenue and shift sales to ARR, like we have done with other acquisitions in the past” said Gustav Line. “We are eager to embark on a new chapter of profitable growth as part of the SmartCraft team. The SmartCraft culture, construction software competence and the strong track record in building successful SaaS companies for the construction industry feels like a natural and positive step for us at Locka,” said Johan Corke, CEO of Locka. The transaction is based on an enterprise value of SEK 24 million, which will be settled in cash. The transaction closed today, on 15 April 2024. Contact Gustav Line, CEO Email: gustav.line@smartcraft.com Phone: +47 952 67 104 About SmartCraft SmartCraft is the leading Nordic provider of mission-critical SaaS solutions to SME's in the construction sector. The company's business model is highly scalable, based on 97% recurring revenue and low churn. The construction sector is among the least digitalized industries and represents a NOK 10bn software market in the Nordics, growing at a double-digit rate. SmartCraft's solutions help customers to increase their productivity, margins, and resource efficiency.

SLP acquires building right in strategic location in Jönköping

"This is the first time we have acquired a separate building right. Jönköping is an expansive logistics hub that ranks as one of the best in Sweden as 80 percent of Sweden's population is reached within a radius of 40 miles. In addition, the property is strategically located in the best logistics location and there is great interest in new construction from both our existing and new tenants," says Tommy Åstrand, CEO of SLP. The land is ready for construction and is one of the last unexploited lots in the fully developed logistics area. SLP already has five logistics properties in the Jönköping region. The property is acquired through a corporate transaction at an agreed property value of approximately SEK 34m. The seller is Nivika Fastigheter AB. The transaction is financed with own funds. For further information, please contact:Tommy Åstrand, CEO of SLP, telephone: +46 705 455 997  About SLP – Swedish Logistic PropertySwedish Logistic Property - SLP – is a Swedish property company that acquires, develops, and manages logistic properties with sustainability in focus. Value growth is created through development of the properties which are located in Sweden’s most important logistic hubs. The property portfolio comprises a lettable area of approx. 980,000 sqm. SLP is a partner that takes responsibility and through this creates value for both tenants as well as for the company and its shareholders. SLP’s share of series B is listed at Nasdaq Stockholm Mid Cap. For further information about SLP: slproperty.se

Careium appoints Joe McLoughlin as the Regional Managing Director in the UK

Careium, the European champion in technology enabled care, appoints Joe McLoughlin as the Regional Managing Director in the UK. Mr McLoughlin is an industry veteran, with a technical and commercial background. He has profound experience within sales, business transformation, and executive leadership. Joe currently holds the role of Managing Director at the Careium competitor, Astraline, a high growth and strong innovation company, that is a part of the Johnnie Johnson Housing and the Sanctuary Group. Over the course of his career, Joe has contributed to the work of the TSA – The governing body for UK technology enabled care by serving on boards, panels, and leading working groups. “I am excited to join Careium at this pivotal point in its evolution! My complete focus will be on continuing to positively shape the future of the UK business. My vision is to capitalise on and nurture the distinctive and remarkable culture, the amazing skillset, and strengths inherent in the UK teams, while drawing on the invaluable experience and solution capability of our European counterparts. Together, we will propel growth, cultivate our partnerships, and raise the bar for customer experience.”, says Joe McLoughlin. The UK business has undergone a significant and remarkable transformation over the past twelve months, establishing a strong foundation for the future. Great work has been carried out throughout the organisation: roll out of acquisitions as one company, implementation of shared platforms across the Group - strengthening the overall business integration level, and the establishment of increased profitability levels. The business is now re-set to re-take its position as a key player in the industry, as the UK market accelerates the switch from analogue to digital across the technology enabled care sector. “Joe's background and experience ensures that our markedly reinforced UK business will take the right next steps in the most competitive, innovative, and exciting market in Europe. I am proud that we are attracting individuals with such talent and experience, and I really look forward to welcoming Joe to the Group and to the incredible UK team.", says Careium’s CEO Christian Walén (interim for the role since September 2023).

Medivir’s partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its partner Vetbiolix, a veterinary biotechnology company based in France, reported positive results from a Proof-of-Concept clinical study in periodontal disease in dog with its drug candidate VBX-1000, previously known as MIV-701. VBX-1000 (MIV-701) is the first specific cathepsin-K inhibitor, for the treatment of periodontal disease in dogs. During the early development of a selective cathepsin-K inhibitor, MIV-701 was discovered to have properties suitable for non-human animal use and it was out-licensed to Vetbiolix in 2019 to explore clinical utility in non-human animal. In the study conducted by Vetbiolix, the drug was well tolerated and the primary efficacy endpoint was met, achieving a statistically significant reduction of the plasma biomarker for bone degradation (CTX1). Vetbiolix is now working with experts in the field to set up a regulatory Pilot clinical study to further strengthen the demonstration of the effects of VBX-1000 (MIV-701) in a double blind, randomized, placebo-controlled clinical trial in dogs. As part of the agreement with Vetbiolix, Medivir is entitled to minor development and regulatory milestone payments with value upside potential coming from future royalty payments on net sales and/or share of partnering payments received by Vetbiolix in case of future partnering transactions with VBX-1000. -          “Partnering and collaborations are important parts of Medivir’s business model to accelerate the development of all assets and reduce financial risk. MIV-701 is another example of the company’s ability and track-record in out-licensing to generate additional value for shareholders. The positive results of the Proof-of-Concept study are also a testament to the quality of research performed by Medivir and add yet another molecule to the number of candidates that have been shown to provide clinical benefit” says Jens Lindberg, Chief Executive Officer at Medivir. For additional information, please contact; Magnus Christensen, CFO, Medivir AB Telephone: +46 8 5468 3100. E-mail: magnus.christensen@medivir.com About Medivir Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. www.medivir.com. About Vetbiolix Vetbiolix develops innovative products for the treatment and prevention of diseases affecting pets. Vetbiolix has built a unique pipeline of First-in-class small molecules in-licensed (exclusive and worldwide license) from Human Biotech worldwide which will answer to veterinary unmet medical needs in periodontitis, osteoarthritis and gut motility disorders. Vetbiolix focuses exclusively on clinical developments of its drug candidates: the company invests on (i) clinical proof of concept studies, (ii) CMC-Pharmaceutical developments, (iii) regulatory Pilot clinical studies and (iv) regulatory Pivotal clinical studies. Revenue generation of the company will be based on out-licensing and/or co-developments deals with the Veterinary Pharmaceutical Industry. www.vetbiolix.com

AQ Group finalizes the acquisition of JIT Mech

AQ Group AB signed on March 11, 2024, an agreement to acquire 100% of the shares in JIT Mech se Industri AB with the subsidiaries JIT Mech i Robertsfors AB and JIT Mech i Örnsköldsvik AB. The transaction is subject to, and conditioned by, declaration to The Inspectorate of Strategic Products (ISP), in accordance with the FDI Act (Foreign Direct Investment). ISP, has now decided that no further action is required according to FDI Act, hence AQ Group can now finalize the acquisition of JIT Mech. The closing is planned to take place during second quarter 2024. JIT Mech is a leading supplier of large and complex machined and welded components to customers in the electrification, forestry automation and defense industries. The companies have a consolidated turnover for 2023 of approximately SEK 130 million, an operating margin in line with the AQ average and have 75 employees. Operations are conducted in Robertsfors and Örnsköldsvik. ______________________________________________________________________________________________________­­­­­_­­­­­_________ For further information, please contact:CEO and IR, James Ahrgren,tel. +46 76 052 58 88 or CFO, Christina Hegg, tel. +46 70318 92 48 This disclosure contains information that AQ Group is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was released by James Ahrgren for publication at 14:30 CEST on April 15, 2024. _______________________________________________________________________________________________________________________ AQ is a global manufacturer of components and systems to demanding industrial customers and is listed on Nasdaq Stockholm’s main market. The Group consists mainly of operating companies each of which develop their special skills and in cooperation with other companies, striving to provide cost effective solutions in close cooperation with the customer. The Group headquarter is in Västerås, Sweden. AQ has 8,000 employees in Bulgaria, Poland, Lithuania, Sweden, China, Estonia, Hungary, Mexico, Finland, India, Canada, USA, Germany, Italy, and Brazil. In 2023 AQ had net sales of SEK 9 billion, and the Group has since its start in 1994 shown profit every quarter. www.aqgroup.com 

Neste to supply sustainable aviation fuel to Air New Zealand at Los Angeles International Airport

Neste Corporation, News, 15 April 2024 Photo: Air New ZealandNeste and Air New Zealand have signed an agreement for the supply of nine million liters (around 7,200 tons or 2.4 million gallons) of neat Neste MY Sustainable Aviation Fuel™ . The agreement represents the largest purchase of sustainable aviation fuel (SAF) from Neste made by any airline outside North America and Europe for delivery before the end of 2024.The agreement follows an earlier SAF delivery to Air New Zealand in 2022 . The sustainable aviation fuel will be produced at Neste’s Singapore refinery, which expanded its SAF production capability last year and is currently ramping up SAF production. The neat SAF will be blended with conventional jet fuel to meet the required fuel specifications and supplied to Los Angeles International Airport between 1 April and 30 November 2024. “Decarbonising Air New Zealand’s operations is essential for its long-term ability to connect New Zealanders to the world, as well as support the country’s trade and tourism sectors, and SAF is a key enabler of this”, says Air New Zealand’s Chair Dame Therese Walsh. “Sustainable aviation fuel is currently the only solution to significantly reduce emissions from long haul flight, but it currently makes up less than 1% of the global fuel supply. For aviation to reach its net zero carbon emissions goals by 2050, the SAF industry will need to scale significantly. While the SAF supply is small compared with the airline’s overall fuel use, it is nine times the size of Air New Zealand’s first shipment of SAF from Neste in 2022 and demonstrates growing cooperation between two like-minded organizations to advance the supply and use of SAF,” Walsh adds. “Neste is fully committed to supporting the decarbonization of aviation and is working closely together with partners like Air New Zealand to accelerate SAF usage. We are proud to support Air New Zealand’s decarbonization focus and are looking forward to continuing working together with Air New Zealand and the New Zealand Government to reach their climate goals,” said Alexander Kueper, Vice President Renewable Aviation at Neste.Sustainable Aviation FuelSustainable aviation fuel is a renewable aviation fuel providing a more sustainable alternative to conventional, fossil-based jet fuel. Using Neste MY Sustainable Aviation Fuel™ reduces greenhouse gas emissions by up to 80%* over the fuel’s life cycle, compared to using conventional jet fuel. Neste’s SAF is made from sustainably sourced, 100% renewable waste and residue raw materials, such as used cooking oil and animal fat waste. SAF is blended with conventional jet fuel before use and works seamlessly with existing aircraft engines and fueling infrastructure. *) When used in neat form (i.e. unblended) and calculated with established life cycle assessment (LCA) methodologies, such as CORSIA methodology

ExpreS2ion to present in investor and R&D events in March

By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website . 17 April 2024 | Aktiespararna Life Science Investor Conference16:25 CET | VirtualJoin us for a live update from our CEO, Bent Frandsen, at Aktiespararna’s Life Science Investor Day in Stockholm. The event can be streamed through Aktiespararna’s YouTube channel  or directly from their website at aktiespararna.se/tv/live. To register for the event, please follow the provided link . 23-25 April 2024 | Immune-Oncology Summit Europe 2024London, UKWe look forward to presenting at the eighth annual Immuno-Oncology Summit Europe where we will contribute to the Cambridge Healthtech Institute's Inaugural program "Therapeutic Cancer Vaccines, Immunological Advances for Cancer Treatment." On April 23 at 4:30pm, as part of the Peptide-Based Vaccines track, ExpreS2ion CSO Farshad Guirakhoo will present "Preclinical Proof of Concept Studies of a Novel Human HER-2 Virus Like Particle as a Vaccine Candidate for Human Breast Cancers." To schedule a meeting with Dr. Guirakhoo at the event, please email info@expres2ionbio.com. For more information about the event and to register, please visit the event website . Certified AdviserSvensk Kapitalmarknadsgranskning AB

ACE the future of mobile card payments – New whitepaper by Crunchfish

[A diagram of a software application Description automatically generated] Card payments is a common payment method that banks offer their customers. To enable card payments from a mobile device in a secure way that is scalable to all customers have proven to be difficult. It is either limited to users of select mobile devices or operators (MCE) or alternatively only available for e-commerce or terminal purchases that requires online clearing. The ground-breaking mobile technology that Crunchfish has developed for offline payments is also applicable for mobile card payments.    This whitepaper by Crunchfish introduces App-integrated Card Emulation (ACE) as a novel way of card emulation. The initial section relates ACE to other ways of Card Emulation (CE) – Mobile Card Emulation (MCE) using a hardware-based Secure Element (SE) and Host-based Card Emulation (HCE) with tokenized payment credentials. The second section discusses Implementation Architectures using hardware-based as well as software-based protection. The third section discusses Data Integrity during runtime operation, for stored data at rest and for data in transit. The conclusion includes a comparison table of MCE, HCE and ACE that summarizes the points raised in the three sections of this whitepaper. Find the whitepaper on this link . For more information, please contact: Joachim Samuelsson, CEO of Crunchfish AB +46708 46 47 88 joachim.samuelsson@crunchfish.com This information was provided by the above for publication on 15th April 2024 at 15:30 CET. Västra Hamnen Corporate Finance AB is the Certified Adviser. Email: ca@vhcorp.se. Telephone +46 40 200250. About Crunchfish –crunchfish.com  Crunchfish is a deep tech company developing a Digital Cash platform for Banks, Payment Services and CBDC implementations and Gesture Interaction technology for AR/VR and automotive industry. Crunchfish is listed on Nasdaq First North Growth Market since 2016, with headquarters in Malmö, Sweden and with a subsidiary in India.

Changes to the Securitas Group Management team

Securitas is a world-leading safety and security solutions partner and provides outstanding services for our clients by combining our extensive presence with connected technology and intelligent use of data. Greg Anderson, Divisional President North America and member of Group Management, has decided to leave Securitas to pursue an opportunity outside the business. This change is effective immediately, and José Castejon, COO North America Guarding and member of Group Management, takes on the role of acting Divisional President until a permanent successor has been appointed. All other Group Management members continue in their current roles. - Greg is one of the important leaders who has helped develop our Guarding organization in North America into the successful, modern business it is today. I would like to take the opportunity to thank Greg for all the commitment to our business and dedication to our people which he has demonstrated since joining the business as an Area Vice President in 2010. I wish him the best of luck in the future, says Magnus Ahlqvist, President and CEO. - I am confident that José, who has been an active part of our transformation together with the rest of our strong North America Guarding leadership team, will effectively manage both our existing successful business as well as continue to deliver on our strategic development plan. José has deep operational expertise and a track record of delivering results during his 17-year tenure at Securitas, and I am pleased to have our North America business in such safe hands during this transition period, continues Magnus Ahlqvist, President and CEO. ABOUT José Castejon José Castejon has served as the Chief Operating Officer, North American Guarding and has been a member of Securitas Group Management since January 2020. In addition, Jose has led the Global Guarding Center of Excellence. held the positions of Region President of the South Region and Area Vice President in Central Florida over his 17 years with Securitas. He has deep guarding experience and has consistently delivered strong results. José Castejon holds a BS in Business Administration from Florida International University. This press release is available at www.securitas.com 

Groundbreaking Report from ABS and AAPA Shines Light on American Ports’ Readiness to Meet Decarbonization Demands

(HOUSTON) While most American ports have decarbonization plans in place, a new report shows there are significant challenges to advancing emission-reduction projects, including financial constraints, low technology readiness and physical space limitations. Those are some of the key takeaways from a new joint publication between ABS and the American Association of Port Authorities (AAPA), Port Decarbonization Survey: Trends and Lessons Learned. The report is based on feedback from AAPA members and represents the culmination of a joint development project (JDP), a unique collaboration between AAPA and ABS providing perspectives from both port authorities and vessel operations experts.   “ABS is actively involved in several infrastructure planning projects around the world, especially regarding shore power connection technologies and the electrification of ports. This report provides an important benchmark for ABS to understand the ability and interest in decarbonization infrastructure at U.S. ports. ABS is uniquely positioned with our deep expertise in regulatory compliance and technological breakthroughs to bring together diverse maritime stakeholders to advance the conversation around sustainability and emissions reduction strategies,” said Panos Koutsourakis, ABS Vice President, Global Sustainability. “Maritime is by its very nature a cleaner form of transportation, and this survey shows that various ports are already leading emissions mitigation efforts in alternative fuel and electrification options. AAPA intends to leverage this research to push for wise and realistic policies - with collaboration from public and private partners - towards an increasingly sustainable future for the port and maritime industry,” said Cary S. Davis, AAPA President and CEO. “The Georgia Ports Authority is dedicated to decarbonization on a number of fronts, including through the electrification of cargo-handling equipment,” said Tiffoni Buckle McCartney, Manager of Corporate Sustainability at the Georgia Ports Authority and Chair of the AAPA Environment Committee. “This report will help port staff across the country learn from their colleagues, and it will help policymakers understand what is needed to advance port decarbonization.” Download a copy of the report here  and join ABS and AAPA for a webinar to discuss the findings in more detail. Register here .

Roboquest releases ‘Arsenal’ update, enhancing gameplay with exciting new additions

The Arsenal Update introduces lots of new features, enhancing the gaming experience for both newcomers and seasoned players alike. Key Gameplay Additions; 9 New WeaponsEach brings unique strategies and firepower to the battlefield. From the precision of the Shuriken to the explosive force of the Missile Battery, players will have a diverse arsenal at their disposal. Shooting RangePlayers can explore the all-new Shooting Range, a dedicated area within the Basecamp where they can hone their skills and test their weaponry. By completing the "Burger Bill" quest, players unlock additional elements within the Shooting Range, providing even more opportunities for target practice and experimentation. New QuestPlayers will encounter the NPC, Burger Bill, who finds himself in a precarious situation. By rescuing Burger Bill, players gain access to the full potential of the Shooting Range, further expanding their gameplay experience. New Shop NPC - Willy WonderNew Shop NPC within the Basecamp. Players can unlock Willy Wonder through Basecamp Upgrades and utilize his services to add specific affixes to their weapons and upgrade their quality, enhancing their effectiveness in battle. SummonsExtended build variety by adding the concept of "Summons". This new mechanic adds a new layer to the builds by allowing players to improve and enhance the power of the little bot allies they summon. Crystal PowderPlayers can now also collect Crystal Powder, a new resource obtained by completing corrupted levels, which can be used to upgrade weapon quality from Epic to Fantastic at Willy Wonder's shop. The addition of this resource makes it more interesting to come back to corrupted levels, effectively changing the routes players take every run. New QOL Options and Fixes:Additionally, the Arsenal Update brings several quality-of-life improvements and fixes, including an overlay displaying all weapon stats in Max's Museum, HUD elements for enhanced gameplay visibility, and options for players to customize their controls to their preference. With 10 new affixes for weapons, 7 new items, and enhanced level variation for Haven City and The Moon, the Arsenal Update is set to deliver even more excitement and replayability to the Roboquest experience! For more information about the Arsenal Update and Roboquest, visit the Steam Store Page . Press kit for Roboquest is available here . For more information, please contact; Gustav Nisser, Head of Third Party Publishing, Starbreeze EntertainmentE-mail: 3PP@starbreeze.comPhone: +46(0)8-209 208 About RyseUpRyseUp Studios is an independent game studio founded in 2014 in Lyon, France, composed of 20 passionate developers, artists and friends. Our aim is to create innovative IPs and gaming experiences that entertain and inspire players everywhere. About Starbreeze’ Third-Party PublishingYour ideas. Our expertise. We empower and amplify the creativity of game developers by providing them with the support and resources to bring their visions to a global audience. Starbreeze offers turnkey publishing services, including; game development funding, release management, marketing, creative development of video and imagery, CRM, community management, data management & analytics as well as quality assurance, and more. About StarbreezeStarbreeze is an independent developer, creator, publisher and distributor of PC and console targeting the global market, with studios in Stockholm, Barcelona, Paris and London. Housing the smash hit IP PAYDAY, Starbreeze develops games based on proprietary and third-party rights, both in-house and in partnership with external game developers. Starbreeze shares are listed on Nasdaq Stockholm. For more information, please visit www.starbreeze.com.

Ericsson reports first quarter results 2024

First quarter highlights – Driving gross margin improvements and cost efficiencies · Sales declined organically[1] by -14% YoY, due to a -19% decline in Networks. Reported sales decreased to SEK 53.3 (62.6) b. · Gross income excluding restructuring charges decreased to SEK 22.8 (24.9) b. as lower sales were partly offset by an improvement in gross margin. Reported gross income was SEK 22.7 (24.2) b. · Gross margin excluding restructuring charges improved to 42.7% (39.8%) supported by a competitive product portfolio, cost actions, improved commercial discipline, as well as increased IPR licensing revenues. Reported gross margin was 42.5% (38.6%). · EBITA excluding restructuring charges amounted to SEK 5.1 (4.8) b. with a margin of 9.6% (7.7%), which included a one-time gain of SEK 1.9 b. Reported EBITA was SEK 4.9 (3.8) b. · Net income was SEK 2.6 (1.6) b. EPS diluted was SEK 0.77 (0.45). · Free cash flow before M&A was SEK 3.7 (-8.0) b. reflecting improved management of working capital. · Net cash on March 31, 2024, was SEK 10.8 b. compared with SEK 7.8 b. on December 31, 2023. +----------------------------+------+------+------+------+------+|SEK b. |Q1 |Q1 |YoY |Q4 |QoQ || |2024 |2023 |change|2023 |change|+----------------------------+------+------+------+------+------+|Net sales |53.325|62.553|-15% |71.881|-26% |+----------------------------+------+------+------+------+------+| Sales growth adj. for |-  |-  |-14% |-  |-  ||comparable units and | | | | | ||currency[2]  | | | | | |+----------------------------+------+------+------+------+------+|Gross margin[2] |42.5% |38.6% |-  |39.8% |-  |+----------------------------+------+------+------+------+------+|EBIT  |4.100 |3.046 |35% |5.848 |-30% |+----------------------------+------+------+------+------+------+|EBIT margin[2] |7.7% |4.9% |-  |8.1% |-  |+----------------------------+------+------+------+------+------+|EBITA[2]  |4.893 |3.848 |27% |6.694 |-27% |+----------------------------+------+------+------+------+------+|EBITA margin[2] |9.2% |6.2% |-  |9.3% |-  |+----------------------------+------+------+------+------+------+|Net income  |2.613 |1.575 |66% |3.409 |-23% |+----------------------------+------+------+------+------+------+|EPS diluted, SEK  |0.77 |0.45 |71% |1.02 |-25% |+----------------------------+------+------+------+------+------+|Measures excl. restructuring ||charges[2] |+----------------------------+------+------+------+------+------+|Gross margin excluding |42.7% |39.8% |-  |41.1% |-  ||restructuring charges  | | | | | |+----------------------------+------+------+------+------+------+|EBIT excluding restructuring|4.305 |4.026 |7% |7.368 |-42% ||charges  | | | | | |+----------------------------+------+------+------+------+------+|EBIT margin excluding |8.1% |6.4% |-  |10.3% |-  ||restructuring charges  | | | | | |+----------------------------+------+------+------+------+------+|EBITA excluding |5.098 |4.828 |6% |8.214 |-38% ||restructuring charges  | | | | | |+----------------------------+------+------+------+------+------+|EBITA margin excluding |9.6% |7.7% |-  |11.4% |-  ||restructuring charges  | | | | | |+----------------------------+------+------+------+------+------+|Free cash flow before M&A  |3.671 |-8.016|-  |12.464|-71% |+----------------------------+------+------+------+------+------+|Net cash, end of period  |10.805|13.573|-20% |7.832 |38% |+----------------------------+------+------+------+------+------+ [1] Sales adjusted for comparable units and currency[2] Non-IFRS financial measures are reconciled at the end of this report to the most directly reconcilable line items in the financial statements. Comments from Börje Ekholm, President and CEO of Ericsson (NASDAQ:ERIC) In Q1, we continued to execute on our strategy to strengthen our leadership in mobile networks, drive a focused expansion in enterprise, and pursue cultural transformation. We maintained our leading market position, but as expected our customers continued to exercise caution with their investments. Against this tough market backdrop, we delivered solid expansion in gross margins. This underscores the competitiveness of our solutions, our commercial discipline, and our actions on costs. We will continue to proactively optimize the business, including through strategic cost-saving measures, to ensure Ericsson is best positioned to increase shareholder value. Q1 – Market headwinds and execution focus While organic sales[1] declined by -14%, we reached a gross margin[2] of 42.7%, generated EBITA[3] of SEK 5.1 billion and a 9.6% EBITA margin[3]. Networks sales[1] decreased organically by -19% YoY as our customers continued to be cautious with their investments. Despite this, we generated a strong gross margin[2] of 44.3% – a testament to our technology leadership, our competitive product portfolio, and the strategic actions we are taking, including on costs. In Cloud Software and Services, we continued to execute on our strategy to strengthen delivery performance and commercial discipline. We delivered a gross margin[2] of 37.4% and our EBITA margin[2] improved year-on-year for a fifth consecutive quarter. The rolling four quarter EBITA margin[2] was 3.0%. In Enterprise, sales grew organically overall but declined in Global Communications Platform, impacted by a low-margin customer contract loss in Q4 and our decision to reduce our operations in some countries, with the impact expected to continue throughout the year. We continue to focus on leveraging the current business to support the build-out of our Global Network Platform for network APIs. Our IPR revenues continued to grow, with a new 5G patent license agreement with a handset manufacturer. We are confident of delivering further growth in IPR revenues, benefiting from additional 5G agreements and an expansion into additional licensing areas. The timing of contracts will fluctuate, as we seek to optimize the value of new agreements. We delivered SEK 3.7 billion of free cash flow[4] in Q1, benefiting from our operational improvements, and lower working capital as we concluded an intense 5G roll-out phase in India. We announced further measures in the quarter to improve our cost efficiency and streamline operations, including headcount reductions. This is a necessary action to position the Company for longer-term success. In March, our independent Monitor certified our compliance program. This is an important step to conclude our plea agreement. Our focus on culture and integrity will continue. Executing on our strategy Our strategy is aimed at building a stronger and more profitable Ericsson in the long term, with a vision to capture the next major wave of networks innovation with a substantial platform business. At Mobile World Congress in Barcelona, we showcased industry-leading hardware and software solutions required in order to build the high-performance and programmable networks necessary to digitalize society. Our industry is shifting from a vertically integrated architecture to a horizontal and cloud-based network architecture – and Ericsson is leading this development. We also took critical steps in our strategy to build a Global Network Platform for network APIs, and announced three key partnerships with Verizon, AT&T and Amazon Web Services, as well as a communications API agreement with KDDI. Exposing network features through APIs will support the creation of new differentiated services and will be crucial in the next step of digitalization of enterprise and society. Looking ahead We expect a further decline in the RAN market, at least through the end of this year, as customers remain cautious with their investments and the pace of investment in India continues to normalize. Dell’Oro estimates the global RAN equipment market will decline by -4% in 2024, which may prove optimistic. If current trends persist, we expect our sales to stabilize during the second half of the year, benefiting from recent contract wins and the normalization of customer inventory levels in North America. In Q2, we expect Networks gross margin excluding restructuring charges to be in the range of 42-44%. In the second half, our margins should benefit from improved business mix. We also remain highly focused on delivering stronger cash flow, based on our operating discipline.  Our enterprise strategy aims to leverage network capabilities to increase telecoms industry revenue growth above the level that traffic growth alone could deliver. We are creating new, differentiated, products and services, supporting our customers in this transformation. In turn, this will support industry investment levels in the longer term. While near-term dynamics are challenging, we remain fully committed to our long-term targets, and we continue to be focused on increasing shareholder value. Börje Ekholm President and CEO [1] Sales adjusted for comparable units and currency.[2] Excluding restructuring charges.[3] Excluding restructuring charges. Includes a one-time gain of SEK 1.9 b., reported in segment Other.[4] Before M&A. NOTES TO EDITORS You find the complete report with tables in the attached PDF or on www.ericsson.com/investors Video webcast for analysts, investors and journalists President and CEO Börje Ekholm and CFO Lars Sandström will comment on the report and take questions at a video webcast at 9:00 AM CEST (8:00 AM GMT London, 3:00 AM EST New York). Join the webcast  or please go to www.ericsson.com/investors To ask a question:Access dial-in information here  The webcast will be available on-demand after the event and can be viewed at www.ericsson.com/investors. FOR FURTHER INFORMATION, PLEASE CONTACT Contact person Daniel Morris, Head of Investor RelationsPhone: +44 7386657217E-mail: investor.relations@ericsson.com Additional contacts Stella Medlicott, Senior Vice President, Marketing and Corporate RelationsPhone: +46 730 95 65 39E-mail: media.relations@ericsson.com Investors Lena Häggblom, Director, Investor RelationsPhone: +46 72 593 27 78E-mail:  lena.haggblom@ericsson.com Alan Ganson, Director, Investor RelationsPhone: +46 70 267 27 30E-mail: alan.ganson@ericsson.com Media Ralf Bagner, Head of Media RelationsPhone: +46 76 128 47 89E-mail: ralf.bagner@ericsson.com Media relationsPhone: +46 10 719 69 92E-mail: media.relations@ericsson.com This is information that Telefonaktiebolaget LM Ericsson is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:00 CEST on April 16, 2024.

Sinch publishes restated historical segment reporting after implementation of new operating model

Stockholm, Sweden – 16 April, 2024 – Sinch AB (publ), which is pioneering the way the world communicates through its Customer Communications Cloud, is today making restated historical segment reporting available on the company’s investor relations website investors.sinch.com. The disclosure is made to simplify the understanding of Sinch’s upcoming quarterly report, where the new segment reporting will be implemented. The restated historical segment reporting does not affect Sinch’s previously reported total revenues or profit. The new operating segments follow the new operating model announced in October 2023, and consist of the three regions Americas, EMEA and APAC. In addition, a complementary view consisting of the three product categories Applications, API platform and Network Connectivity will be presented. · Restated historical reporting is available for the four quarters of 2023. · For each of the three new regional operating segments, the restated historical segment reporting includes Net sales and Gross profit. Net sales and Gross profit for each of the three product categories within each operating segment is also made available. · EBITDA is reported for the group in its entirety. Sinch will continue to report the income statement by nature but will add disclosure of Adjusted operating expenses by function. · The change in segment reporting means that the four previous operating segments Messaging, Voice, Email and SMB, will no longer be reported. A conference call and a webcast will take place 16 April at 14:00 CEST where Sinch’s CFO Roshan Saldanha and CSO Thomas Heath will present. There will be a possibility to ask questions after the presentation. Please note that Sinch is in its silent period preceding the Q1 report and will therefore only answer questions relating to the restated historical segment reporting. Sinch refers possible remaining questions to the reporting day for the first quarter 2024, which is scheduled on 7 May. The restated historical segment information has not been subject to review by the company’s independent auditor. Time for conference call and webcast Tuesday 16 April 2024, 14:00 CEST. Conference call dial-in details If you wish to participate via teleconference, please register on the link below.After registration you will be provided with phone numbers and a conference ID to access the conference. https://conference.financialhearings.com/teleconference/?id=5007819 Webcast and financial information Restated historical financial segment reporting, slide deck, and link to the webcast is available at investors.sinch.com The webcast can also be accessed directly via https://ir.financialhearings.com/sinch-restated-segment-reporting-2024 For further information, please contact Ola ElmelandInvestor Relations DirectorMobile: +46 721 43 34 59E-mail: investors@sinch.com About Sinch Sinch is pioneering the way the world communicates. More than 150,000 businesses – including many of the world's largest tech companies – rely on Sinch’s Customer Communications Cloud to improve customer experience through mobile messaging, voice and email. Sinch has been profitable and fast-growing since it was founded in 2008. It is headquartered in Stockholm, Sweden, with shares traded at NASDAQ Stockholm: XSTO:SINCH. Learn more at sinch.com .

Nightingale Health to establish a laboratory in the United States with Weill Cornell Medicine as the first customer

Press release, 16 April 2024 at 08:45 a.m. (EEST) Nightingale Health, a pioneer in health risk detection and preventative health, announces today that it will open a laboratory in the United States. Additionally, Nightingale Health and the Englander Institute for Precision Medicine at Weill Cornell Medicine have signed a Letter of Intent in which the parties agree to collaborate on the adoption of Nightingale Health’s proprietary technology in healthcare and medical research in the United States. The Englander Institute for Precision Medicine is a translational research hub at Weill Cornell Medicine committed to translating research findings into clinical practice, including at its branch campus in Doha, Qatar. The institute has already significantly impacted the field of precision medicine by developing new treatments for a variety of diseases, including cancer, rare diseases, and cardiovascular disease. As part of the collaboration between the Englander Institute for Precision Medicine and Nightingale Health, in addition to medical research, the parties aim to integrate Nightingale Health’s proprietary blood analysis technology and disease risk assessment capabilities to Weill Cornell Medicine’s clinical and research services. The healthcare applications can be based on Nightingale Health’s existing capabilities such as multi-disease risk prediction models and individual diagnostic biomarkers that can replace clinical chemistry measures. “We are pleased to strengthen Nightingale Health’s international presence by establishing a laboratory in the United States. This initiative complements our global network of laboratories located in Finland, Singapore, the United Kingdom and Japan, and allows us to serve the most ambitious precision medicine and healthcare projects in the world. The collaboration with Englander Institute for Precision Medicine at Weill Cornell Medicine will explore and implement ways for comprehensive risk assessment from our unique blood testing technology for patient treatment, health checks and screening programs for multiple common chronic diseases,” said Teemu Suna, Nightingale Health’s CEO and Founder. "Our precision metabolomics pilot project marks the beginning of a new era in healthcare. The vision is to use metabolic profiling to tailor treatments uniquely for each patient, advancing precision medicine to benefit patients globally,” said Olivier Elemento, Director of Englander Institute of Precision Medicine. The new partnerships combined with a new laboratory will make Nightingale Health well equipped to make its proprietary blood analysis technology available locally in the largest healthcare market in the world and expand its partnerships within the medical research community. The location and opening schedule of the new laboratory will be announced at a later date. For further information, please contact: Teemu Suna, CEOir@nightingalehealth.com About Englander Institute of Precision Medicine at Weill Cornell Medicine The Englander Institute for Precision Medicine (EIPM) is a translational research hub at Weill Cornell Medicine that is dedicated to using precision medicine to improve patient care. Precision medicine is a personalized approach to healthcare that considers a patient's genetic makeup, lifestyle, and environment to tailor treatments to their specific needs. Founded in 2015, the EIPMadvances the delivery of personalized medicine, fosters collaboration across medical and scientific disciplines, and serves as the center of innovative precision medicine care, research, and education at Weill Cornell Medicine. As a prominent research hub, EIPM is committed to translating research findings into clinical practice - Institute members implementapplied genomic sequencing, artificial intelligence, informatics, and other cutting-edge technologies to personalize disease research, treatment, and prevention.Discoveries stemming from these efforts are central to identifying novel biomarkers and developing powerful targeted therapies. About Nightingale Health Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years. Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com

Faron confirms plans under new leadership

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron confirms plans for the coming months under new leadership -        Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next month -        Incoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for obtaining marketing approval for MDS patients that have failed HMA Press Release, April 16, 2024 at 9:00 (EEST) / 7:00 AM (BST) / 2:00 AM (EDT) TURKU, FINLAND/ BOSTON, MA – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces ongoing plans and activities for the coming months following the recent announcement of the proposed appointment of Dr. Juho Jalkanen as Chief Executive Officer, effective 1 May 2024. Initial data from the ongoing Phase 2 part of the BEXMAB trial, evaluating the safety and efficacy ofbexmarilimabin combination with standard of care (SoC) in patients with hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndrome (MDS),is expected to be announced during the week commencing 20 May 2024. This data read out will be important for ongoing partnering discussions and the major upcoming industry events that Faron will be attending, including the American Society for Clinical Oncology (ASCO) annual meeting and the Bio International Convention, taking place in June 2024. Given the promising data already seen in the Phase 1 part of the trial, among HMA-failed MDS patients who have no approved treatment options, the Company plans to approach the US Food and Drug Administration (FDA) earlier than planned this year, seeking a Scientific Advice meeting regarding its registrational study plan, in order to coordinate and finalize plans that may lead to marketing approval.  “2024 is set to be a pivotal year for Faron in the delivery of key milestones that will be critical to the further development of bexmarilimab,” said Dr. Juho Jalkanen, Faron’s incoming Chief Executive Officer. “In my new role as CEO I am excited to start executing on some of these key activities and to accelerating important discussions with the FDA as we map our future plans for bexmarilimab together. There is a tremendous need for an effective treatment in HMA-failed MDS patients and so we are very keen to ensure we get this treatment option to patients as soon as we can.” For more information please contact: Faron Pharmaceuticals Investor Contact LifeSci Advisors Daniel Ferry Managing Director daniel@lifesciadvisors.com +1 (617) 430-7576 ICR Consilium Mary-Jane Elliott, David Daley, Lindsey Neville Phone: +44 (0)20 3709 5700 E-mail:faron@consilium-comms.com Cairn Financial Advisers LLP, Nomad Sandy Jamieson, Jo Turner Phone: +44 (0) 207 213 0880 Peel Hunt LLP, Broker Christopher Golden, James Steel Phone: +44 (0) 20 7418 8900 Sisu Partners Oy, Certified Adviser on Nasdaq First North Juha Karttunen Phone: +358 (0)40 555 4727 Jukka Järvelä Phone: +358 (0)50 553 8990 About Faron Pharmaceuticals Oy Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments and as a monotherapy in last line solid cancers. Further information is available at www.faron.com.

Britta Rosenqvist new Head of Institutional Client Solutions at Swedbank Robur

Britta Rosenqvist joins the fund company from Swedbank, where she held the role of Head of Savings & Advisory Transformation Office. Prior to that, she spent several years at Skandia, where she was Chief Product Officer Savings and Payments, Head of Sustainability and Board member of Skandia Fonder. "Our ambition is to be the market leader in sales to institutions and third-party distributors, and we are very pleased that Britta Rosenqvist wants to join us driving this work forward. She will make a strong contribution with her inspiring leadership and solid knowledge of the Swedish fund and savings market," says Jens Grebäck, Head of Sales and Client Solutions, Swedbank Robur. Swedbank Robur's multi-channel strategy gives the fund company a strong platform and mix to start from in its work to follow up on customer requirements with new and well-thought-out offerings. "I am very pleased to have been entrusted with the opportunity to lead the work of the institutional sales organization at Swedbank Robur. I look forward to using my previous experience to help Swedbank Robur take the next step in the development of the customer relationship with third-party distributors and institutional customers," says Britta Rosenqvist, Head of Institutional Client Solutions, Swedbank Robur. Britta Rosenqvist assumed her role as Head of Institutional Client Solutions as of April 8, 2024. Contact:Carina Sesser Nylund, Head of Press and Information, Swedbank Robur, +46 72 230 52 64

Stora Enso Oyj: Notification of Change in Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act (12 April 2024)

Stora Enso Oyj has received a notificationpursuant to chapter 9, section 5 of the Securities Market Act fromBlackRock, Inc on 15 April 2024. On 12 April 2024, BlackRock's total holding, including holding through financial instruments, in Stora Enso’s shares increased above the 5 percent threshold. +----------------+--------------+-----------------------------+---------------+| |% of shares |% of shares and voting rights|Total of both || |and voting |through financial instruments|in % (7.A + || |rights |(total of 7.B) |7.B) || |(total of 7.A)| | |+----------------+--------------+-----------------------------+---------------+|Resulting |4.87%shares |0.17% shares |5.05% shares ||situation on the| | | ||date on |Below 5% |Below 5% voting rights |Below 5% voting||which threshold |voting rights | |rights ||was crossed or | | | ||reached | | | |+----------------+--------------+-----------------------------+---------------+|Position of |Below 5% |Below 5% shares |Below 5% shares||previous |shares | | ||notification | |Below 5% voting rights |Below 5% voting||(if applicable) |Below 5% | |rights || |voting rights | | |+----------------+--------------+-----------------------------+---------------+ +------------+--------+----------+-----------------+----------------------+|A: Shares ||and voting ||rights |+------------+--------+----------+-----------------+----------------------+|Class/type |Number of |% of shares and voting rights ||of |shares and | ||shares |voting | || |rights | |+------------+--------+----------+-----------------+----------------------+|Direct |Indirect|Direct |Indirect || | | | ||(SMA 9:5) |(SMA 9:6|(SMA 9:5) |(SMA 9:6 and 9:7)|| |and 9:7)| | |+------------+--------+----------+-----------------+----------------------+|FI0009005961| |38,474,040| |4.87% shares || | |shares | | || | | | |Below 5% voting rights|| | |Below 5% | | || | |voting | | || | |rights | | |+------------+--------+----------+-----------------+----------------------+|SUBTOTAL A |38,474,040 |4.87% shares || |shares | || | |Below 5% voting rights || |Below 5% | || |voting | || |rights | |+------------+--------+----------+-----------------+----------------------+ B: FinancialInstrumentsaccordingto SMA 9:6aType of Expiration Exercise/ Physical Number of % of sharesfinancial date Conversion or shares and votinginstrument Period cash and rights settlement voting rightsAmerican N/A N/A Physical 464,610 0.05% sharesDepositary sharesReceipt Below 5%(US86210M1062) Below 5% voting rights voting rightsSecurities N/A N/A Physical 860,000 0.10% sharesLent shares Below 5% Below 5% voting rights voting rightsCFD N/A N/A Cash 79,000 0.01% shares shares Below 5% Below 5% voting rights voting rights SUBTOTAL B 1,403,610 0.17% shares shares Below 5% Below 5% voting rights voting rights Stora Enso has two series of shares. Each A share and every ten R shares carry one vote. Stora Enso has 175,979,614 A shares and 612,640,373 R shares in issue. The company does not hold its own shares. The total number of Stora Enso shares is 788,619,987 and the total number votes at least 237,243,651. Full chain of controlled undertakings through which the voting rights and financial instruments are effectively held starting with the ultimate controlling natural person or legal entity is presented in the enclosed annex. Investor enquiries:Anna-Lena ÅströmSVP Investor Relationstel. +46 70 210 7691 Part of the global bioeconomy, Stora Enso is a leading provider of renewable products in packaging, biomaterials and wooden construction, and one of the largest private forest owners in the world. We create value with our low-carbon and recyclable fiber-based products, through which we support our customers in meeting the demand for renewable sustainable products. Stora Enso has approximately 20,000 employees and our sales in 2023 were EUR 9.4 billion. Stora Enso shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded in OTC Markets (OTCQX) in the USA as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors STORA ENSO OYJ

Hexagon Composites to start search for new Group CEO

Oslo, 16 April 2024: Hexagon Composites (OSE: HEX.OL) today announces that Jon Erik Engeset will step down as Group President and Chief Executive Officer. The Company will shortly commence a search process. Engeset will continue as CEO until the position is filled, following which he will continue to support the company in an advisory role. “After 11 years at the helm, Jon Erik Engeset has decided to step down,” says Knut Flakk, Chair of the Board of Hexagon Composites. “Under his management the Group has undergone significant transformation. The company has been successfully repositioned from primarily a composite cylinder manufacturer to an integrated clean fuel solutions provider. Top line revenues have increased more than five times, and the company has assumed globally leading market positions. We thank Jon Erik for the passion, commitment, and leadership he has brought – and brings - every day to his work here at Hexagon.“ “I have had the great privilege of leading this group for more than a decade. It is now time for me to give higher priority to my family,” says Jon Erik Engeset.  “The need to switch to clean energy requires urgent action from industry and governments alike and I take great pride in the contributions we at Hexagon have made together with our partners, customers, and suppliers. I predict that the market demand for our solutions will continue to grow at a very high pace in the years to come.” For more information:Ingrid Aarsnes, VP Investor Relations & ESG, Hexagon Composites ASA Telephone: +47 950 38 364 | ingrid.aarsnes@hexagongroup.com  Karen Romer, SVP Communications, Hexagon Composites ASA Telephone: +47 950 74 950 | karen.romer@hexagongroup.com  About Hexagon Composites ASA Hexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation, and conversion to clean energy in a wide range of mobility, industrial and consumer applications. Learn more at www.hexagongroup.com and follow @HexagonASA on Twitter and LinkedIn.

2020 Bulkers Ltd. (2020) - Notice of Annual General Meeting 2024

Oslo, Norway, April 16, 2024 2020 Bulkers Ltd. (the “Company”) advises that the 2024 Annual General Meeting of the Company will be held on Tuesday, May 7th, 2024 at 4:30 p.m. CET at the Company’s offices at Tjuvholmen Allé 3, 0252 Oslo, Norway. The Board of Directors has fixed the close of business on Wednesday April 17, 2024 as the record date for determination of the shareholders entitled to attend and vote at the Annual General Meeting or any adjournment thereof. A copy of the Notice of General Meeting and Form of Proxy can be found on the Company’s website www.2020bulkers.com and attached to this press release. The Notice of General Meeting and Form of Proxy will also be distributed to shareholders by normal distribution methods. Shareholders who have not opted to receive electronic communications from the Company will receive the main notice and the Form of Proxy only and are referred to the documentation published herewith and on the Company’s website for further information and the Company’s proposals in connection with the matters on the agenda for the Annual General Meeting. Pursuant to the company’s bye-laws, it is a term of issue of each share in the company that each shareholder provides an address for electronic communications from the Company. Hence, the Company kindly ask that shareholders who have not already done so, consent to electronic communication from Euronext Securities Oslo by updating their communications information at MyVPS at https://www.euronext.com/en/post-trade/euronext-securities/oslo/login or contact their account operator to provide such consent.

Ninja Kiwi acquires AutoAttack Games, the studio behind Legion TD 2

AutoAttack Games was established in 2014 by Brent Batas, following his incredibly successful Legion TD mod for Warcraft III. Julian Gari joined shortly after in 2016, and together they have co-led AutoAttack Games for 8 years. They are responsible for the development, marketing, and community activities around Legion TD 2, supported by a small team. AutoAttack's journey began in 2009 when Brent created the original Legion TD as a mod for Warcraft III. Legion TD grew quickly in popularity and became the second most popular mod for Warcraft III (second only to DotA). After a successful Kickstarter, the duo then launched Legion TD 2 in early access in 2017 and released the full game in 2021. Legion TD 2 has a vibrant and engaged player community and attracts a passionate and committed fanbase, which is one of the many connection points with Ninja Kiwi. The game continues to grow with regular updates, and the studio has also started development on a brand new game in the Legion franchise. Scott Walker, CEO of Ninja Kiwi commented: “We love the deep gameplay and the rich single and multiplayer challenges players have in Legion TD 2. We also feel that there is a close alignment between us at Ninja Kiwi and Brent and Julian when it comes to our love of the Tower Defense genre, our passion for making fun and highly balanced game experiences, and how we approach and value our player communities. I am thrilled for AutoAttack to join the Ninja Kiwi family and look forward to achieving great things together.” Brent Batas, Founder and CEO of AutoAttack Games commented: “The more we got to know Ninja Kiwi, the more it became clear that we shared a passion not only for crafting awesome games, but also for investing in and supporting our communities for the long haul. Combined with Ninja Kiwi's industry-leading presence in the Tower Defense space, we couldn't imagine a better group of people to partner with. We are excited for a bright future as part of the Ninja Kiwi team, as we join forces to continue making games we love and sharing them with the world!” Legion TD 2 is available for download on Steam .

Wyld Networks announce partnership with British company SugaROx to monitor soil moisture and weather stations for Soybean farming in Brazil

Brazil produces more soybean than any other country. For the year 2022–2023, Brazil produced an all-time high of 154.0 million Mt of soybeans. With much of the soybean yield going to livestock feed, production and consumption are predicted to remain strong. However, with limited new land available for soybean farming, Agritech companies are seeking to find new ways to meet the need for higher yields. SugaROx’s technology is based on 20 years of cutting-edge science by Rothamsted Research and Oxford University. Their innovative biostimulants have a key role to play in helping farmers increase crop productivity and resilience. Field trials conducted over several years show that SugaROx’s unique single molecule T6P biostimulant, a natural plant sugar-based molecule that acts as a signalling compound can increase yield as much as 3-5 times. The product, applied by spray, enables farmers to enhance carbon allocation in the crop. Wyld Connect will provide data from the field to support monitoring the efficiency of applying bio stimulants. “We are delighted to announce this new partnership with SugaROx to bring IoT connectivity via low earth orbiting satellites to Brazilian agriculture,” said Alastair Williamson, CEO Wyld Networks. For further information, please contact: Alastair Williamson, CEO Wyld NetworksE-mail: alastair.williamson@wyldnetworks.com Tel: +44 7 824 997689 About Wyld Networks AB Wyld Networks develop and sell innovative wireless technology solutions that enable affordable connectivity anywhere in the World, addressing the problems for businesses and people regarding the lack of global mobile network coverage. The solutions are mainly targeted to wireless connectivity for the Internet of Things (IoT) and people. Wyld Networks Ltd was formed in Cambridge, UK in 2016 and is a wholly owned subsidiary of Wyld Networks AB. The Wyld Networks share (WYLD) is traded on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB (tel +46 8-5030 1550, email ca@mangold.se). Read more on www.wyldnetworks.com

Update on Phase IV Study: 40 of 50 Patients Recruited

As previously communicated, the Phase IV study ZEQ001 concerning the oral film Zeqmelit® commenced at the end of January. The purpose of the study is to collect scientific data on patient usage of Zeqmelit®. The results will be published in scientific journals to enhance the product's marketing. The recruitment of patients for the study meets AcuCort's high expectations, with 40 patients, out of 50 in total, currently enrolled. "It's always a challenge to recruit patients for drug studies. It's gratifying that our study has already recruited 40 patients in a short time, demonstrating the high interest in the product among allergy patients," says Jonas Jönmark, CEO of AcuCort. The study is running concurrently with the product's market launch in the Nordic region, where allergy patients are provided Zeqmelit® for use when needed for acute allergic reactions. The purpose of the study, an open-label non-randomized low-intervention trial, is to gather valuable scientific data on Zeqmelit® usage from patients previously prescribed corticosteroids in tablet form for self-treatment of acute allergic reactions. The study's results are expected by the end of 2024. "The study aims to show how real patients experience using Zeqmelit®. We believe the scientific findings will be a crucial part of the marketing and upcoming market launches," says Jonas Jönmark, CEO of AcuCort. Dr. Bahram Javizian, the principal investigator of the study and allergist, elaborates on the study's purpose: "We want to understand patients' experiences with this biofilm, such as feeling safe with it, their experience using it, and importantly, whether patients carry the medication with them," says Bahram Javizian.

ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate

This significant milestone marks an important step towards enabling a clinical trial application. The Company is currently focusing on Good Manufacturing Practice (GMP) production and designing the Phase I clinical trial, with the aim to initiate the Phase I trial within the next year. CEO of ExpreS2ion, Bent U. Frandsen, comments, "The completion of the GLP safety study for our ES2B-C001 (HER2-VLP) breast cancer vaccine candidate is a testament to our team's dedication and hard work. This is a significant step forward in our mission to bring a potentially life-saving treatment to patients. We are now focusing our efforts on GMP production and designing the clinical trial, with the goal of initiating clinical trials within the next year. We look forward to driving this project further and making a meaningful impact in the fight against breast cancer." About ES2B-C001 (HER2-VLP)ES2B-C001 represents a novel development in the field of breast cancer therapeutics, specifically targeting human epidermal growth factor receptor 2 (HER2) positive breast cancers. This innovative vaccine is based on proven clinical Phase III-validated technology platforms, leveraging ExpreS2ion's production platform, ExpreS2, and AdaptVac's virus-like particle (VLP) technology. Extensive preclinical data underscore the safety and efficacy of ES2B-C001 across multiple animal models for breast cancer, as documented in the work of Ruzzi et al. (2022) . HER2-positive breast cancer, marked by the overexpression of the human HER2 protein, represents a significant subset of breast cancer cases, impacting a notable proportion of patients. The treatment landscape for HER2-positive breast cancer has witnessed significant advancements, notably with targeted therapies like trastuzumab playing a pivotal role. However, ES2B-C001 sets itself apart by offering a novel approach. By harnessing the patient's immune system, it stimulates the production of polyclonal antibodies tailored to combat HER2-positive breast cancers. This approach not only adds a complementary dimension to existing therapeutic strategies but also holds promise in addressing the complexities of this challenging oncological domain. Certified AdviserSvensk Kapitalmarknadsgranskning AB

The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB

The Nomination Committee proposes that the board shall consist of seven members, without deputies. The Nomination Committee proposes that Eugen Steiner, Cecilia Edström, Pär Gellerfors, Lars Lannfelt, Lotta Ljungqvist and Mikael Smedeby be re-elected as board members and that Anna-Lena Engwall be elected as new board member, each for a term of office until the end of the next annual general meeting. Furthermore, the Nomination Committee proposes that Eugen Steiner be re-elected as chairperson. The board members Ivar Verner and Håkan Englund have informed the Nomination Committee that they are not available for re-election. Anna-Lena Engwall holds a degree in nursing from Karolinska Institutet and a degree in market economics from IHM Business School. She has more than 25 years of experience in the life science and pharmaceutical industry with leading roles in commercialization, marketing and business development and has during her career held several positions at AstraZeneca, Shire and Novartis. Her broad experience, industry knowledge and significant network are expected to provide the board with additional valuable expertise. Anna-Lena Engwall has previously been a member of the board of directors of Lif, Läkemedelsindustriförenings Service AB, and is independent in relation to the Company, its management and its major shareholders. Information on all proposed board members for BioArctic, the Nomination Committee's rationale regarding the proposal for the election of board members and the Nomination Committee's complete proposals to the annual general meeting will be available on the company's website, www.bioarctic.se, in connection with the issuance of the notice to attend the annual general meeting 2024, which is expected to be published around April 24, 2024. The Nomination Committee has been appointed according to the principles adopted by the annual general meeting 2023 and consists of Jannis Kitsakis (chairperson), appointed by the Fourth Swedish National Pension Fund (Swedish: Fjärde AP-fonden), Margareta Öhrvall, appointed by Demban AB and Claes Andersson, appointed by Ackelsta AB. The composition of the Nomination Committee was published on October 20, 2023, and has been made available on the company's website. The members of the Nomination Committee have been appointed by shareholders who together represent approximately 59 percent of the shares and around 84 percent of the votes in the company. The chairperson of the board has been adjunct at the Nomination Committee’s meetings. The Nomination Committee of BioArctic AB (publ) --- The information was released for public disclosure, through the agency of the contact person below, on April 16, 2024, at 15.00 a.m. CET. For further information, please contact: Jannis Kitsakis, chairperson of the Nomination Committee, telephone +46 (0)70 603 80 23 About BioArctic ABBioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

Dolphin Drilling AS - Notice of extraordinary general meeting

(Oslo, 16 April 2024) Dolphin Drilling AS ("Dolphin Drilling", ticker: DDRIL) – An extraordinary general meeting of Dolphin Drilling AS will be held on 30 April 2024 at 10:00 hours (CEST) as a virtual meeting. The notice of the extraordinary general meeting is attached to this release. The notice will be sent to all registered shareholders on 16 April 2024. The notice and all other documents related to the items to be considered at the extraordinary general meeting will, on the same date, be available on Dolphin Drilling's website https://www.dolphindrilling.com/investor-relations and might consequently not be distributed with the notice. To register your attendance or grant a proxy to vote for your shares, please follow the instructions set out in attached notice. We encourage shareholders to give proxy or participate virtually. A guide for online participation is appended to the notice attached hereto.   For further information, please contact: Ingolf Gillesdal, email: ingolf.gillesdal@dolphindrilling.com, tel: +47 920 45 320 Dolphin Drilling is a leading harsh environment drilling contractor for the offshore oil and gas industry. Dolphin Drilling owns a fleet of four high technical standard 4th and 5th generation enhanced Aker H3 and H4 units, Borgland Dolphin, Blackford Dolphin, Paul B. Loyd, Jr. and Dolphin Leader operated by an experienced team with a strong operational track record. The company has offshore and onshore offices and operations in Norway, Scotland, Brazil, and Nigeria.

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On April 15, 2024, BlackRock's holding in Metso’s shares fell below the 5 percent threshold and amounted to 41,159,143 shares or 4.96 percent of total shares and votes. BlackRock's holding through financial instruments in Metso amounted to 1,032,083 shares, which corresponds to 0.12 percent of the total amount of Metso’s shares. On April 15, 2024, BlackRock's total position amounted to 42,191,226 or 5.08 percent of Metso’s shares and votes. Metso’s total number of shares and voting rights is 828,972,440.BlackRock, Inc.’s holdings according to the notification: % of % of shares and voting rights Total of both shares through financial instruments in % (7.A + and (total of 7.B) 7.B) voting rights (total of 7.A)Resulting 4.96% 0.12% 5.08%situation on thedate onwhich thresholdwas crossed orreachedPosition of 5.19% 0.14% 5.33%previousnotification A: Shares and votingrightsClass/type of Number of % ofshares shares and shares and voting voting rights rightsISIN code Direct(SMA Indirect(SMA Direct(SMA Indirect(SMA 9:5) 9:6 and 9:7) 9:5) 9:6 and 9:7)FI0009014575 41,159,143 4.96%SUBTOTAL A 41,159,143 4.96%B: FinancialInstruments accordingto SMA 9:6aType of financial Expiration Exercise/ Physical or Number of % of sharesinstrument date Conversion cash shares and voting Period settlement and rights voting rightsAmerican Depositary N/A N/A Physical 8,969 0.00%Receipt(US5926721094)Securities Lent N/A N/A Physical 1,023,114 0.12% SUBTOTAL B 1,032,083 0.12% Further information: Juha Rouhiainen, Vice President, Investor Relations, Metso Corporation, tel. +358 20 484 3253, email: juha.rouhiainen(a)metso.com   Distribution:  Nasdaq Helsinki Ltd Main media www.metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com, x.com/metsoofficial

Boeing makes its largest purchase of blended Neste MY Sustainable Aviation Fuel to be supplied by EPIC Fuels and Avfuel

Neste Corporation, News, 16 April 2024 Photo: Boeing ecoDemonstrator in flight. Source: BoeingBoeing has agreed to purchase 7.5 million gallons (over 22,700 tons) of blended Neste MY Sustainable Aviation Fuel™  in 2024 to support its U.S. Commercial Airplanes business operations in reducing its greenhouse gas (GHG) emissions. The volume of Neste’s sustainable aviation fuel (SAF) is part of Boeing’s total purchase of 9.4 million gallons of blended SAF, representing Boeing’s largest annual SAF purchase to date, 60% more than in 2023. The fuel blend consisting of 30% SAF, made from renewable waste and residue raw materials such as used cooking oil, and 70% conventional jet fuel, will be supplied to Boeing by EPIC Fuels and Avfuel to support the Boeing ecoDemonstrator program and Boeing’s U.S. commercial operational flights through 2024. “As our focus remains on safety and quality, sustainability continues to be a priority. Sustainable aviation fuel is essential to decarbonize aviation. About 20% of our fuel usage is a SAF blend, and we continue to increase our use of this fuel to encourage growth in the SAF industry. We are also working to make SAF more available and affordable to our commercial airline customers through collaboration, investment, research and policy development,” said Ryan Faucett, Vice President of Environmental Sustainability at Boeing.“Sustainable aviation fuel is a key lever to reduce aviation emissions. Working together with aviation sector leaders like Boeing is crucial in accelerating SAF usage and production. We are proud to support their efforts working together with our partners EPIC Fuels and Avfuel,” said Carrie Song, Senior Vice President, Commercial, Renewable Products at Neste.The total volume of blended SAF purchased will be supplied to Boeing’s commercial operations directly or through book-and-claim. Boeing will receive 4 million gallons (around 12,000 tons) of blended SAF produced by Neste into its fuel farms in the Pacific Northwest. EPIC Fuels, a Signature Aviation company, will supply 2.5 million gallons and Avfuel will provide 1.5 million gallons of blended SAF from Neste. Boeing will also purchase SAF certificates corresponding to the emission reduction provided by the use of 3.5 million gallons of blended SAF produced by Neste through a book and claim system. Book and claim is an accounting process in which a company purchases SAF certificates to displace conventional jet fuel. Instead of putting the fuel into a Boeing fuel farm, distributors will deliver it to nearby airports for use by airlines and other carriers ensuring the corresponding SAF use and related GHG emission reductions. Based on Boeing’s book-and-claim purchases, EPIC Fuels will supply the 3.5 million gallons of blended SAF.Sustainable Aviation FuelSustainable aviation fuel is a renewable aviation fuel providing a more sustainable alternative to conventional, fossil-based jet fuel. Using Neste MY Sustainable Aviation Fuel™ reduces greenhouse gas emissions by up to 80%* over the fuel’s life cycle, compared to using conventional jet fuel. Neste’s SAF is made from sustainably sourced, 100% renewable waste and residue raw materials, such as used cooking oil and animal fat waste. SAF is blended with conventional jet fuel before use and works seamlessly with existing aircraft engines and fueling infrastructure. *) When used in neat form (i.e. unblended) and calculated with established life cycle assessment (LCA) methodologies, such as CORSIA methodology

Notice to attend the Annual General Meeting of Sivers Semiconductors AB (publ)

Notification to attend etc. Shareholders who wish to attend the Annual General Meeting must · be recorded in the share register kept by Euroclear Sweden AB no later than on Monday, 6 May 2024; and · notify the Company their intention to participate no later than Wednesday, 8 May 2024, via mail to the address Setterwalls Advokatbyrå AB, att: Anna Barnekow, Box 1050, 101 39 Stockholm or via e-mail anna.barnekow@setterwalls.se. The notification shall state name, personal identification number/ company registration number, daytime telephone number, number of shares held and proxies if applicable. To be entitled to participate in the Annual General Meeting, shareholders whose shares are held in the name of a nominee must, in addition to providing notification of their participation in the Annual General Meeting, re-register the shares in their own name so that the shareholders are registered in the share register on the record date on Monday, 6 May 2024. This re-registration may be temporary (so-called “voting right registration”) and is carried out through the nominee according to their procedures at a time predetermined by the nominee. Voting rights registration that has been completed by the nominee no later than Wednesday, 8 May 2024, are considered when preparing the share register. Proxies If shareholders wish to attend through a proxy, a written and dated power of attorney signed by the shareholder must be enclosed with the notification. The power of attorney form is available on the Company’s website www.sivers-semiconductors.com.  If the shareholder is a legal entity, a registration certification or an equivalent authorization document must be enclosed along with the notification.  Number of shares and votes As per 15 April 2024, there are a total of 234,649,894 shares in the Company, comprising 234,649,894 ordinary shares, corresponding to in total 234,649,894 votes. There are no shares issued of class C. The Company owns 2,542,860 ordinary shares which may not be represented at the Annual General Meeting. Shareholders’ right to request information The shareholders are reminded of their right, in accordance with Chapter 7 Section 32 of the Swedish Companies Act (2005:551), to request information from the Board and the CEO at the Meeting. For information on how personal data is processed, see:https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf. Proposal for agenda  1. Election of Chairman of the meeting 2. Election of one or two persons to verify the minutes 3. Preparation and approval of the voting list 4. Approval of the agenda 5. Determination as to whether the meeting has been duly convened 6. Address by the CEO and by the Chairman 7. Presentation of the annual report and the auditor’s report as well as the consolidated annual report and the consolidated auditor’s report 8. Resolution on a. adoption of the profit and loss statement and the balance sheet as well as the consolidated profit and loss statement and the consolidated balance sheet b. appropriation of the Company’s profit or loss as set forth in the adopted balance sheet c. discharge of the Board members and the CEO from liability 9. Determination of the number of Board members and auditors10. Determination of fees for Board members and auditors11. Election of Board members and Chairman of the Board of Directors12. Election of auditor13. Resolution on approval of remuneration report14. Approval of allotment of stock options15. Resolution on authorisation for the Board of Directors to resolve on issues of shares and/or convertible bonds Proposals by the Nomination Committee The Nomination Committee has consisted of Joachim Cato, Chairman of the Nomination Committee, representing Erik Fällström via company, Todd Thomson, representing Kairos Ventures, Oscar Bergman, representing Swedbank Robur Fonder AB as well as Bami Bastami, Chairman of the Board of Directors of Sivers Semiconductors AB. Election of Chairman of the meeting (item 1) The Nomination Committee proposes that Advokat Jörgen S. Axelsson is elected as Chairman of the Meeting. Determination of number of Board members and auditors (item 9) The Nomination Committee proposes that the Board of Directors shall consist of five Board members elected by the General Meeting without deputies. The Nomination Committee also proposes that the Company shall have one registered auditing company as auditor. Determination of fees for Board members and auditors (item 10) The Nomination Committee proposes that the total remuneration for the Board of Directors shall amount to SEK 2,665,000 of which SEK 1,050,000 shall be paid to the Chairman of the Board of Directors, SEK 600,000 shall be paid to the Deputy Chairman and SEK 350,000 shall be paid each to of the other members of the Board elected by the General Meeting. The proposed member Todd Thomson waive Board remuneration. The Nomination Committee also proposes that the following remunerations shall be paid for work in the Board of Director’s committees: Audit Committee: SEK 100,000 annually to the Chairman and SEK 50,000 annually to other members, Investment Committee: SEK 60,000 annually to the Chairman and SEK 30,000 annually to other members, and Remuneration Committee: SEK 50,000 annually to the Chairman and SEK 25,000 annually to other members. The Nomination Committee proposes that the audit fees shall be paid in accordance with approved invoices. Election of Board members and Chairman of the Board of Directors (item 11) As members of the Board of Directors until the end of the next Annual General Meeting, the Nomination Committee proposes re-election of Bami Bastami, Tomas Duffy, Erik Fällström and Todd Thomson, and new election of Karin Thurberg. Beth Topolovsky has declined re-election. The Nomination Committee also proposes re-election of Bami Bastami as the Chairman of the Board of Directors and Tomas Duffy as the Deputy Chairman. The Nomination Committee intends to supplement the proposal for board members aiming for up to two additional female board members. Any further proposals for board members will be presented well in advance of the Annual General Meeting. Karin Thurberg Education: Degree of Master of Science in Engineering Physics, KTH. Executive MBA, Uppsala Universitet. Other board assignments: No ongoing board assignments. Previous board assignments: Forsway Scandinavia AB. Other experience: Chief Technology Officer at Acuvi AB. Former Chief Product Officer in JonDeTech Sensors AB and more than 20 years of experience in leading positions at Huawei Technologies Sweden AB and Ericsson. Independent in relation to Sivers Semiconductors and its management: Yes. Independent in relation to the larger shareholders: Yes. Information regarding the other proposed members of the Board of Directors is available on the Company’s website, www.sivers-semiconductors.com. Election of auditor (item 12) The Nomination Committee proposes in accordance with the Remuneration Committees proposal to re-elect Deloitte AB as auditor with authorised public accountant Alexandros Kouvatsos as auditor in charge for the audit. Proposals by the Board of Directors Resolution on appropriation of the Company’s profit or loss as set forth in the adopted balance sheet (item 8 b) The Board of Directors proposes that the Annual General Meeting shall resolve not to distribute any dividends for the financial year 2023 and the distributable profits are carried forward.  Resolution on approval of remuneration report (item 13) The Board of Directors proposes that the Annual General Meeting resolves to approve the Board's report on remuneration in accordance with Chapter 8, Section 53 a of the Swedish Companies Act (2005:551). Approval of allotment of stock options (item 14) The Annual General Meeting 2023 resolved on an incentive program (“P08”) comprising stock options for the Group’s employees (the “Stock Options”). The Chairman of the Board of Directors, also being Executive Chairman of Sivers Semiconductors Inc., has been allotted 400,000 Stock Options in accordance with the resolution of the Annual General Meeting on P08. In addition, the Chairman has been allotted 50,000 Stock Options, conditional upon the Annual General Meetings subsequent approval. As a result thereof, the Board of Directors proposes that the Annual General Meeting shall resolve to approve the allotment of 50,000 additional stock options to the Chairman within the framework of P08. The performance conditions shall not apply to the Stock Options. The proposal means that the Chairman of the Board of Directors, by serving as the  Executive Chairman of Sivers Semiconductors Inc., is granted Stock Options, which entitle the holder to subscribe and purchase shares in the Company. Such transfer is subject to Chapter 16 of the Swedish Companies Act, which means that the above proposal is valid only if it is supported by at least nine tenths of both the votes cast and the shares represented at the Annual General Meeting. Further, the Board of Directors intends to come back at a later date with a proposal for an incentive program for the employees in the Group, to be approved at an Extraordinary General Meeting. Resolution on authorisation for the Board of Directors to resolve on issues of shares and/or convertible bonds (item 15) The Board of Directors proposes that the Annual General Meeting authorises the Board of Directors to, on one or several occasions during the period until the next Annual General Meeting, with or without deviation from the shareholder’s preferential rights, resolve on share issues and/or issues of convertible bonds that involve the issue of or conversion to a maximum of 26,100,000 ordinary shares, corresponding to a dilution of approximately 10.0 per cent of the share capital and the voting rights, based on the current number of shares in the Company. Payment for subscribed shares and/or convertible bonds shall be made in cash, in kind or by way of set-off. The purpose of the authorisation and the reason for the deviation from the shareholders’ preferential rights, is to give the Board of Directors flexibility in the work to secure that the Company in a time-efficient and appropriate way can achieve capital for financing of the operation and to enable continued expansion both organically as well as through acquisitions, alternatively to increase the number of shareholders with one or several owners of strategical importance for the Company. The issuance of shares and/or convertible bonds under this authorisation shall be made at a subscription price according to the prevailing market conditions at the time of the issuance of the shares and/or convertible bonds. A resolution pursuant to this item 15 is only valid if approved by shareholders representing at least two thirds of the votes cast as well as the shares represented at the Annual General Meeting. Documents The annual report and the auditor’s report, the nominating committee motivated statement over the Board of Directors composition as well as other documents under the Swedish Companies Act will be available for the shareholders at the Company’s head office at the address Torshamnsgatan 48 in Kista, Sweden and on the Company’s website www.sivers-semiconductors.com, during at least three weeks before the Annual General Meeting. Copies of the documents will be sent free of charge to shareholders who so request and who provide their mailing address. __________  Kista in April 2024Sivers Semiconductors AB (publ)The Board of Directors

Stora Enso Oyj: Notification of Change in Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act (15 April 2024)

Stora Enso Oyj has received a notificationpursuant to chapter 9, section 5 of the Securities Market Act fromBlackRock, Inc on 16 April 2024. On 15 April 2024, BlackRock's total holding, including holding through financial instruments, in Stora Enso’s shares fell below the 5 percent threshold. +----------------+--------------+-----------------------------+---------------+| |% of shares |% of shares and voting rights|Total of both || |and voting |through financial instruments|in % (7.A + || |rights |(total of 7.B) |7.B) || |(total of 7.A)| | |+----------------+--------------+-----------------------------+---------------+|Resulting |Below 5% |Below 5% shares |Below 5% shares||situation on the|shares | | ||date on | |Below 5% voting rights |Below 5% voting||which threshold |Below 5% | |rights ||was crossed or |voting rights | | ||reached | | | |+----------------+--------------+-----------------------------+---------------+|Position of |4.87% shares |0.17% shares |5.05% shares ||previous | | | ||notification |Below 5% |Below 5% voting rights |Below 5% voting||(if applicable) |voting rights | |rights |+----------------+--------------+-----------------------------+---------------+ +------------+--------+---------+-----------------+----------------------+|A: Shares ||and voting ||rights |+------------+--------+---------+-----------------+----------------------+|Class/type |Number |% of shares and voting rights ||of |of | ||shares |shares | || |and | || |voting | || |rights | |+------------+--------+---------+-----------------+----------------------+|Direct |Indirect|Direct |Indirect || | | | ||(SMA 9:5) |(SMA 9:6|(SMA 9:5)|(SMA 9:6 and 9:7)|| |and 9:7)| | |+------------+--------+---------+-----------------+----------------------+|FI0009005961| |Below 5% | |Below 5% shares || | |shares | | || | | | |Below 5% voting rights|| | |Below 5% | | || | |voting | | || | |rights | | |+------------+--------+---------+-----------------+----------------------+|SUBTOTAL A |Below 5% |Below 5% shares || |shares | || | |Below 5% voting rights || |Below 5% | || |voting | || |rights | |+------------+--------+---------+-----------------+----------------------+ B: FinancialInstrumentsaccordingto SMA 9:6aType of Expiration Exercise/ Physical Number % of sharesfinancial date Conversion or of and votinginstrument Period cash shares rights settlement and voting rightsAmerican N/A N/A Physical Below 5% Below 5%Depositary shares sharesReceipt(US86210M1062) Below 5% Below 5% voting voting rights rightsSecurities N/A N/A Physical Below 5% Below 5%Lent shares shares Below 5% Below 5% voting voting rights rightsCFD N/A N/A Cash Below 5% Below 5% shares shares Below 5% Below 5% voting voting rights rights SUBTOTAL B Below 5% Below 5% shares shares Below 5% Below 5% voting voting rights rights Stora Enso has two series of shares. Each A share and every ten R shares carry one vote. Stora Enso has 175,979,614 A shares and 612,640,373 R shares in issue. The company does not hold its own shares. The total number of Stora Enso shares is 788,619,987 and the total number votes at least 237,243,651. Full chain of controlled undertakings through which the voting rights and financial instruments are effectively held starting with the ultimate controlling natural person or legal entity is presented in the enclosed annex. Part of the global bioeconomy, Stora Enso is a leading provider of renewable products in packaging, biomaterials and wooden construction, and one of the largest private forest owners in the world. We create value with our low-carbon and recyclable fiber-based products, through which we support our customers in meeting the demand for renewable sustainable products. Stora Enso has approximately 20,000 employees and our sales in 2023 were EUR 9.4 billion. Stora Enso shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded in OTC Markets (OTCQX) in the USA as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors STORA ENSO OYJ

BPC assumes full ownership of Chinese joint venture, renamed BPC Instruments (Zhejiang) Co Ltd

CEO at BPC, Dr. Jing Liu, comments: “The journey of establishing a dynamic and loyal team in China to promote BPC’s products and provide technical support has been a rewarding four-year endeavor. Thanks to the dedication and hard work of our Chinese team members and their mentors from Sweden. The joint venture has achieved remarkable success in a relatively short period, even amidst the challenges of the pandemic. The transition to full ownership of the joint venture is a well-planned and executed step that positions BPC for expanded opportunities in both the Chinese and international markets.” As communicated in the memorandum in connection to BPC Instruments AB’s IPO, BPC Instruments AB and Dr. Jing Liu formed a joint venture in July 2019 called BPC Instruments (Haining) Co Ltd. The ownership was split at 30 percent and 70 percent respectively and aimed at strengthening the market penetration of BPC’s products in China and establishing a supply chain. In November 2021, the parties signed a mutual shareholder agreement stipulating that BPC Instruments AB would acquire full ownership of the joint venture by July 2024 at the latest. This agreement has been fulfilled, and BPC now owns 100 percent of both the votes and capital in the joint venture, which has been renamed BPC Instruments (Zhejiang) Co Ltd. The Chinese joint venture has played a pivotal role as a strategic business partner, facilitating BPC’s expansion and market penetration, as well as combating infringement in China, while also complementing its supply chain. Over the years, the joint venture has cultivated a professional and dedicated team, fostering seamless collaboration with BPC and contributing significantly to the Company’s market leadership in China. The expansion is assessed by the Board of Directors as a cost-efficient step to futureproof BPC’s long-term market leadership position in China and position BPC for broader business opportunities in international markets. As a subsidiary of BPC, the financial performance of the joint venture will be consolidated with BPC’s figures starting from the second quarter of this year. For more information regarding BPC Instruments, please contact: Dr. Jing Liu, CEO BPC Instruments AB Tel: +46 (0) 46 16 39 51 E-mail: ir@bpcinstruments.com About BPC Instruments AB BPC Instruments is a global Swedish-based pioneering technology company developing and offering analytical instruments enabling more efficient, reliable, and higher quality research and analysis for industries in renewable bioenergy and environmental biotechnology. The result is not only higher accuracy and precision, but also a significant reduction in time consumption and labor requirement for performing analysis. BPC Instruments’ innovative products offer high-quality hardware and software based on deep knowledge and experience of target applications. The solutions are the first of their kind, making the company a pioneer in its field. Today, BPC Instruments exports to nearly 70 countries around the world. BPC is listed on the Spotlight Stock Market in Sweden. For more information, please visit BPC’s webpage: www.bpcinstruments.com

Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients

The phase 2 trial is part of Curasight’s collaboration with Curium for uTRACE[®] in prostate cancer, announced in May 2023 and the first patient is expected to be dosed in Q2 2024. The trial is aimed at providing clinical insight into the use of uTRACE[®] as a non-invasive way of providing more accurate diagnosing and grading of prostate cancer, an area with a recognized high unmet medical need. “The acceptance of the CTA illustrates the strong progress being made in developing uTRACE[®] as a potential solution providing better diagnosis and categorization of tumors for prostate cancer patients. Today’s news is also testament to the positive collaboration we have with Curium” said Curasight’s CEO Ulrich Krasilnikoff. “We look forward to dosing the first patient in this phase 2 trial with Copper-64 uPAR-PET and to continuing momentum in our efforts to bring uTRACE[®] as a new option for patients.” About the Phase 2 trial with uTRACE[®] in prostate cancer The primary objective of the phase 2 trial is to investigate Curasight’s first-in-class PET tracer, 64Cu-DOTA-AE105 as a non-invasive grading tool of prostate cancer patients that are followed in active surveillance. Patients in active surveillance are continuously monitored for changes in the aggressiveness of their prostate cancer and can be followed for years without identifying the need for treatment. The trial design is informed from research and earlier studies with uTRACE[®] as well as protocol discussions with the US Food and Drug Administration (FDA).  The phase 2 trial is part of the development framework agreed under the deal with Curium.  About the uPAR diagnostic platform The uTRACE[®] platform is part of Curasights uPAR radiopharmaceutical theranostic solution, made up of its uTRACE[®] diagnostic technology and its uTREAT[®] radioligand therapy technology. In prostate cancer, uTRACE[®] is presently developed for diagnostic purposes only. Curasight’s ambition is to develop both uTREAT[®] and uTRACE[®] to improve diagnosis and treatment solutions of several solid cancers.

Green Landscaping Group strengthens its presence in southern Germany through acquisition of Gartenidee Kuchler GmbH

17 April 2024, at 07:00 CEST Green Landscaping Group (Publ) acquires Gartenidee Kuchler GmbH, a company providing landscaping and maintenance services for outdoor environments in the greater Munich area in Bavaria, Germany. The company was established in 1999 and is today run by the founder Wolfgang Kuchler together with over 100 employees. Gartenidee Kuchler is based in Geisenfeld, Germany and provides landscaping, maintenance, and winter services for outdoor environments around Ingolstadt and Munich. The company has also established a strong market position in creating green roofs. Sales in 2023 amounted to approximately EUR 14.6 million. "With the acquisition of Gartenidee Kuchler, Green Landscaping Group has established itself in the attractive Greater Munich area and created a solid base for further expansion in Bavaria. The company has deep roots in southern Germany and complements our regional reach very well. Gartenidee Kuchler has a reputation for high quality services, excellent customer relations and a pleasant company culture. We are pleased to welcome Mr. Kuchler and all employees to us,” comments Stephan Stieglauer, Country Manager, Green Landscaping Group Germany. “We look forward to becoming part of the Green Landscaping Group. With this step, we ensure that Gartenidee Kuchler GmbH is prepared for the future and remains a reliable partner for our customers, employees, and suppliers. During this process, we have got to know several employees of the Green Landscaping Group and have built up the relationship of trust necessary for such a transaction. In Green Landscaping, we have found a partner who understands our business and market and who can continue to develop the company with our best interest in mind. Joining the Green Landscaping Group therefore feels like a natural step for us. We are very motivated and will do our part to represent Bavaria in a worthy manner," says Mr. Wolfgang Kuchler, Co-Owner, and CEO, Gartenidee Kuchler. Green Landscaping Group acquires 100 percent of the shares Gartenidee Kuchler GmbH with immediate access. The acquisition is financed with cash and through the transfer of shares in Green Landscaping Group AB. The previous owners of Gartenidee Kuchler are now shareholder in Green Landscaping Group AB. The information was submitted for publication, through the agency of the contact person, on 17 April 2024, at 07:00 CEST. For more information:Magnus Larsson, Head of Investor Relations, Green Landscaping Group AB+46 70 270 52 83, magnus.larsson@glgroup.se Stephan Stieglauer, Regional Manager Germany, Green Landscaping Group +49 151 5046 3119, stephan.stieglauer@greenlandscaping.de Green Landscaping Group AB (Publ) is a home for entrepreneurs. The service areas it is involved in are landscaping and construction, ground maintenance and snow & ice removal. The Group has more than 2 000 employees and net sales amounted to SEK 4.8 billion. The shares are listed on Nasdaq Stockholm with the ticker GREEN. For more information visit www.greenlandscaping.com. Gartenidee Kuchler GmbH was founded in 1999 in Geisenfeld and is today run by the founder, Mr. Kuchler together with more than 100 employees. The company provides landscaping, maintenance, and winter services for outdoor environments as well as green roofs. For more information visit www.gartenidee-kuchler.com

Nel ASA: First quarter 2024 financial results

Quarterly highlights · Nel ASA (Nel) reported revenue in the first quarter 2024 of NOK 387 million, up 14% from the first quarter 2023 (Q1 2023: 341). Revenue was positively impacted by payments related to the renegotiation of the Nikola supply agreement and negatively impacted by a lack of major milestones on alkaline electrolyser customer projects in the quarter. · EBITDA in the quarter was NOK -16 million (Q1 2023: -121). The quarter included a positive impact of NOK 96 million from renegotiation of Nikola supply agreement. · Net loss was NOK -22 million (Q1 2023: -192). The improvement from the same quarter last year was mainly explained by the improved EBITDA and the same quarter last year included NOK -69 million fair value adjustment from shareholdings in Everfuel. · Order intake in the quarter amounted to NOK 459 million (87% from electrolyser), in line with the corresponding quarter last year (Q1 2023: 467). · Order backlog was NOK 2 437 million (87% related to electrolyser) at the end of the quarter, down 13% from the first quarter of 2023 and down 1% from previous quarter. · Cash balance was NOK 3 260 million at quarter end (Q1 2023: 4 621). · Subsequent to the quarter: · April 4th: Nel awarded up to USD 41 million in investment tax credits from DoE, bringing the total support for a Michigan expansion up to about USD 170 million The first quarter 2024 results show that the company is on the right path towards a positive EBITDA, and the Alkaline electrolyser division achieved an important milestone reaching a positive EBITDA of NOK 106 million. The good results can partly be explained by Nel’s renegotiated supply agreement with Nikola. “Our revenues and EBITDA continue to improve, showing that the business model works with scale,” says Nel’s President and CEO, Håkon Volldal. In February, Nel announced that Fortescue had taken over Phoenix Hydrogen Hub from Nikola, including electrolyser stacks already delivered by Nel. “I am happy we managed to renew our relationship with Nikola and that we are partnering up with Fortescue on their Phoenix Hydrogen Hub, which will become one of North America’s largest electrolyser systems,” he says. In March, Nel was awarded USD 75 million from the US Department of Energy (DoE) and the State of Michigan to fund its planned electrolyser facility in Plymouth Charter Township, a suburb of Detroit, Michigan. After the first quarter of 2024, Nel was awarded an additional USD 41 million in investment tax credits as part of the Qualifying Advanced Energy Project Tax Credit program. In total, Nel has secured close to USD 170 million in accumulated support from the State of Michigan and the Department of Energy for its planned Michigan facility. “The support we secured this quarter increases the attractiveness of investing and expanding our capacity and capability in the US,” says Nel’s President and CEO, Håkon Volldal. The expansions of Nel’s existing electrolyser manufacturing facilities at Herøya and Wallingford are also moving ahead according to plan. “We have a large pipeline of prospective projects that continues to mature, and we are ready and well positioned to scale up production capacity significantly as soon as the demand picks up,” says Volldal. As communicated in the previous quarterly presentation, Nel has initiated a process to explore and prepare for a potential spin-off and separate listing of its Fueling division. These preparations are moving forward according to plan. The first quarter 2024 report and presentation are enclosed and available on newsweb.no  (Ticker: NEL) and nelhydrogen.com . The presentation will be a virtual event only, followed by a Q&A session, and can be accessed on the company’s website www.nelhydrogen.com/quarterly-presentation/ or by following this link.  A recording of the presentation will be made publicly available following the event. ENDS  For additional information, please contact: Kjell Christian Bjørnsen, CFO, +47 917 02 097 About Nel ASA | www.nelhydrogen.com Nel has a history tracing back to 1927 and is today a leading pure play hydrogen technology company with a global presence. The company specializes in electrolyser technology for production of renewable hydrogen, and hydrogen fueling equipment for road-going vehicles. Nel’s product offerings are key enablers for a green hydrogen economy, making it possible to decarbonize various industries such as transportation, refining, steel, and ammonia. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. This information was issued as inside information pursuant to the EU Market Abuse Regulation, and was published by Kjell Christian Bjørnsen, CFO, at NEL ASA on the date and time provided.

Sweco wins EUR 6 million project for new light rail in Finland

The new tramway will extend for approximately 12 kilometres with 19 stops from the harbour via the city centre to the Varissuo area. The tramway will increase the capacity of Turku’s public transport, accelerate the city’s growth and support the achievement of the city’s climate goals.  “We are excited to be involved in designing the new tramway in Turku. This is a comprehensive urban development project that will impact the development of the city, and its urban region, for decades to come. The establishment of a sustainable public transport system will contribute to Turku’s goal of being carbon neutral by 2029 and, in the future, becoming one of the world’s leading cities in the climate transition and in protecting nature,” says Thomas Hietto, President of Sweco Finland. The development phase will start in April 2024 and based on a preliminary estimation, construction will take place between 2026 and 2031. Passenger traffic is expected to start in the early 2030s. The large-scale project will be implemented through an alliance model consisting of Sweco, GRK Suomi, Ramboll Finland and NRC Group Finland.  Sweco is a leading European consultancy in transportation, with 6,000 experts in mobility and active travel, electrification and fossil-free fuels, traffic safety, and climate adaptation of infrastructure. Sweco has extensive experience from rail projects across Europe and is part of expanding the light rail system in the City of Tampere  and Helsinki in Finland.  

Volvo Group – the first quarter 2024

     · In Q1 2024, net sales were on the same level as in the previous year and amounted to SEK 131.2 billion (131.3). Also when adjusted for currency movements, net sales were flat. · Adjusted operating income amounted to SEK 18,159 M (18,566), corresponding to an adjusted operating margin of 13.8% (14.0). There were no adjustments in Q1 2024. In Q1 2023, a negative effect of SEK 1,300 M was excluded from adjusted operating income. · Reported operating income amounted to SEK 18,159 M (17,266). · Currency movements had a negative impact on operating income of SEK 346 M. · Earnings per share amounted to SEK 6.92 (6.35). · Operating cash flow in the Industrial Operations amounted to SEK 8,896 M (5,004). · Return on capital employed in the Industrial Operations amounted to 37.7% (30.3)    Press and Analyst Conference CallAn on-line presentation of the report, followed by a question and answer session will start at 09.00 CEST. Link to webcast: https://qreport.volvogroup.com. More information, including an interview with CEO Martin Lundstedt, is soon available on https://www.volvogroup.com/en/investors.html.       April 17, 2024       Aktiebolaget Volvo (publ) 556012-5790 Investor RelationsSE-405 08 Göteborg, SwedenTel +46 31 66 00 00www.volvogroup.com Contact Media Relations:Claes Eliasson                         +46 765 53 72 29 Contacts Investor Relations:Johan Bartler                           +46 739 02 21 93Anders Christensson               +46 765 53 59 66    This information is information that AB Volvo (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 07.20 CEST on April 17, 2024.     For more information, please visit volvogroup.com For frequent updates, follow us on Twitter: @volvogroup  The Volvo Group drives prosperity through transport and infrastructure solutions, offering trucks, buses, construction equipment, power solutions for marine and industrial applications, financing and services that increase our customers’ uptime and productivity. Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions. The Volvo Group is headquartered in Gothenburg, Sweden, employs more than 100,000 people and serves customers in almost 190 markets. In 2023, net sales amounted to SEK 553 billion (EUR 48 billion). Volvo shares are listed on Nasdaq Stockholm.

Wihlborgs lets 4,800 m² at Ideon in Lund

One of the leases at Cube comprises 3,000 square metres with occupancy in November 2024. The other lease concerns an existing tenant that will relocate within Wihlborgs’ portfolio in Lund from 400 square metres to 800 square metres of newly renovated premises after the summer. Both leases are for five years. At Bricks, a public sector tenant will relocate within Wihlborgs’ portfolio from 400 square metres in Malmö to just over 1,000 square metres in Lund with scheduled occupancy at the start of 2025. The lease is for six years.  When Wihlborgs acquired the Node, Bricks and Cube properties (Nya Vattentornet 2–4) on Mobilvägen between 2018 and 2019, the area was clearly impacted by the long-term dominance of mobile-phone companies with relatively large vacancies leading to a selection of premises. Today, the properties comprise a variation of larger and smaller premises, efficient floor plans and some 50 companies operating in various areas. Previously dominant industries such as electronics and IT have gradually been supplemented with fields such as electrification, food tech, medtech, city planning, and information and communication technology. Work on the properties has resulted in increased demand in the area that currently has an occupancy rate of over 90 percent. “It is pleasing to see how our ambition to create a new, complementary product offering and environments for innovation, networking and collaboration in the area has become a reality. The clusters we are forming not only create scope for ideas and growth, but also promote business in the region and increase the attractiveness of the area, which has become a natural part of Lund Innovation District and Ideon Science Park,” says Ulrika Hallengren, CEO of Wihlborgs. Wihlborgs Fastigheter AB (publ)

Circio terminates TG01 cancer vaccine license option agreement with IOVaxis in China for non-payment

Oslo, Norway 17 April 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy and cancer vaccines, announces that it has terminated the exclusive TG01 KRAS cancer vaccine license option agreement with IOVaxis therapeutics in Greater China and Singapore On 1 March 2024, IOVaxis Therapeutics´ IND-application to initiate TG01 clinical development in China was approved, triggering a USD 3 million license fee to Circio. Circio initially granted IOVaxis a six-month payment extension following an immediate USD 300,000 down-payment. However, despite multiple exchanges with IOVaxis, the agreed USD 300,000 down-payment has not been made and no plan has been provided to do so. “IOVaxis has not met the first financial payment milestone and Circio has therefore decided to terminate the TG01 license agreement in China. The three collaborative clinical studies in the USA and EU are proceeding according to plan and remain the primary TG01 development priority,” said Dr. Erik Digman Wiklund, CEO at Circio. “Circio will now seek alternative partnering options in China for the TG01 program. Should IOVaxis demonstrate in the future that it has secured the required capital to cover its obligations and initiate TG01 clinical development, then discussions can potentially be reactivated to find a path forward.” Circio currently has three ongoing collaborative TG01 clinical trials with industry and academic partners in the USA and Europe in RAS-mutated multiple myeloma, pancreatic and lung cancer, which are unaffected by this license termination in China.

Circio announces in vivo proof-of-concept for its circVec circular RNA platform technology and reinforced gene therapy focus

· circVec results demonstrate significantly enhanced protein expression and durability vs. conventional mRNA-based expression with DNA vectors in vivo · Circio´s R&D strategy is centered on gene therapy, where circVec can deliver substantial improvement over current gold-standard approaches · Circio has selected AAV-based gene therapy for Alpha-1-antitrypsin deficiency (AATD) as the lead program · Circio aims to secure the first circVec partnering deal within twelve months · The recent circVec data and a financial update are presented in a company update webcast available on Circio´s website      Oslo, Norway 17 April 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, today announces that it has established technical in vivo proof-of-concept for its proprietary circVec circular RNA platform by demonstrating statistically significant improvement in durability over mRNA-based expression. The circVec technology has broad potential, particularly to enhance the potency and reduce cost of current gold-standard gene therapy, and the R&D strategy is centered on this rapidly expanding therapeutic area. “The circVec 2.1 design is performing very well in vitro, and this is now being translated in vivo with demonstration of enhanced expression level and durability for circVec 2.1 DNA vectors in mouse models. This provides an important technical proof-of-concept for Circio´s technology platform in a real biological system, which we expect will translate into improved gene therapies for patients in the future,” said Dr. Thomas B Hansen, CTO at Circio. “This new data indicate that circVec has the potential to outperform current gold-standard gene therapy approaches, and we are rapidly advancing to design and test circVec in several AAV and DNA-based therapeutic vector formats.”   In parallel to the in vivo characterization, Circio has tested and incorporated further features into the circVec platform. A dual-function ‘remove-&-replace’ concept has been designed and validated in vitro for Alpha-1-antitrypsin deficiency (AATD), with the ability to both replace functional AAT protein and remove the disease variant. This genetic disease causes severe symptoms in the lung and liver, and there are currently no satisfactory therapeutic options available. AATD represents a major unmet medical need and there are over 200,000 patients affected in the USA and EU. “Establishing a robust technical in vivo proof-of-concept is a major milestone for the development of the circVec platform. Based on this validation, Circio will now explore which targets and diseases represent the best therapeutic and commercial opportunities,” said Dr. Erik Digman Wiklund, CEO at Circio. “Initially, we have selected AATD as the lead program where our unique ‘remove-&-replace’ circVec design has an opportunity to solve two pathological issues in a single differentiated product. Our aim is to establish in vivo proof-of-concept in AATD within the next twelve months and select a lead therapeutic candidate by the middle of next year. We are confident that circVec can be highly effective in AATD and produce novel gene therapies that outperform current approaches.” To Circio´s knowledge, circVec 2.1 far exceeds other known intra-cellular circRNA-based expression systems, both in terms of circRNA biogenesis efficiency and protein yield. The platform still has further potential, and Circio is continuously improving the technology towards circVec 3.0 and beyond. The platform is protected by deep internal expertise and know-how, with three patents protecting the core technological features filed to date, and additional applications in progress. “Although AATD is Circio´s lead internal focus, we are continuously exploring new applications and disease targets to build and broaden our technology platform and have several ongoing external dialogues to identify opportunities for future collaborations. Circio is currently working to address specific questions and requests from these prospective partners and aim to complete our first business development transaction within the next twelve months,” said Dr. Lubor Gaal, CFO and Head of Business Development at Circio. The recent circVec data, as well as a financial update and information about the intended fundraising during Q2 2024, are presented and discussed in a webcast available via Circio´s webpage and the Redeye platform link: Link to webcast - access via Redeye  Circio company update 17 April PDF.pdf 

Metso’s energy-efficient Vertimill just got bigger: over 50% more power than the previous models

Metso is excited to introduce the world’s most powerful vertical screw type stirred mill, the Metso Vertimill[®] 7000. Developed as a solution to lower total cost of ownership, the large mill allows for more available grinding power. One Vertimill® 7000 grinding mill replaces the need for multiple smaller stirred mills to achieve the same power output. “The Metso Vertimill[® ]7000 features the same high energy efficiency as the previous models, but with over 50% more power. In addition, it is equipped with double door access, so less space is needed to open the doors. The unit has also been equipped with side discharge grinding media ports to avoid double handling of the media during service operations. Just like the other Vertimill[®] models, this new giant can be used for grinding almost any type of ore bodies. Typically, these robust stirred mills are used for regrinding, secondary and tertiary grinding as well as for lime slaking,” explains Graham Davey, Director, Stirred Mills at Metso. “Metso Vertimill[®] stirred mills offer the lowest total cost of ownership thanks to their superior energy efficiency, long maintenance intervals and improvement in the profitability of concentrators. With over 500 installations worldwide, the Vertimill[®] has proved to be a reliable grinding solution,” notes Davey. Vertimill[®] grinding mills are part of Metso’s Planet Positive  offering and provide up to 40% better energy efficiency than ball mills. The robust and vertical design benefits customers through long component lifetimes and as much as a 50% reduction in plant footprint. For stirred milling technologies, Metso offers a wide portfolio: Vertimill[®], HIGmill™, and Stirred Media Detritor (SMD) allowing the optimum mill type to be selected for the process duty. The Metso stirred mills are suitable for a large range of feed and product sizes. All our stirred mills are part of the Planet Positive  product portfolio, thanks to the sustainability benefits they deliver. Additionally, our portfolio includes solutions for wear monitoring. VertiSense™ complements Vertimill[®] stirred mills by enabling the real-time wear monitoring of screw liners and maximizing operational efficiency through intuitive software and analytics. Find out more about our Vertimill[® ]offering on our website . Further information: Graham Davey, Director, Stirred Mills, Metso, tel. +44 777 081 0973, email: graham.davey(at)metso.com Helena Marjaranta, Vice President, Communications and Brand, Metso, tel. +358 20 484 3212, email: helena.marjaranta(at)metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com , x.com/metsoofficial 

Essity joins United Nations initiative to promote inclusive advertising

The Unstereotype Alliance seeks to eradicate harmful stereotypes from advertising and media to help create a more equal world. Convened by UN Women, an organization within the United Nations dedicated to gender equality and the empowerment of women, the Alliance collectively acts to empower people in all their diversity by using advertising as a force for good to drive positive change all over the world.  Essity and its brands have a long history of breaking taboos, raise awareness against bias and act for equality. For example through campaigns by its feminine care brands Bodyform/Libresse/Nosotras/Saba, and the global market leading incontinence care brand TENA, such as “Blood Normal ” which was the first TV advertisement for period products to replace blue liquid with a more representative red, “Viva La Vulva ” and “Befriend your Body” which helps normalize the conversation about the female body and “The Last Lonely Menopause ” which encourages conversations about menopause.   “Essity has presence in 150 countries, and we take great responsibility in building our brands with our consumers and customers in a responsible and inclusive way. By joining the Unstereotype Alliance we want to contribute to accelerating progress and look forward to collaborating with UN Women and peers worldwide to empower people in this endeavor”, says Tuomas Yrjölä, President Global Brand, Innovation & Sustainability at Essity.   Essity has been a partner to the United Nations Foundation since 2016 with the aim of contributing to the achievement of the Sustainable Development Goals (SDGs), with Goal 5: Gender Equality being one of Essity’s prioritized SDGs.   For information about the Unstereotype Alliance, go to: http://www.unstereotypealliance.org 

Proact becomes the first partner to deliver NetApp's Data Protection and Security Assessment service

The NetApp Data Protection and Security Assessment is available for customers both as a standalone security assessment and as a recurring security validation service for businesses and organisations running on NetApp storage infrastructure. The service enhances the resilience and security of our customers' storage by pinpointing recovery risks, validating data protection policies, and addressing security gaps.  “As one of NetApp's largest EMEA partners and launch partner for DPSA, we are thrilled about the opportunity to combine Proact's extensive experience and capabilities with the DPSA frameworks and reporting standards from NetApp. I am also excited about our contribution to the development of DPSA based on our technical knowledge and understanding of customer needs, says Danny Duggal, Head of Cybersecurity Business & CISO Operations at Proact. "This will benefit our customers as the service will bring yet another dimension to how we can help them build a multi-layered defense against cyber threats.” "Proact meets our high requirements for capabilities to conduct the service on behalf of NetApp, ensuring that our joint customers utilise all the security features available to protect their data, to make use of next-level security reporting, and to enable fast recovery in case of incidents," says Jenni Flinders, Senior Vice President, Worldwide Partner Organization, at NetApp. “It also underscores the strength of both our partnership with Proact and their advanced skills within NetApp technologies.” The DPSA service is available in the Nordic region (Sweden, Norway, Denmark and Finland) as of 1 April 2024, with an ambition to scale across all countries within the Proact group during 2024.

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

Uppsala, Sweden – April 17, 2024 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent specifically related to OX640, Orexo’s nasal epinephrine powder product based on the AmorphOX® drug delivery platform. In August 2023, the USPTO granted the first patent for OX640 in the US, providing protection until May 2041. The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term, now extending until November 2042. Orexo has multiple patent applications filed on a global basis and expects to continuously strengthen the patent portfolio for OX640. Nikolaj Sørensen, President and CEO, said: “Once again, I am pleased with the USPTO recognising the inventiveness of our OX640 product and the AmorphOX technology. This is the eighth patent based on the technology, underscoring its uniqueness and value. In parallel, we continue to broaden the applications of AmorphOX by testing the technology with new substances, which is expected to lead to more patents. The extended exclusivity for OX640 build additional long-term value and improves the attractiveness for potential partners for commercialization in the US market.” For further information, please contact: Orexo AB (publ.) Nikolaj Sørensen, President and CEO Lena Wange, IR & Communications DirectorTel: +46 (0)18780 88 00 Tel: +46 (0)18780 88 00Email: ir@orexo.com Email: ir@orexo.com About OrexoOrexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US. For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.  About AmorphOX® Orexo’s proprietary drug delivery platform, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure. About OX640 OX640 is based on AmorphOX and its powder-based technology provides excellent chemical and physical stability. In addition to providing allergic patients with a more convenient, needle-free alternative to auto-injectors currently on the market, an epinephrine product that provides greater flexibility in relation to how it can be handled and stored should provide significant benefits to patients and healthcare systems worldwide. The information was submitted for publication at 8 a.m. CET, on April 17, 2024.

Simone Margulies appointed new President and CEO of Axfood

Simone Margulies will from 15 August 2024 succeed Klas Balkow as President and CEO of Axfood. Simone has been working in different roles within the Axfood Group during eight years and has been a member of Axfood’s Executive Committee for four years. Currently, she is Managing Director of Hemköpskedjan AB, which consists of Hemköp and Tempo, and prior to that her role was Deputy CEO of Axfood’s purchasing and logistics company Dagab. In total, Simone has more than 18 years of experience in food retail. – Following a comprehensive recruitment process, I am very happy to announce that Simone Margulies is assuming the role as President and CEO of Axfood. Simone is a passionate and engaged leader with a strong commercial drive and a focus on employees, customers and the business. She has extensive experience from food retail and knows Axfood well after her eight years in the Group. She is the right person to continue to develop Axfood for the future, together with the team, says Axfood’s Chairman of the Board Thomas Ekman. – It is with great joy and humbleness that I take on the role as President and CEO of Axfood. There is so much capacity within the entire Axfood Group, and my role will be to create the necessary conditions for the organisation to continue to develop the business and deliver on the large development programs that we are carrying out. I am very much looking forward to being a part of and writing the next chapter in Axfood’s history, says Axfood’s appointed President and CEO Simone Margulies. To facilitate the best possible handover, Axfood’s current President and CEO Klas Balkow will be available until year-end 2024. The recruitment process for Simone’s successor in the role as Managing Director of Hemköpskedjan is initiated immediately. The information herein is such that Axfood AB (publ) is required to make public in accordance withthe EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person listed above, at 8:10 a.m. CET on 17 April 2024.This document is an English translation of the Swedish original. In the event of any discrepancies, the Swedish version shall govern.

SyntheticMR and SimonMed Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from SyntheticMR’s SyMRI NEURO Software at SimonMed Facilities.

SimonMed has currently 9 installed scanners in three states with synthetic capability from SyMRI NEURO: Arizona, California, and Illinois. The expansion will add 10 scanners to include three new states: Florida, Nevada, and Colorado. More will follow. SyntheticMR’s unique SyMRI technology supports a faster MR imaging workflow and allows doctors and patients to follow disease progression and therapy efficacy with more accuracy. It provides tissue maps, volumes, and industry-first myelin measurements that give healthcare professionals the ability to provide objective decision support. “We anticipate the addition of synthetic capability from SyMRI NEURO on scanners across many more SimonMed facilities,” said Dr. Lefkowitz, Medical Director of MRI at SimonMed. “We are now using SyMRI’s Quantitative Neuro Reports routinely to draw attention to the most important global metrics which arise from synthetic: brain parenchymal fraction (BPF) and myelin-correlated parenchymal fraction (MyCPF). Both are important metrics of brain health, with the MyCPF providing a critical qualitative component that goes beyond simple gross brain volume.” Since initial trials began in January 2020 and licensure in August 2020, SimonMed has used SyMRI NEURO not just for routine substitution of synthetic for conventional images (e.g. synthetic minus T2 and T2-FLAIR), but to study the myelin composition of WM lesions.  We continue to research additional synthetic-based investigative parameters that will serve to further characterize brain tissue as FDA 510(k) clearance is achieved. “By broadening SyMRI's reach to more states and scanners, this partnership reflects our joint commitment to pioneering technology that places the patient's experience at the heart of healthcare innovation,” says Jared Dixon, President of Sales, NAM at SyntheticMR Inc. “SimonMed's dedication to excellence ensures that patients and their providers receive nothing short of the best-in-class solutions, enriching lives and advancing healthcare standards." SimonMed, with contributions from SyntheticMR, has integrated SyMRI’s Quantitative Neuro Reports into semi-automated PowerScribe templates with autotexts and autofills to facilitate reporting. These serve to incorporate 6 distinct quantitative metrics of brain health based on an age-matched reference population. This work complements SimonMed’s contributions to personalized imaging for early diagnosis and treatment of disease spearheaded by its SimonONE division. SimonMed remains at the forefront of innovation and research in radiology and continues to pioneer research for more accurate results and an improved patient experience. About SimonMedHeadquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient medical imaging providers and radiology practices in the United States. SimonMed has approximately 170 sites across 11 states and over 200 subspecialty-trained radiologists. SimonMed offers the full modality of diagnostic scans, including 3T MRI, CT, ultrasound, 3-D mammography, PET/CT, nuclear medicine, DEXA, X-rays, among others. The company uses the newest, most advanced, diagnostic imaging technologies while maintaining affordability and accessibility. SimonMed is a worldwide leader in the clinical use of AI to improve diagnoses with one of the largest global deployments to enhance early breast cancer detection and in the evaluation of brain disorders. Through its simonONE division, SimonMed is also at the forefront of personalized imaging for the early diagnosis and treatment of disease. For more information, visit simonone.com and simonmed.com.

Reltime strengthens African business with a Joint Venture and signs first customer - C32PEX

Oslo-Norway, Ebène-Mauritius, 17 April 2024: C32pex is a leading Africa-based alternate banking platform serving customers across 19 countries and targeting the billion-plus unbanked and underbanked population in emerging markets. Reltime has built an award-winning white label Web3 Financial Services platform with wide-ranging services, such as mobile wallet, payments, lending, loyalty and rewards, and more. Given a growing demand for blockchain-powered transparent, secure and cost-effective financial services. C32pex has selected Reltime’s Web3 platform to offer innovative financial solutions in Africa and beyond. Both parties have already scoped use cases and plan to launch pilots during Q2-Q3 2024. To further deepen their collaboration, both parties have also established “Reltime Africa Ltd.”, a joint venture company headquartered in Mauritius where C32pex owns 51% stake. C32pex Holdings is a global leader in driving financial inclusion and innovation. With a portfolio of cutting-edge technologies including PEX Fintech, BrilliantTS Africa - Fuze Payment Cards, Kaizen Venture Studio, C32 Cross Over Neo Bank, PEX (Most reputed Africa 3rd party payments processor), and now Reltime Africa, C32pex is at the forefront of revolutionizing the financial industry. PEX Fintech, a pioneer in blockchain payments, tokenization, open banking, Web3 e-commerce, and payments, is revolutionizing the financial industry. Through its evaluation of Realtime’s platform capabilities, PEX Fintech has identified exciting opportunities for innovations and services. In collaboration with Reltime Africa and Democracy X (Web3 platform), C32pex aims to go live with its Africa Web 3 & AI enabled digital banking platform in August 2024. By leveraging their technological strengths and existing business relationships, PEX Fintech, Realtime Africa and other partners aim to launch C32 Digital Banking across select 9 African countries, as well as in the UAE, Oman, India, Sri Lanka, the United States, the United Kingdom, and Netherlands. Reltime CEO Marlene Julo said, "We are delighted to have C32pex as a customer and strategic partner in our fast-expanding ecosystem. Over many months, our teams have discussed and outlined detailed use cases and go-to-market approach, starting with the first pilots in coming months. Given the massive growth opportunities that the unbanked and underbanked population represent, we are really looking forward to working with the C32 team.”Commenting on this development, Prabhu Moorthy, Co-Founder & Chief Business Architect of C32Pex Fintech, added, "With over 10 years of experience in Africa, we are now expanding our business in Europe and other markets. Integrating Web3 capabilities in future financial and digital services will add to technology excellence and bring immense value to our business and retail customers. Reltime has built an impressive suit of financial and digital applications on their own Layer-1 chain and we look forward to a winning partnership ahead. About C32PexPEX Fintech Ltd, or C32PEX, is a leading provider of white-label solutions for mobile transaction services, digital onboarding, Instant multi-fuze card issuance, and open digital payment wallet solutions. PEX solutions enable Service Providers to easily and quickly deploy innovative mobile transaction services based on the latest technologies (NFC, HCE, tokenisation, QR Code, software and hardware security. For Afro-Asian banks, non-banks, and telco partners, C32Pex’ fintech offers a complete end-end turnkey financial innovation and digital transformation platform that connects with everything and everywhere. For more information about C32pex visit: https://www.c32pex.co/ Press Contact: Prabhu Moorthy, prabhu@c32pex.coAbout Reltime Africa Reltime is revolutionising the financial and digital services industry with its advanced Web3 platform. Reltime has developed its own Layer-1 Proof of Authority Blockchain with zero transaction and gas fees. The platform includes a range of applications such as non-custodian wallets, SuperApp, loyalty programs, payment solutions, lending services, QR codes, CBDCs and digital fiats, and utility tokens. Additionally, the Reltime platform provides customer administration features like eKYC, identity management, SLA, and reporting. By incorporating a decentralised identity, Reltime drives the next generation of digitisation in supply chain management, tokenisation, asset ownership, and global trade. For more information about Reltime AS, visit, https://www.reltime.com/  Press Contact Reltime: Bishwajit Choudharybc@reltime.com

Wirtek Strengthens Leadership Team with New Chief Revenue Officer to Drive International Sales Expansion

Niels Erik Wøhlk brings over 25 years of experience in sales, marketing, and leadership within the tech industry. His expertise spans numerous roles where he excelled in building and leading teams, driving business development, and enhancing customer engagement across global markets. Prior to joining Wirtek, Niels Erik served as VP of Sales and Marketing at INSCALE, where he was instrumental in expanding the company's market presence through strategic sales and marketing initiatives. Michael Aaen, CEO of Wirtek, stated, "Niels Erik is a seasoned leader whose extensive commercial know-how and deep market insights have consistently delivered strong results. His appointment as CRO is integral to our strategy to accelerate our presence in select geographical markets and achieve our organic revenue goals for the following period." In his new role, Niels Erik Wøhlk will head the revenue-generating activities of Wirtek, focusing on leveraging his extensive network and expertise to expand the company's footprint in the targeted regions. "I am excited to join Wirtek and contribute to the ambitious growth plans," said Niels Erik Wøhlk. "I see great potential and unleashed opportunities at Wirtek. I look forward to working with the massively talented team here to expand our customer base and build strong, long-lasting business relationships. I eagerly anticipate that we will harness our collective potential to drive meaningful, real-world results that propel our company forward." In line with the commitments outlined in their 2023 annual report, Wirtek is actively fortifying its business development efforts. This strategic focus aligns with the company's dedication to delivering on its promises and driving sustained growth and value creation for its stakeholders. This appointment is expected to accelerate Wirtek's revenue streams and strengthen its market position as a leader in IT consultancy. Niels Erik Wøhlk's proven track record and forward-thinking strategies are anticipated to play a key role in Wirtek's journey towards achieving its Accelerate25XL goals. Further information · Michael Aaen, CEO, Wirtek A/S, Phone: +45 2529 7575, E-mail:ir@wirtek.comNiels Jernes Vej 10, 9220 Aalborg, Denmark,www.wirtek.com About Wirtek Wirtek A/S is a Danish IT consultancy company that provides software development, testing, and consultancy services to help clients worldwide. Wirtek specializes in Digitalization, Energy, Workforce & Facility Management, Wireless Communication & Automation, and Trade & E-commerce. At Wirtek, we prioritize building long-term client relationships, with some lasting over a decade. We believe that quality partnerships are just as important as software quality in achieving our client's goals. Established in 2001, we have offices in Denmark and Romania and have been listed on Nasdaq First North Copenhagen since 2006. Ticker Code:WIRTEK (DK0060040913) 

Fortum and Vargön Alloys sign a five-year power purchase agreement

FORTUM CORPORATION PRESS RELEASE 17 APRIL 2024  Fortum and Swedish ferroalloys producer Vargön Alloys AB have signed a five-year power purchase agreement (PPA) with progressive pricing for delivery of approximately 0.4 TWh of electricity and Guarantees of Origin for nuclear power per annum in Sweden. The contract term starts in December 2024 and runs until the end of 2029. The power is sourced from Fortum’s nuclear portfolio in the SE3 (Stockholm) price area in central Sweden. Long-term partnerships play a vital role in ensuring predictability in long-term energy procurement and advancing electrification in the clean transition. The nuclear power supply agreement between Fortum and Vargön Alloys represents the commitment by both companies to work towards a more sustainable and environmentally conscious future. “I am excited about the opportunities this agreement with Fortum brings to our company. This partnership reflects our dedication to securing sustainable energy sources for our operations and underscores our commitment to environmental responsibility. We look forward to the positive impact this collaboration will have on our business and the environment”, Managing Director of Vargön Alloys Anders Lehman says. This PPA contributes to Fortum’s strategic target to have at least a 20% share of its rolling 10-year outright generation volume hedged. The PPA and long-term contracts are included in Fortum’s disclosure of the reported Nordic outright generation hedges. Fortum Corporation Communications Further information:Fortum News Desk, newsdesk@fortum.com, tel. +358 40 198 2843 Fortum Fortum is a Nordic energy company. Our purpose is to power a world where people, businesses and nature thrive together. We are one of the cleanest energy producers in Europe and our actions are guided by our ambitious environmental targets. We generate and deliver clean energy reliably and help industries to decarbonise their processes and grow. Our core operations in the Nordics comprise of efficient, CO2-free power generation as well as reliable supply of electricity and district heat to private and business customers. For our ~5 000 employees, we commit to be a safe, and inspiring workplace. Fortum's share is listed on Nasdaq Helsinki. fortum.com

Successful clinical pilot study with EndoDrill GI published in peer reviewed scientific journal

The results from BiBB's Swedish clinical pilot study, EDMX01, with EndoDrill[®] GI, were announced in the form of a poster presentation at Digestive Disease Week (DDW) in San Diego on May 21-22, 2022. Now, an original article with more details has been published in the peer reviewed Scandinavian Journal of Gastroenterology titled "The advent of the first electric-driven EUS-guided 17-gauge core needle biopsy – A pilot study on subepithelial lesions" (F. Swahn et al.). " We are very grateful for the convincing results. It is a very good effort that has been carried out by the participating clinics. An acknowledgment of the solid effort is that the study is published as a peer reviewed original article in a respected medical journal," says Dr. Charles Walther, CMO at BiBB. About study EDMX01The pilot study compared tissue sampling using the EndoDrill[®] GI vs. standard fine needle instrument in deeply situated gastric tumors in 7 patient cases. In each tumor, tissue samples were taken in randomized order with electric-driven EndoDrill[®] GI and with leading fine needle instruments, EUS-FNB (Medtronic, SharkCore™). With the EndoDrill[®] GI, a rotating needle cylinder cuts out tissue samples, and with the standard EUS-FNB, samples are taken with a manual stabbing motion. It was a broad group of patients (n=7, 28-75 years) with 6 different types of tumors in the upper gastrointestinal tract and with a tumor size from 17 mm to 90 mm, i.e. a significant challenge for endoscopic sampling. For EndoDrill®, samples of visible "core biopsies" were obtained in 7/7 cases (100%) while manual EUS-FNB resulted in 5/7 (71%) samples of ditto. Histological diagnosis was obtained in 7/7 cases (100%) with EndoDrill[®] and in 6/7 cases (86%) with EUS-FNB. No serious complications were noted after the examinations.  EndoDrill[®] was rated as "simple" or "very simple" in terms of handling (7/7), preparation (7/7), adjustment of the needle (7/7), and sampling performance (6/7, one difficult case). The research team concludes that the pilot study has shown that EndoDrill[®] GI can safely be used to obtain true core biopsies (CNB, Core Needle Biopsy) in a single needle puncture, reducing the need for a second sampling. The authors write that the EndoDrill[®] GI obtained coherent histological tissue samples that superseded conventional FNB samples, in both amount and quality. It is also noted that the EndoDrill[®] needle is hyperflexible, which was particularly beneficial in one of the cases. The researchers write that EndoDrill[®] GI takes core biopsies that resemble the tissue samples taken with rigid core needles in breast and prostate cancer. If this can be applied to other tumor areas, EndoDrill[®] will also have the potential to become a valuable tool for effective tissue sampling and precise diagnostics beyond the gastrointestinal tract. The authors conclude by stating that they are confident that the learning curve to use EndoDrill[®] GI is relatively short and that the technology can be applied in routine clinical practice. The article is ”peer reviewed” meaning that experts and researchers in the field have reviewed the study and its scientific quality before it is accepted for publication.  Link to the scientific publication: https://doi.org/10.1080/00365521.2024.2336611 About EndoDrill[®] GIEndoDrill[®] GI is the world's first market-cleared electric-driven biopsy instrument for endoscopic ultrasound (EUS). The instrument is used for EUS-guided tissue sampling for all indications in the gastrointestinal tract, e.g. pancreas, stomach, oesophagus, lymph nodes and liver. EndoDrill[®] GI received FDA 510(k) clearance in the US in 2023 and CE approval in Europe in early 2024. This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails. For more information about BiBB, please contact:Fredrik Lindblad, CEOE-mail: fredrik.lindblad@bibbinstruments.comPhone: +46 70 899 94 86www.bibbinstruments.comAbout BiBB The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill[®], a patented product line of electric-driven endoscopic biopsy instruments. The EndoDrill[®] instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, such as stomach, pancreas, liver, lung, and bladder. The product portfolio is aimed at the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments, which constitute the most advanced and fast-growing area of endoscopy. BiBB received 510(k) clearance from the US FDA for the lead product EndoDrill[®] GI in 2023. At the beginning of 2024, CE marking according to MDR was also obtained for all three product variants: EndoDrill® GI, EndoDrill[®] EBUS and EndoDrill[®] URO. Thus EndoDrill[®] is the first cleared electric endoscopic biopsy system in both the US and Europe. The EndoDrill[®] system includes sterile disposable biopsy instruments with associated drive system. The company was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and the BiBBInstruments share (ticker: BIBB) is listed on Spotlight Stock Market.

DanCann Pharma A/S: MINUTES OF EXTRAORDINARY GENERAL MEETING

On 17 April 2024 at 09:00 am (CET), an extraordinary general meeting was held in the Company at the Company’s address, Rugvænget 5, 6823 Ansager, Denmark. The agenda for the extraordinary general meeting was as follows: Proposed resolution to reduce the Company's share capital by transfer of 1. the amount to a special reserve fund (in Danish: henlæggelse til særlig reserve) by way of reduction of the nominal value per share of the Company, including consequential amendments to the articles of association (proposed by the board of directors) Proposed resolution to authorise the Board of Directors to increase the 2. Company’s share capital with pre-emption rights for the Company’s shareholders (proposed by the board of directors) Proposed resolution to authorise the Board of Directors to increase the 3. Company’s share capital without pre-emption rights for the Company’s shareholders (proposed by the board of directors) Lawyer Michael Kristensen was appointed chairman of the meeting pursuant to clause 11.20 of the Company’s articles of association. The chairman of the meeting announced that the general meeting had been duly convened, as the notice of the extraordinary general meeting was given on 2 April 2023. The chairman of the meeting described the formal requirements with respect to the notice and concluded that these were met. The chairman of the meeting stated that the maximum number of votes on the general meeting was 166,627,989 votes and that a total of 29,522,548 votes were represented divided between 26,022,548 votes by proxy to the board of directors and 3,500,000 votes by those shareholders in physical attendance. The chairman concluded that the general meeting formed a quorum with respect to the agenda. Re 1 It was proposed to reduce the share capital of the Company by nominally DKK 4,582,269.6975 from nominally DKK 6,248,549.5875 to nominally DKK 1,666,279.89 by transfer of the amount to a special reserve fund (in Danish: henlæggelse til særlig reserve), cf. article 188(1)(3) of the Danish Companies Act. The purpose of the proposal is to reduce the nominal value of the shares of the Company below the market price of the shares with the purpose of initiating and completing a rights issue (an issue of new shares with pre-emption rights for the Company’s shareholders) following completion of the capital reduction, cf. item 2 of the agenda. The capital reduction will be completed at a price of 100 (in Danish: kurs 100), equal to a market value (in Danish: kursværdi) of DKK 4,582,269.6975.  The capital reduction is completed by way of a proportionate reduction of the nominal value of each share of the Company from nominally DKK 0.0375 to nominally DKK 0.01. The total number of outstanding shares is unaffected by the capital reduction, and each shareholder’s holding of shares is unchanged. Adoption of the proposal will imply: t. the Company’s share capital as set out in article 3.1 of the articles of association is changed from “DKK 6,248,549.5875” to “DKK 1,666,279.89”; u. any reference to a nominal value per share of DKK 0.0375 in the Company’s articles of association is amended to a reference to a nominal value of DKK 0.01 per share; v. any remaining and unexercised part of existing authorisations to the Board of Directors as set out in articles 5 and 6.1-6.8 of the articles of association (regarding capital increases and issues of warrants) is reduced correspondingly (0.0375 : 0.01). w. the maximum nominal amount of the shares that can be subscribed for upon exercise of any outstanding and unexercised warrants issued by the Company is reduced correspondingly (0.0375 : 0.01) Before completing the capital reduction, the creditors of the Company are given notice requesting them to file their claims against the Company during a 4-week notice period (“proklama”) which commence with effect from the date of registration of the capital reduction with the Danish Business Authority, cf. article 192(1) of the Danish Companies Act. Such notice is given on 17 April 2024 by way of registration in the IT-system of the Danish Business Authority. It was proposed that the general meeting authorises the Board of Directors to complete and register the capital reduction upon expiry of the 4-week notice period and complete the amendments to the articles of association in accordance with the proposed resolution. In reference to article 156(2), cf. article 185, of the Danish Companies Act, the following documents were presented on the general meeting for the purpose of this proposal: · The Company’s annual report of 2022 · A report by the Board of Directors of the Company regarding events of major importance to the Company's position that have occurred after presentation of the annual report of 2022 · A declaration by the Company's auditor about the report from the Board of Directors Draft new articles of association were presented. The proposal was adopted unanimously and with all votes cast. Re 2 It was proposed that the Board of Directors, pursuant to clause 155 of the Danish Companies Act, in the period until 1 April 2029 is authorised to issue shares in the Company and thereby increase the share capital in one or more issues of new shares with pre-emption rights for the Company’s existing shareholders by up to a nominal amount of DKK 20,000,000. The capital increase can be by way of cash contribution, contribution in kind and/or conversion of debt (to be decided by the Board of Directors) and can be below market price. Shares issued pursuant to this authorisation shall be issued in the name of the holder and registered in the Company’s register of shareholders, be fully paid up, be negotiable instruments, there shall be no restrictions on the negotiability of the shares, and the shares shall in every respect carry the same rights as the existing shares. The Board of Directors is authorised to lay down the terms and conditions for the capital increases pursuant to this authorisation and to make such amendments to the Company’s articles of association as may be required as a result of the Board of Directors’ exercise of said authorisation. Adoption of the proposal will imply that a new clause 5.6 is inserted in the articles of association and clause 5.8 (previously clause 5.6) shall be amended. Draft new articles of association were presented. The proposal was adopted unanimously and with all votes cast. Re 3 It was proposed that the Board of Directors, pursuant to clause 155 of the Danish Companies Act, in the period until 1 April 2029 is authorised to issue shares in the Company and thereby increase the share capital in one or more issues of new shares without pre-emption rights for the Company’s existing shareholders by up to a nominal amount of DKK 3,500,000. The capital increase can be by way of cash contribution, contribution in kind and/or conversion of debt (to be decided by the Board of Directors). The capital increase can be below market price. Shares issued pursuant to this authorisation shall be issued in the name of the holder and registered in the Company’s register of shareholders, be fully paid up, be negotiable instruments, there shall be no restrictions on the negotiability of the shares, and the shares shall in every respect carry the same rights as the existing shares. The Board of Directors is authorised to lay down the terms and conditions for the capital increases pursuant to this authorisation and to make such amendments to the Company’s articles of association as may be required as a result of the Board of Directors’ exercise of said authorisation. Adoption of the proposal will imply that a new clause 5.7 is inserted in the articles of association and clause 5.8 (previously 5.6) shall be amended. Draft new articles of association were presented. The proposal was adopted unanimously and with all votes cast. ------ The meeting was closed. Chairman of the meeting: __________________________Michael Kristensen Please note: The capital decrease (item 1) and the resulting amendments of the articles of association cannot be completed before expiration of the 4-week notice period (“proklama”) which commences today. Attached are updated articles of association without the capital decrease (effective today) and updated articles of association including the capital decrease. About DanCann Pharma A/S DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm. For more information, visit: www.dancann.com For further information, please contact: Jeppe Krog Rasmussen, CEO E-mail: jkr@dancann.com Forward-looking-statement: Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Safello publishes reversed profit warning after significantly increased EBITDA and operating profit

Stockholm, 17 April 2024 | Today, Safello Group AB (“Safello”) publishes a reversed profit warning after a preliminary positive EBITDA for Q1 2024 of SEK 4.7 million, representing an increase of 224 percent compared to Q1 2023 and 4500 percent compared to Q4 2023 respectively, and a preliminary operating profit of SEK 4.7 million, representing an increase of 58 percent compared to Q1 2023 and 103 percent compared to Q4 2023 respectively. The company chooses to publish this preliminary result due to this strong increase in EBITDA and operating profit during the first quarter of 2024. The background to the increase in earnings during the first quarter of 2024 is mainly increased income attributable to withdrawal fees (fees for transferring cryptocurrency from the platform) and transaction fees, linked to the strong price development of Bitcoin and other crypto-assets. The first quarter has historically been one of the stronger quarters on an annual basis affected by seasonality. The company's results are also strongly linked to the current market situation for crypto-assets, which will continue to apply and may lead to fluctuations in the company's results between quarters, in addition to seasonal variations. Seasonal variations, as well as the fact that both Q1 2023 and Q1 2024 were characterized by a strong crypto market, are the main reasons why the result for Q1 2024 differs significantly compared to Q4 2023 in particular. The net turnover during the first quarter of 2024 amounted to approximately SEK 193.1 million, corresponding to an increase of 40 percent compared to Q1 2023 and 12 percent compared to Q4 2023 respectively. The company’s quarterly report for Q1 will be published on May 17, 2024, as previously communicated. ### This information is such that Safello Group AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below, for publication at 12.40 CEST on 17 April 2024.  For more information, please contactViktoria Berglund Blohmé, Head of Finance, ir@safello.com Certified AdviserAmudova AB is Safello’s certified adviser.Safello is the leading cryptocurrency exchange in the Nordics, with over 358,000 users. The company is empowering financial independence by making crypto accessible to everyone. Safello offers a secure way to buy, sell and store crypto in seamless transactions at industry-leading speeds. Operating in Sweden, Safello has been registered as a financial institution with Finansinspektionen (Swedish Financial Supervisory Authority) since 2013 and is listed at Nasdaq First North Growth Market since 2021. For more information visit www.safello.com. 

Aker Horizons ASA: Minutes of Annual General Meeting

All resolutions were made in accordance with the proposals set out in the meeting notice, cf. the notice of the Annual General Meeting that was published on Oslo Stock Exchange on 21 March 2024. Minutes of the meeting are attached and available on https://akerhorizons.com/investors/shareholder-center/annual-general-meeting/. The general meeting re-elected all shareholder-appointed directors to the board. Kimberly Mathisen and Trond Brandsrud were re-elected in their current positions as directors for a period of two years, and Lene Landøy was re-elected as deputy for a period of two years. ENDS For further information, please contact: Marianne Stigset, Director of Communications and External AffairsTel: +47 41 18 84 82Email: marianne.stigset@akerhorizons.com Stian Andreassen, head of Investor RelationsTel: +47 41 64 31 07Email: stian.andreassen@akerhorizons.com About Aker Horizons Aker Horizons develops green energy and green industry to accelerate the transition to Net Zero. The company is active in renewable energy, carbon capture and hydrogen and develops industrial-scale decarbonization projects. As part of the Aker group, Aker Horizons applies industrial, technological and capital markets expertise with a planet-positive purpose to drive decarbonization globally. Aker Horizons is listed on the Oslo Stock Exchange and headquartered in Fornebu, Norway. Across its portfolio, the company is present on five continents. www.akerhorizons.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS IN FERRONORDIC AB (publ)

The shareholders of Ferronordic AB (publ) (the “Company”) are invited to attend the annual general meeting (“AGM”) to be held at Radisson Blu Strand Hotel, Nybrokajen 9, Stockholm, on Wednesday 16 May 2024 at 2 p.m. Shareholders wishing to participate at the venue must be recorded in the share register kept by Euroclear Sweden AB on 7 May 2024 and notify the Сompany of their intention to participate no later than 9 May 2024. When providing such notice, the shareholder should state name, personal or corporate registration number, address, telephone number and the number of any accompanying assistant(s) (maximum two assistants). Shareholders who are represented by proxy must issue a written, dated proxy for the representative. Proxy forms are available on the Company’s website, www.ferronordic.com. The proxy must not be older than 12 months unless it is stated that it is valid for a longer period, although no longer than five years. If the proxy is issued by a legal entity, a copy of the registration certificate or an equivalent certificate of authority must be submitted. Notification of intention to participate at the AGM as well as other required documents shall be sent per e-mail to AGM@ferronordic.com or by post to the Company’s address Box 5855, 102 40 Stockholm and should have been received by the Company no later than 9 May 2024. Shareholders who have their shares registered in the name of a trustee or nominee must have their shares owner-registered in the shareholders’ register kept by Euroclear Sweden AB by 7 May 2024. Such owner-registration should be requested at the bank or broker holding the shares in due time to be effective on 9 May 2024. Information on the resolutions passed at the AGM will be published on 16 May 2024.   Further information and instructions are available in the Notice of AGM, available on the Company’s webpage (www.ferronordic.com). Proposed agenda Matters: 1. Opening of the meeting 2. Election of chairman 3. Verification of voting list 4. Approval of the agenda 5. Election of controllers 6. Determination whether the meeting has been duly convened 7. Presentation of the work of the Board and the Board committees 8. Presentation by the CEO 9. Presentation of the annual report and the auditor’s report, as well as the consolidated accounts and the auditor’s report on the consolidated accounts10. Resolution on adoption of the income statement and balance sheet and the consolidated income statement and balance sheet11. Resolution on disposition of the Company’s profits12. Resolution on discharge from liability of the members of the Board and the CEO13. Determination of the number of members of the Board to be elected by the meeting14. Determination of remuneration for the members of the Board and the auditor15. Election of the Board16. Election of the chairman of the Board17. Election of the auditor18. Resolution on the Nomination Committee19. Resolution on the adoption of a policy on remuneration for executives20. Resolution on a long-term incentive program based on warrants previously issued by the Company21. Closing of the meeting Motions Point 2: The Nomination Committee for the AGM, consisting of Jörgen Olsson (chairman), representing Skandinavkonsult i Stockholm AB, Peter Zonabend, representing Per Arwidsson with associated companies, Anders Blomqvist, representing Lars Corneliusson with associated companies, and Lars Hagerud, representing AltoCumulus, proposes Staffan Jufors as chairman of the meeting. Point 3: The voting list proposed for approval under this point on the agenda is the voting list drawn up by Euroclear Sweden AB on behalf of the Company based on the AGM’s share register. Point 11: Distributable profits available for distribution by the meeting amount to SEK 1923270 998. The Board proposes that no dividend shall be distributed. The distributable profit, amounting to SEK1923270 998, would be carried forward. Point 13: The Nomination Committee proposes the number of Board members to remain six members without deputies. Point 14: The Nomination Committee proposes that the chairman of the Board be awarded SEK 800,000 and that each other Board members, except Lars Corneliusson, be awarded SEK 400,000. The total remuneration to the Board amounts to SEK 2,400,000. No separate remuneration is paid for work in the Board’s committees. The Nomination Committee further proposes that fees to the auditor be paid according to agreement between the Company and KPMG AB. Point 15: The Nomination Committee proposes re-election of Annette Brodin Rampe, Lars Corneliusson, Håkan Eriksson, Staffan Jufors, Aurore Belfrage and Niklas Florén. Presentations of proposed candidates are available on the Company’s website www.ferronordic.com . Point 16: The Nomination Committee proposes re-election of Staffan Jufors as chairman of the Board. Point 17: The Nomination Committee proposes re-election of KPMG AB as the Company’s auditor for the period until the next AGM. Point 18: The Nomination Committee proposes that the meeting adopts the following principles regarding the Company’s Nomination Committee: The Nomination Committee consists of four members. The chairman of the Board shall at the end of the third quarter 2024 contact the four largest identified shareholders and encourage them to appoint their representatives for the Nomination Committee. If a shareholder elects not to appoint a representative, the right to appoint a member passes to the next largest shareholder (provided such shareholder has not already appointed or is entitled to appoint a member). If a member resigns, the shareholder appointing the resigning member shall be asked to appoint another member. The chairman of the Nomination Committee shall be the member appointed by the largest shareholder (unless the Nomination Committee agrees otherwise). The Nomination Committee shall act in the interest of all shareholders. The duties of the Nomination Committee shall include to evaluate the Board’s constitution and work, and to make proposals for the AGM regarding: -           election of chairman for the AGM, -           number of Board members, -           election of the Board and the chairman of the Board, -           election of auditor (in cooperation with the Board’s audit committee), -           remuneration of the Board, the Board’s committees and the auditor, and -           the Nomination Committee for the next AGM. The mandate of the Nomination Committee is valid until a new Nomination Committee has been constituted. In case of material ownership changes during the mandate period, the Nomination Committee shall ensure that a new large shareholder is represented in the Nomination Committee. The constitution of the Nomination Committee shall be announced not later than six months before the AGM. The members of the Nomination Committee receive no compensation from the Company but are entitled to reimbursement for reasonable expenses. Point 19: The Board proposes that the meeting adopt the following guidelines on remuneration for executives: These guidelines concern remuneration and other employment terms for Ferronordic’s management. The guidelines apply to employment contracts made after the approval of these guidelines by the meeting and to amendments to existing agreements made thereafter. Basic principles Remuneration to executives is based on current market terms on the markets where Ferronordic operates. Remuneration shall also be competitive in order to attract and retain competent executives. Fixed salaries Fixed salaries are established individually based on the criteria specified above, as well as the individual executive’s areas of responsibility and performance. For expatriates with salaries in local currency, the fixed salaries can be adjusted to reflect changes in foreign exchange rates. Variable salaries Executives may receive variable salaries in addition to fixed salaries. Variable salaries are paid upon fulfilment of pre-determined and measurable performance criteria, primarily based on the development of the Group as a whole, and/or the part of the group’s business that the executive is responsible for. Variable salary for the CEO as well as executives shall not exceed 100% of the fixed salary. LTI-program A share or warrant-based long-term incentive program for the Company’s and its subsidiaries’ senior management may be introduced as per separate decision. Other benefits Executives are entitled to customary non-monetary benefits such as company cars and company health insurance. In addition, company housing and other benefits can be offered on an individual basis, such as housing allowances and school/kindergarten allowances for expatriates. Pension benefits In addition to those pension benefits that executives are entitled to according to law, executives may be offered pension benefits that are competitive in the country where the individual in question is or has been a resident or to which the individual has a relevant connection. Pension plans shall be defined contribution plans without guaranteed pension levels. Severance pay Severance pay shall not exceed 12 months. The Board’s preparation and decision-making on issues concerning remuneration and other terms of employment The Remuneration Committee is responsible for: 1)          preparing the Board’s decisions on issues concerning principles of remuneration, remuneration and other terms of employment for executives, 2)          monitoring and evaluating ongoing and during the year ended programs for variable remuneration, 3)          monitoring and evaluating the application of these guidelines, and 4)          monitoring and evaluating current remuneration structures and remuneration levels in the Group. The Remuneration Committee prepares and the Board resolves on: 1)          remuneration and employment terms of the CEO, and 2)          principles for remuneration for the other executives (including pension and severance pay). The Remuneration Committee also reviews and recommends to the Board share-based incentive programs to be decided by the AGM. Authority to decide on deviations from these guidelines The Board may deviate from these guidelines if there are specific reasons in individual cases. Earlier decisions on remuneration not due at the time of the AGM’s consideration of these guidelines Remuneration approved but not due at the time of the AGM 2024 fall within the frames of these guidelines. Point 20: As per decision by EGM on 15 December 2022, the Company issued a total of 1178000 warrants of series 2022/2025 that were distributed among members of the Company’s and its subsidiaries’ senior management as part of a long-term incentive program. Since a number of management persons have left the Company or its subsidiaries, the Company has through a subsidiary taken back warrants and has now approximately 185000 warrants of series 2022/2025 in its possession. To further align the long-term interests between the Company and its shareholders with those of the senior management and also to be able to offer competitive terms to attract and retain senior management, the Board proposes a long-term incentive program for 2024 under which the Company offers members of the Company’s Executive Management Team the possibility to acquire additional warrants of Series 2022/2025 at market price as per valuation by the Company’s financial advisor on the basis of Black and Scholes option pricing model at the time of acquisition. The Company will receive the purchase price when the warrants are sold to the participants that in case of a share price of SEK 68 is approximately SEK 14 per warrant. According to the terms and conditions of the warrants of Series 2022/2025, subscription of shares is to be made against payment of a strike price equal to SEK 65 per warrant and the subscription period is 16 – 19 December 2025. Assuming full allotment and subsequent subscription of 185000 shares, the Company’s equity would then increase with approximately SEK 12025000 at the time of subscription. The terms and conditions of the warrants remain the same as when the warrants were initially issued and are available on the Company’s web page. Participation in the LTI-program and subsequent subscription of shares requires that a participant remains an employee of the Company or its subsidiaries and that no termination of the employment has occurred during the duration of the program. In case a participant in the program, for whatever reason, ceases to be an emplyee of the Company or its subsidiaries, the Company has the right to repurchase the warrants the participant has acquired under this LTI-program of year 2024 for a price equal to a market price valuation at the time of transfer. The Company will not compensate the participants for any part of the purchase price for acquiring the warrants. Hence the costs for executing this program are limited to the costs for external advisors such as for market valuation of the warrants at the times of transfer that are estimated at SEK 50000. The final allocation of warrants between the participants is to be decided by the Board. This LTI-program has been prepared by the Board in consultation with external advisors. In addition, the proposal has been prepared by the Board’s remuneration committee and has been reviewed at meetings of the Board during 2023 and 2224.      Resolution according to this item must be supported by shareholders with at least nine tenths of the votes cast as well the shares represented at the AGM. ------------------------------------------------------- About Ferronordic Ferronordic is a service and sales company in the areas of trucks and construction equipment. It is dealer of Volvo Trucks, Renault Trucks and Sandvik Mobile crushers and screens in Germany. Ferronordic is the dealer for Volvo CE in all or parts of nine states in the United States and also represents Hitachi, Sandvik and Link-Belt in parts of the same area. Ferronordic is also dealer of Volvo CE, Mecalac and Sandvik Mobile Crushers and screens in Kazakhstan. Ferronordic began its operations in 2010 and currently has 42 outlets and approx. 800 employees. Ferronordic’s vision is to be the leading service and sales company in its markets. The shares in Ferronordic AB (publ) are listed on Nasdaq Stockholm. www.ferronordic.com

Raigmore Hospital in Scotland selects RayCare

The radiotherapy center at Raigmore Hospital is the northernmost center for radiotherapy in the UK, treating close to 1,000 patients per year. The center has two Varian Truebeam® linear accelerators and has been using RayStation clinically since 2016.  Raigmore Hopsital is currently using an older version of ARIA from Varian Medical Systems as their oncology information system. The existing system needs to be upgraded or replaced. After an extensive evaluation the center has decided to select RayCare as their new, sole oncology informations system. RayCare will cover the full patient pathway including treatment delivery using the Varian Treatment Interface for connecting RayCare to the Varian treatment console. The implementation will start during the summer and the center will use the advanced workflow engine of RayCare for creating clinic specific workflows, with the aim of a complete clinical implementation in the beginning of 2025. The radiotherapy center at Raigmore Hospital is a very busy cancer center facing the pressure of an increasing number of patients. Key for the center in the selection process was efficent scheduling, workflow support, smooth integration with the existing treatment planning system, and automation using scripting.    Steven Colligan, Head of radiotherapy physics, Raigmore Hospital, says: “We have used RayStation since 2016 and look forward to the introduction of RayCare to the department. As well as the improved integration with RayStation that it will provide, we were impressed with the automation of tasks which has the potential to improve the workflows. The possibility of using scripting as we do in RayStation further enhances this ability. We also see great potential to improve the communication and documentation which is currently fragmented across a number of different systems.” Johan Löf, founder and CEO, RaySearch, says: “Our installed base of RayCare customers is steadily increasing and I am happy to welcome Raigmore Hospital as a new RayCare customer. I am impressed by the center’s efficient use of RayStation and the fact that they now have selected RayCare will further improve their efficiency. I am looking forward to working with the team at Raigmore Hospital for a smooth transition.” The order value is GBP 730,000 (approximately SEK 9.7 million), excluding service contract, which will be recognized as revenue in the beginning of 2025.

Invitation to telephone conference concerning Duni AB (publ) interim report 1 January – 31 March 2024

The interim report for Duni AB will be disclosed to the media for publication at 7.45 AM CET on Wednesday 24 April. TELEPHONE CONFERENCE  The interim report will be presented on Wednesday, 24 April at 10.00 AM CET at a telephone conference, which can also be followed via the web.To access the audio conference call, please visit this link:https://emportal.ink/4cIVxvn This link allows participants to register to obtain their personal audio conference call details. To follow the webcast, please visit this link: https://onlinexperiences.com/Launch/QReg/ShowUUID=50CCCC13-0CE4-43AC-ADAE-51FC92A37DAB This link gives participants access to the live event. For more information, please contact: Magnus Carlsson, EVP Finance/CFO, +46 40-10 62 00, magnus.carlsson@duni.comKatja Margell, IR and Communications Director, +46 76-819 83 26, katja.margell@duni.com Duni Group is a market leader in sustainable dining and food packaging solutions for the restaurant market. The Group markets and sells its products under primarily the brands Duni, BioPak and Paper+Design, which are represented in more than 40 markets. Duni Group has around 2,300 employees in 22 countries, its headquarters in Malmö and production units in Sweden, Germany, Poland and Thailand. Duni Group is listed on NASDAQ Stockholm under the ticker “DUNI”. Its ISIN code is SE0000616716. Dunigroup.com

CO280 and Aker Carbon Capture collaborate with Microsoft to scale-up permanent, affordable carbon removal in US and Canada

CO280 and Aker Carbon Capture have signed a Memorandum of Understanding (MoU) agreement with Microsoft to explore opportunities for scaling the full physical and digital value chain of carbon removal in the US and Canada. Together the three companies have the expertise, technologies, and resources to develop this market by creating a scalable model to deploy large-scale projects quickly to meet global net zero targets. The collaboration aspires to leverage the strengths and capabilities of each partner to enable the ecosystem for the voluntary carbon market by providing traceability of data and enabling high-integrity carbon credits. The three companies will collaborate to address the technological, regulatory, and commercial challenges and opportunities for creating carbon removal, with each party playing distinct commercial roles. The parties intend to collaborate on a non-exclusive basis.  Under the terms of the MoU agreement, the parties agree to explore to: · Develop biogenic carbon capture project(s), including projects currently in CO280’s development pipeline, as well as additional projects;  · Apply CO280’s expertise to jointly develop a standard and efficient screening process to evaluate the technical and economic feasibility of carbon capture on pulp and paper mills, with the subsequent deployment of Aker Carbon Capture’s plants, including the modularized Just Catch series; · Standardize the lifecycle assessment (LCA) and measurement, verification, and reporting (MRV) systems for capture projects in pulp and paper, with the ambition to leverage Microsoft’s digital capabilities, cloud computing platforms, services, and solutions; · Create a digital tool to compare CO280’s planned projects against Microsoft Criteria for High Quality Carbon Removal;  · Advocate for policies and demonstrate thought leadership to promote the pulp and paper carbon capture market, with the corresponding creation and use of high-integrity carbon removal credits. North America’s pulp and paper industry represents a carbon removal opportunity of up to 130 million tons per year, due to the fact that the average mill has a CO2 emissions profile that is 80-90% biogenic. By capturing and storing these emissions permanently, negative emissions are achieved as more carbon dioxide is removed from the atmosphere than is being emitted from the process.  CO280 is the leading developer of Carbon Dioxide Removal (CDR) projects in the pulp and paper industry. In partnership with pulp and paper companies, CO280 develops, finances, owns, and operates large-scale CDR projects. CO280’s projects address a critical supply gap in the CDR market by supplying permanent, verifiable, and affordable CDR to corporate buyers in the voluntary market. CO280 currently has more than 10 million tons per year of permanent CDR under development.  “This commitment on the part of three best-in-class companies is exactly the kind of bold move the industry needs to unlock the enormous removal opportunity in the pulp and paper industry and scale up the CDR market. Together, we are developing the largest scale, lowest cost, permanent carbon removal projects in the world,” said Jonathan Rhone, Chief Executive Officer of CO280. Microsoft announced its ambitious Carbon goals back in 2020: To be carbon negative by 2030 and remove the company’s aggregated carbon footprint by 2050. This journey starts with reducing carbon emissions as much as possible, replacing electricity consumption with carbon-free energy, and removing the emissions that remain. Microsoft has run an open process for carbon removal since 2020 and the company has shared learnings publicly. Microsoft is committed to creating a robust market for CDRs, including by building a digital value chain that authoritatively tracks carbon attributes and generates robust credits as simply as possible. For this to happen, engaging with companies that share the same goals is essential.  “Our collaboration with Aker Carbon Capture and CO280 builds on important large-scale initiatives across asset-intensive industries including pulp and paper”, says Darryl Willis, Corporate Vice President of Energy and Resources Industry at Microsoft. “By leveraging the power of technology to create a digital value chain for carbon tracking and reporting, we can equip the market for high-integrity carbon removal credits and further enable the industrial sector to decarbonize.” “It’s time to move past the first-of-a-kind and the demonstration projects for carbon removal. The deployment rate needs to be accelerated by the hundreds to deliver the ‘net’ in net zero. We have demonstrated the strength of working together in the past, and we are excited to expand our collaboration with Microsoft and CO280 to further deliver impact” says Egil Fagerland, CEO of Aker Carbon Capture. Aker Carbon Capture is dedicated to enabling carbon removal and reduction and the company’s proven Just Catch modular solutions enable industries to deploy their capture technology at speed and at scale. The company is currently delivering seven carbon capture units: five Just Catch 100 units to Ørsted, one Just Catch 100 unit to Twence and a Big Catch delivery to Heidelberg Materials at Brevik.  Accelerating the large-scale deployment of carbon dioxide removals (CDR) is critical to the net-zero transition. The International Energy Agency (IEA) estimates that more than one gigaton of CO2 per year will need to be captured by 2030, scaling up to more than six gigatons per year by 2050.  A launch event featuring representatives from CO280, Aker Carbon Capture, and Microsoft’s management teams took place at Microsoft’s corporate headquarters in Redmond on 17 April 2024, in conjunction with the official visit of the Crown Prince of Norway to the US.  ENDS

Hansa Biopharma interim report January-March 2024

Lund, Sweden, April 18, 2024, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to March 2024. Highlights for the first quarter of 2024 · Strong commercial performance. Total Q1 revenue of SEK 56m including product sales of SEK 47m – sales growth during Q1 2024 was driven by product sales in our largest European markets including France, UK, and Germany, as well as initial sales in Belgium. Represents first time Company has delivered two consecutive quarters of strong growth. · IDEFIRIX has achieved pricing and reimbursement in 75% of the European kidney transplant market; Ongoing HTA processes in 11 countries including, most recently, in Ireland. · Evan Ballantyne joined Hansa Biopharma as Chief Financial Officer effective March 1, 2024. Previously served as CFO of Gain Therapeutics, Inc., a U.S. based biotech company. Evan brings to Hansa more than 30 years of international experience as a senior financial executive in both public and private life science companies. Clinical pipeline update · US ConfIdeS trial (kidney transplantation): 122 patients have been enrolled with 49 of 64 targeted patients randomized in this pivotal, Phase 3 U.S. open label, randomized, controlled trial of imlifidase in kidney transplantation. · Post Approval Study (kidney transplantation): 36 patients have been treated (72% completion). The study will support full marketing authorization in Europe and is expected to be completed by 2025. · Phase 3 (anti-GBM disease): 25 of 50 targeted patients enrolled in global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Completion of enrollment is expected in 2025. · Investigator-initiated phase 2 trial (ANCA-associated vasculitis): 3 of 10 targeted patients enrolled. Events after closing period · Cash runway extended into 2026: Raised SEK ~372m (USD ~34.6m) in a directed share issue targeting mainly high-quality international healthcare specialist investors. Financial summary SEKm, unless otherwise Q1 2024 Q1 2023 FY 2023stated – unauditedRevenue 56.0 24.2 134.1- thereof: Product sales 47.4 14.3 103.7SG&A expenses (91.3) (103.3) (450.5)R&D expenses (103.0) (92.8) (411.3)Loss from operation (159.4) (182.3) (788.5)Loss for the period (218.6) (205.4) (831.7)Net cash used in (189.1) (207.0) (755.7)operationsCash and short-term 541.5 1,286.8 732.1investmentsEPS before and after (4.15) (3.92) (15.83)dilution (SEK)Number of outstanding 52,671,796 52,443,962 52,671,796sharesWeighted avg. no of shares 52,671,796 52,443,962 52,540,089before and after dilutionNo of employees at the end 166 159 168of the period Søren Tulstrup, President and CEO of Hansa Biopharma, comments “I am very pleased with the strong commercial performance in the first quarter of 2024, the second consecutive quarter with solid product sales and a promising start to 2024. This strong sales performance is a continuation of the traction we saw at the end of last year where key large markets such as UK and Germany started to contribute.  Our performance continues to be driven by our largest markets underpinned by new and repeat use of IDEFIRIX at leading transplant centers. We have now achieved pricing and reimbursement in 75% of the European kidney transplant market and expect to see utilization in new centers resulting in additional sales growth in 2024. Our clinical programs in kidney transplantation continue to progress at pace. Enrolment and randomization in our pivotal US Phase 3 trial (ConfIdeS) is advancing as expected. During the first quarter of 2024 four new sites have been activated and both screening and randomization of eligible patients have recently accelerated. We expect randomization to complete in mid-2024, as previously guided. We have also made significant progress in the European post approval study – PAES – with more than a doubling of the number of patients treated in the trial in the last couple of quarters. This post approval study is an obligation under the European conditional marketing authorization and will be used to further investigate the long-term graft survival in 50 highly sensitized kidney transplant patients treated with IDEFIRIX. The study will also help generate important clinical experience in leading transplant centers in using IDEFIRIX as a new transformative desensitization therapy in highly sensitized patients. Beyond kidney transplantation, we continue to advance our imlifidase clinical programs in autoimmunity. In the Phase 3 trial in anti-GBM disease, our lead autoimmune indication, we have reached 50% enrolment in the trial and expect completion in 2025 as previously guided.  We also expect to share contextualized efficacy data later this year in our 15-HMedIdeS-09 Phase 2 study in Guillain-Barré Syndrome (GBS). This follows promising first high-level data shared in December 2023. On April 12, 2024, we announced that additional financing had been secured – extending our cash runway into 2026 through a SEK ~372m (USD ~34.6m) directed share issue targeting mainly U.S. and European healthcare specialist investors. I am very pleased to see the strong interest in the Hansa equity story from leading international health specialist investors. This transaction will help finance the preparation of a potential U.S. launch of imlifidase in kidney transplantation, strengthen ongoing product development in autoimmune indications and allow for the continued clinical development of HNSA-5487, the lead candidate from the NiceR program for repeat dosing. Lastly, I am delighted to welcome Evan Ballantyne as Chief Financial Officer. With his deep international experience and successful track record as a CFO at public and private life science companies I am confident that Evan will be a strong addition to our team and will help drive our financial strategy, deliver on key strategic priorities, and build shareholder value. We look forward to keeping you updated on our continued progress, with several upcoming important milestones to be achieved across our platform and franchises as we continue the development of new, transformative medicines for patients suffering from serious, rare immunologic diseases.” Upcoming milestones and news flow 2024     GBS Phase 2: Outcome of the comparative efficacy analysis 2024     Genethon Crigler-Najjar Phase 1/2: Initiate clinical study with imlifidase prior to GNT-0003 2024     HNSA-5487 (Lead NiceR candidate): Further analysis around endpoints in FIH trial incl. lead indication 2024     U.S. ConfIdeS (Kidney transplantation) Phase 3: Complete randomization 2024     First high level data read-out from phase 1b study in DMD with Sarepta 2025     U.S. ConfIdeS (Kidney transplantation) Phase 3: BLA submission 2025     Anti-GBM disease Phase 3: Completion of enrollment Updated financial calendar 2024 Apr 18, 2024                   Interim Report for January - March 2024 June 27, 2024                 2024 Annual General Meeting in Lund, Sweden July 18, 2024                  Half-year Report January - June 2024 Oct 24, 2024                   Interim Report for January - September 2024 Conference call details Hansa Biopharma will host a telephone conference today Thursday, April 18, 2024, 14:00 CET / 8:00am EST. The event will be hosted by Søren Tulstrup, President and CEO, Matthew Shaulis, CCO and US President, Evan Ballantyne, CFO, and Hitto Kaufmann, CSO. The presentation will be held in English. Slides used in the presentation will be live on the company website during the call under “Events & Presentations” and will also be made available online after the call. Link to presentation  To participate in the telephone conference, please use the dial-in details provided below: Sweden: +46 812 410 952 United Kingdom: +44 203 769 6819 United States: +1 646 787 0157 Participant access code: 765135 The webcast will be available on https://hansabiopharma.eventcdn.net/events/interim-report-january-march-2024 For the full financial calendar and list of events in 2024 please visit https://www.hansabiopharma.com/investors/calendar/ This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. For more information: Klaus Sindahl, VP Head of Investor RelationsM: +46 (0) 709 298 269E: klaus.sindahl@hansabiopharma.com Stephanie Kenney, VP Global Corporate AffairsM: +1 (484) 319 2802E: stephanie.kenney@hansabiopharma.com About Hansa Biopharma Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at hansabiopharma.com.

Swedbank Economic Outlook: Recovery in sight

“The outlook for households is starting to improve. After two years of falling income, real disposable income will increase this year and will go up even more next year. Consumption will remain subdued for a while as the labour market weakens during the year, but it will begin to rise after the summer, and then take a leap in 2025 with an increase of 3.4 per cent,” says Mattias Persson, Group Chief Economist, Swedbank.  Inflation is falling rapidly – which will support rate cuts  In Sweden, the inflation trend remained favourable in early 2024. CPIF inflation is expected to fall below the Riksbank’s target of two per cent by the summer, and to remain low in 2025.  “We expect the policy rate to be cut by 25 basis points in May, to 3.75 per cent, followed by three further cuts this year. The Riksbank will continue to cut the policy rate in 2025, down to 2 per cent. Monetary policy will become less stringent, providing a much-needed injection for the Swedish economy,” says Mattias Persson.  Housing prices have bottomed out, with moderate price increases in sight  Housing prices have largely remained flat in the past 12 months and are about 10 per cent below the peak noted in spring 2022. They have now stabilised, with price increases around the corner.  “The Riksbank’s change of direction will give the housing market a boost. In combination with better household purchasing power, this indicates an increase in demand for housing and a moderate price increase of 2–3 per cent this year and around 5 per cent next year,” says Mattias Persson.  A comeback for the Swedish economy  The Swedish government’s recently presented spring amendment budget was the first step towards a more expansionary fiscal policy, and next year the policy will be even more expansionary, with SEK 50 billion in unfunded fiscal measures. The Swedish economy is gradually gearing up, and next year the country’s growth will outpace that of most other European countries.  “A recovery is in sight for the Swedish economy. When the economic policy shifts, with monetary policy becoming less stringent and fiscal policy becoming expansionary, growth in Sweden will truly pick up speed – making Sweden one of Europe’s fastest-growing economies. This also indicates that the Swedish krona will gain strength,” says Mattias Persson.  For the full report, see attachment or visit: www.swedbank.com/seo.   Contact:  Mattias Persson, (Mattias.Persson@swedbak.se) Group Chief Economist, Swedbank, tel. +46 73 094 29 56  Charlotte Nilsson (Charlotte.Nilsson@swedbank.se), Press Communicator, Swedbank, tel. +46 76 534 66 12 

EQT AB (publ) Q1 Announcement 2024

Highlights for the period Jan-Mar 2024 (Jan-Mar 2023) Strategic · EQT X closed at EUR 22bn in total commitments, of which EUR 21.7bn are fee-generating assets under management, hitting the hard cap · EQT Future[1] closed at EUR 3bn in total fund commitments, with total fee-generating commitments to the strategy, which includes co-investments, totaling EUR 3.6bn · EQT hosted a Capital Markets Day, re-confirming its revenue growth and adjusted EBITDA margin targets, providing further color on its fee-related EBITDA margin ambition, and refining its dividend growth target to be on a per share basis · Preparation continued for a transition infrastructure strategy, as well as further products targeting the Private Wealth segment · Preparations also continued for BPEA IX Fundraising · Fee-generating assets under management (FAUM) ‌increased‌ to EUR ‌‌132‌bn (EUR ‌119‌bn). Total AUM was EUR ‌‌‌242‌bn (EUR ‌‌216‌bn). Gross inflows amounted to EUR ‌‌5‌bn and were primarily driven by closed out commitments from EQT X and EQT Infrastructure VI · Fundraisings are generally taking longer in the current fundraising environment, and we expect the fundraising market to meaningfully improve only once realizations pick up materially across private markets · EQT Infrastructure VI had fee-generating commitments of EUR ‌15.1‌bn. Fundraising is expected to continue at least throughout 2024, and the fund is expected to reach its target fund size · EQT launched EQT Healthcare Growth, a dedicated healthcare buyout strategy · Fundraising continued for EQT Exeter US Multifamily Value II, EQT Exeter Europe Logistics Core-Plus II, EQT Active Core Infrastructure and EQT Exeter Asia Pacific Logistics II · Fundraising also continued for BPEA EQT Mid Market Growth, with the increased hard cap of USD 1.4bn · EQT Nexus’ NAV was more than EUR 600m, and EQRT, EQT’s semi-liquid strategy focusing on direct investments in commercial real estate, announced its first acquisition Investment activity[2] · Total investments by the EQT funds in the quarter amounted to EUR ‌4‌bn (EUR ‌‌5‌bn). Investments include the partnership with EdgeConneX to develop hyperscale data centers in APAC (EQT Infrastructure VI); the public to private tender of Believe, the largest independent digital-native music label globally (EQT X); and Avetta, a leading cloud-based supply chain risk management software platform (EQT X) · The transaction with Wind Tre (EQT Infrastructure VI) was terminated Exit activity[2] · Total gross fund exits during the quarter amounted to EUR ‌1‌bn (EUR ‌‌2‌bn). Exits include the sale of CMS Info Systems, India’s largest cash management company; Shinhan Financial Group, the largest financial group in Korea; and RBL Bank, one of India’s leading private sector banks (BPEA VII) · Other exits include Ottobock, the global leader in wearable human bionics (EQT VII); and Cardior Pharmaceuticals, a leader in RNA-targeted therapies for people with cardiovascular diseases (EQT Life Sciences) · Galderma, a leader in dermatology, priced its IPO on the SIX Swiss Exchange gaining >20% on the day of the IPO, with a total offering of USD 2.6bn. The offering comprised mainly of primary shares, to raise capital for Galderma, with only a minimal sale by EQT VIII Investment performance · All ten Key funds are performing On or Above plan, meaning they are on track to deliver on or exceed the return targets communicated to our clients · In the first quarter, Key fund valuations increased by almost 3%, as underlying performance remained healthy and valuation references were supportive. The portfolio remains robust, albeit with certain pockets of underperformance · Strategies focused on earlier-stage investments, such as EQT Ventures and EQT Growth, saw a meaningful value uplift in certain portfolio companies People and future-proofing · The number of full-time employees and on-site consultants (FTE+) amounted to ‌1,859‌ (‌‌1,792‌), of which ‌1,802‌ (‌‌‌1,687‌) were FTEs. Hiring was primarily to support new strategic initiatives such as Private Wealth and prioritized regions such as Asia and the US · Masoud Homayoun, Partner and Head of EQT Value-Add Infrastructure, joined EQT’s Executive Committee · EQT Network appointed Sir Alok Sharma as a Senior Advisor on geopolitical topics and economic trends, drawing on his extensive experience in sustainability, with a background as the President of the 2021 UN’s Climate Change Conference in Glasgow (COP26), and the Secretary of State for Business, Energy, and Industrial Strategy in the UK · Since committing to the Science Based Targets initiative in 2021, EQT has supported 39 portfolio companies in setting science-based targets, out of which 7 completed the validation in Q1. Additionally, 24 are in the process of setting targets Other · EQT won six awards in the 2023 PEI Group Awards, including Infrastructure Investor's "Global Sustainable Investor of the Year" for the second consecutive year, and New Private Markets' "Multi-Strategy Firm of the Year (ESG)" · Further to the ongoing review of certain current and former EQT employees’ carried interest taxation, the Swedish Tax Agency has communicated its intention to review EQT’s related social security contribution obligations Events after the reporting period · Investment levels in EQT Key funds as of 18 April 2024, were 35-40% in EQT X, 30-35% in EQT Infrastructure VI and 40-45% in BPEA VIII · EQT Active Core Infrastructure entered exclusive talks to acquire Ocea Group, a leading French water and heat submetering infrastructure provider · EQT Infrastructure VI acquired a majority position in Universidad Europea, a leading private higher education platform in Spain and Portugal · EQT Mid Market Europe has signed an agreement to sell Rimes, a global leader in enterprise data management solutions for the investment industry · Fundraising was launched for EQT Healthcare Growth 1. EQT Future charges management fees on invested capital 2. Signed transactions, if not otherwise mentioned Presentation of EQT AB’s Q1 Announcement 2024 Financial analysts and media are invited to participate in a conference call, including a presentation at 08:30 CEST. The presentation and a link to follow the webcast and conference call live can be found here  and a recording will be available afterwards. To participate by phone, please register here . You will then receive your personal dial-in details, to be able to ask questions during the Q&A. Information on EQT AB’s financial reporting The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent. The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group's development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq's guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting. Contact Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15EQT Shareholder Relations, shareholderrelations@eqtpartners.com Rickard Buch, Head of Corporate Communications, +46 72 989 09 11EQT Press Office, press@eqtpartners.com, +46 8 506 55 334 This is information that EQT AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07:30 CEST on 18 April 2024.

AQ Group AB (publ), interim report January - March, 2024

First quarter, January-March 2024 in brief · Higher delivery precision and productivity improves profitability · Net sales decreased by 1% to SEK 2,225 m (2,253) · Operating profit (EBIT) increased by 15% to SEK 223 m (194) · Profit before tax (EBT) increased by 20% to SEK 221 m (184) · Profit margin before tax (EBT %) was 9.9% (8.2) · Profit after tax amounted to SEK 185 m (159) · Cash flow from operating activities amounted to SEK 244 m (225) · Earnings per share before dilution amounted to SEK 10.06 (8.61) · Equity ratio was 64% (55) · The Board of Directors proposes a dividend of SEK 6.66/share (3.33) and a 5:1 share split A word from the CEO     AQ 30 years of growth, profit and fun The year has started well. We improve our delivery precision and focus on helping our customers. Sales are still high. We are quick to adapt our capacity and cost base which, together with productivity improvements, gives a good result in the first quarter. Improved delivery precision During the first quarter, we started series production of wiring systems in our new premises in Łódź, Poland. We have also reduced our backlog in our transformer factory in Finland, which supplies transformer systems to ships. Overall, our delivery precision has improved and in March we deliver 93.7% of our order lines on time, which is a 2.3 percentage points improvement compared to Q4 2023. Although delivery precision has improved, our target is 98% and we have three production units with great potential for improvement. Market In the quarter, we had a negative organic growth of 2% compared to the same quarter previous year. This is partly because we delivered several large energy storage projects in the corresponding quarter of the previous year, but we also see a slowdown in components for off-road equipment, trucks, and frequency converters. A positive thing is that during the quarter we have been selected as the supplier of balancing units to market-leading robot manufacturer, we have won new products for several electric truck models, and we have won several major projects in electrical automation of harbor cranes. It should also be mentioned that our engineering company sees great demand in Sweden for design services for electrification and the defense industry, and our engineering offices in Torslanda, Trollhättan, Östersund and Västerås are growing steadily with several new competent employees. Our market segments in electrification, defense industry, marine and railway are growing. Our companies within inductive components have great demand both for the design of new products and for the delivery of existing products. In the transition that is now underway to create, control and store renewable energy, inductive components are a necessary "gatekeeper" that ensures that electrical energy remains clean and fine. Acquisitions During the month of March, we agreed with the owners of JIT Mech to acquire their two production units in Robertsfors and Örnsköldsvik. It gives AQ unique competence in welding and processing of large complex components for electrification, defense industry and forestry automation. The closing takes place during the second quarter. Cash flow and balance sheet Our cash flow from operating activities is in line with our profit. We continue to be rigorous and disciplined in our efforts to reduce our inventory and purchasing costs. Purchasing is an incredibly important part of our mission to be competitive with our customers and we pride ourselves on being thrifty even with small expenses. Our net debt is low, which means that we have plenty of dry powder to use when the right opportunity presents itself to grow organically and through acquisitions. AQ 30 years of growth, profit and fun In 2024, AQ as a company celebrates 30 years. We want to do that by once again showing that we are hardworking entrepreneurs who, guided by our core values, can grow, show good results and have fun together along the way. So, in 2024 we will carry out several activities together with our employees, customers and partners where we celebrate that for 30 years, we have helped our demanding industrial customers to be successful and where we have given a good return to our shareholders. Finally, as usual, I would like to thank our employees who do a fantastic job of satisfying our demanding customers. James AhrgrenCEO ___________________________________________________________________________________________________________________________________________ This disclosure contains information that AQ Group is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 18-04-2024 08:00 CEST. For further information, please contact:James Ahrgren, CEO, +46 76 052 58 88  or CFO, Christina Hegg, telephone +46 70 318 92 48 ___________________________________________________________________________________________________________________________________________ AQ is a global manufacturer of components and systems to demanding industrial customers and is listed on Nasdaq Stockholm’s main market. The Group consists mainly of operating companies each of which develop their special skills and in cooperation with other companies, striving to provide cost effective solutions in close cooperation with the customer. The Group headquarter is in Västerås, Sweden. AQ has 8,000 employees in Bulgaria, Poland, Lithuania, Sweden, China, Estonia, Hungary, Mexico, Finland, India, Canada, USA, Germany, Italy, and Brazil. In 2023 AQ had net sales of SEK 9 billion, and the Group has since its start in 1994 shown profit every quarter. www.aqgroup.com 

Metso supports sustainable mining development in Chile and introduces a unique circularity solution for mill liner recycling

Sustainable mining is a critical ambition in countries like Chile, the world’s leading copper producer. In response to the growing demands of its mining customers, Metso is strengthening its position as a supplier of a substantial range of sustainable solutions with the introduction of its unique circularity recycling solution for Megaliner™, Poly-Met™, and rubber liners in Chile. The solution enables the efficient separation of different liner materials so that the valuable rubber and steel components can either be reused in the manufacturing of new products or recycled. “Our customers have ambitious sustainability targets and commitments to reach net zero in their operations. The liner recycling service is a concrete example of how Metso can drive the mining industry towards more sustainable practices. With less unprocessed waste material sent to landfills, recycling helps to reduce CO2 emissions and improve environmental efficiency,” says Eduardo Nilo, President, South America, Metso.  The recycling solution will be installed at Metso’s rubber and Poly-Met factory in Concón, Chile.   At the same time, Metso is expanding its factory in Concón to further increase its rubber and Poly-Met production capability. Metso has installed a mega-class compression press that will expand the range, sizes, and types of products manufactured. With its robust technology and large size, the press is specifically designed to produce large Megaliner™ mill liners that can weigh up to 8 tons. After the introduction of the new press, the production capacity for large mill liners will increase by 30%. To further support CO\2\ emission reductions towards Metso’s net-zero goal by 2030, renewable electricity will cover 100% of the factory’s needs.  Sustainable mining is an important development area in Chile The Chilean 2050 National Mining Policy outlines how the country could harmonize the development of the mining industry with the needs of the environment by achieving carbon neutrality and growing the circular economy model. Metso is committed to developing pioneering sustainable technologies and solutions for the mining industry globally. Circular economy is one of the important areas of sustainability development throughout the industry. “As a responsible supplier and partner for sustainable wear solutions, we have set ambitious targets to help our customers reduce the environmental impact of mining in the different stages of the production process. We are extremely happy to again achieve an important milestone with the introduction of this unique mill liner recycling solution to the very important Chilean market. As part of our extensive horizontal mill liner offering, we are also exploring ways to increase the number of recycled materials in our liners to further close the circularity loop,” says Heikki Metsälä, President, Consumables business area, Metso.  Mill liner recycling service The pioneering recycling service is a part of Metso’s Planet Positive  offering. The first feasibility studies were conducted back in 2009, the recycling program was initiated in 2015, and the important milestone of 1,000 recycled Megaliner™ liners was achieved in 2016. After careful studies and customer pilots, Metso launched a new separation unit in 2022 for its customers in Europe. Following the introduction to the South American market, the mill lining recycling service will be expanded to the North American market later in 2024. The recycling service is facilitated by an innovative technology enabling safe and efficient separation of different rubber and metal liner components, like cast inserts, wear plates, and backing plates. All composite liners, like Megaliner™, Poly-Met™ liners, as well as rubber mill liners, can be processed using this solution. Metso also has an existing recycling process for metallic mill liners. Read more about Metso’s mill lining recycling services on our website . Further information: Martin Karlsson, Senior Vice President, Mill Lining, Metso, tel. + 358 20 484 100, email: martin.karlsson(at)metso.com Helena Marjaranta, Vice President, Communications and Brand, Metso Corporation, tel. +358 20 484 3212, email: helena.marjaranta(at)metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Headquartered in Espoo, Finland, Metso employs over 17,000 people in close to 50 countries and sales for 2023 were about EUR 5.4 billion. The company is listed on the Nasdaq Helsinki. metso.com , x.com/metsoofficial 

Scania Super Green Truck 2024

“Scania participates in many press tests in Europe, but the Green Truck Award really focuses on what is an absolute core requirement in our industry – offering customers the best possible transport efficiency,” says Stefan Dorski, Senior Vice President and Head of Scania Trucks. “Our Super-based powertrain was introduced in 2021 and brought a new performance level to the market, with its 8% fuel-savings that our customers now benefit from in their daily operations.”  The annual “Green Truck” test is organised by the magazines Trucker and VerkehrsRundschau. It began in 2011 and has been held 14 times. So far, Scania has scored nine (!) wins in total, four second places and one 5th place (in the very first year). Needless to say, no other brand is even close to Scania’s track record.  “Ah, the fifth place – that happened long before my tenure started,” says a smiling Dorski. “Seriously though, we at Scania are very proud and happy at having regained the title as the most efficient long-haul truck in the world. Consuming less fuel means that our trucks contribute a lot for curbing CO2 emissions, since so much of the world’s transports is still dependent on combustion engines.”  The best truck in the test is identified by applying a clever formula that covers all the relevant aspects of being transport-efficient and sustainable: fuel consumption, average speed, used AdBlue volume and the weight of the truck (the lighter the better).  And when one takes a closer look at the actual data that are used in the Green Truck formula, Scania’s results stand out: over 100km distance, the average difference compared to the runner-up is 0.41 litres of fuel. Taking into perspective the fact that  a long-haul truck travels something like 150,000 km each year, this makes Scania’s more than 600 litre per year better off than the nearest competitor. At 7,040 kg, the Scania truck was also the lightest vehicle, and achieved the highest average speed, at 79.70 km/h. Scania also introduced an updated version of its CCAP system (Cruise Control with Active Prediction) in May 2023, something that is believed to have given an edge in the test.  The actual testing takes place on various types of roads (though mainly motorways) in the Munich area. Everything is closely monitored by the organisers and by staff from the participating manufacturers. A reference truck is always used to compensate for changing conditions such as head winds, rain and temperature.  Watch the winning truck in action here. 

Norse Atlantic Airways Introduces New Route Between London Gatwick and Cape Town

Norse Atlantic Airways proudly announces the launch of its newest route connecting London Gatwick and Cape Town, set to commence on October 28th, 2024. With flights operating three times a week on Monday, Wednesday, and Saturday, travellers can now experience the vibrant culture and breathtaking landscapes of Cape Town with ease. With fares starting from just £499 return in Economy and £1199 return in Norse Premium class, Norse Atlantic Airways is committed to delivering exceptional value without compromising on quality. Moreover, this historic route launch signifies a shift in consumer choice, as Norse Atlantic Airways breaks the existing duopoly on the London to Cape Town route. By injecting much-needed competition into the market, Norse Atlantic Airways aims to empower consumers with greater choice, flexibility, and affordability. “We are thrilled to introduce our new route between London and Cape Town. By breaking the duopoly on this route, we are not only expanding travel options for consumers but also driving down costs and putting the customer back in the pilot’s seat. At Norse Atlantic Airways, we believe that everyone deserves the opportunity to experience the wonders of the world and our new route to Cape Town will allow many more people to visit this amazing destination,” said Bjorn Tore Larsen, CEO and Founder of Norse Atlantic Airways. Stephanie Wear, VP Aviation Development, London Gatwick said: “We are proud to welcome another new route from Norse Atlantic, connecting passengers across London and the South East with Cape Town from October. “Norse has continued to grow at London Gatwick and provide excellent connectivity to a number of key markets across the USA. This new route to South Africa is great news not only for those looking for a fantastic holiday destination, but also for trade and inbound tourism.” Cape Town boasts a myriad of attractions, from the iconic Table Mountain to the stunning coastline and world-renowned vineyards of the Cape Winelands. Travelers can immerse themselves in the rich history of Robben Island, explore the bustling Victoria & Alfred Waterfront, or indulge in delectable cuisine at the city’s top restaurants. Outbound flights depart London Gatwick at 20.00 and land in Cape Town at 0930 the following morning. Inbound flights depart Cape Town at 11.45 and arrive at London Gatwick at 21.35 the same day. Norse Atlantic exclusively operates modern Boeing 787 Dreamliner aircraft. The cabin offers passengers a relaxed and comfortable travel experience with each seat including a personal, state-of-the-art entertainment experience. Our Norse Premium cabin offers an industry leading 43” seat pitch and 12” recline, allowing passengers to arrive at their destination feeling refreshed and ready to explore their destination. Norse Atlantic offers two cabin choices: Economy and Norse Premium. Passengers can choose from a simple range of fares, Light, Classic and Flextra, that reflect the way that they want to travel, and which options are important to them. Light fares represent Norse’s value option, while Flextra fares include the maximum baggage allowance, two meal services and increased ticket flexibility. For more information or to book visit www.flynorse.com

Everfuel A/S – Annual General Meeting 2024

Herning, Denmark, 18 April 2024 – The Annual General Meeting 2024 was held today. All the proposed resolutions were approved by the AGM. This includes the re-election of Søren Eriksen, Jørn Rosenlund, Christina Aabo and Anne Kathrine Steenbjerge to the Board of Directors and approval of the resolution to appoint Yasuhiro Miyata a seat in the Board of Directors. The Minutes of Meeting is attached and will be available from the company’s website: www.everfuel.com/investor/ For additional information, please contact Jesper Ejlersen, CFO, Everfuel, jej@everfuel.com Mads T. Mortensen, Director of investor relations and communication, Everfuel, mm@everfuel.com, +45 7730 4727 About Everfuel | www.everfuel.com Everfuel is making green hydrogen for zero emission industry and mobility commercially available across Europe, offering competitive all-inclusive hydrogen supply and fuelling solutions. We own and operate green hydrogen infrastructure and partner with industry and vehicle OEMs to connect the entire hydrogen value chain and seamlessly provide hydrogen fuel to enterprise customers under long-term contracts. Green hydrogen is a 100% clean energy carrier made from renewable solar and wind power and key to decarbonising industry and transportation in Europe. We are an ambitious, rapidly growing company, headquartered in Herning, Denmark, and with activities in Norway, Denmark, Sweden, The Netherlands and Germany, and a plan to grow across Europe. Everfuel is listed on Euronext Growth in Oslo under EFUEL. This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

“We were pleased to share additional analyses from the 2-year Phase 3 NeflgArd trial of Nefecon in IgAN at this year’s World Congress of Nephrology,” said Richard Philipson, Chief Medical Officer of Calliditas. “These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient’s racial and ethnic backgrounds.” Poster presentation details are below and will be available on the Presentations and Publications page  on the Calliditas’ corporate website following the meeting. Poster Presentation Analyses: Poster Title: “Nefecon treatment provides kidney benefits for patients with IgAN that extend to those with low levels of UPCR: A sub-analysis of the phase III NefIgArd trial” An extended analysis of patients with baseline UPCR levels above and below 0.8 g/g was performed to further explore the potential benefits of Nefecon. In the full analysis involving 364 patients regardless of baseline UPCR, Nefecon treatment consistently improved the estimated glomerular filtrate rate (eGFR) over the 2-year study period compared to placebo. 72 patients with a baseline UPCR <0.8 g/g experienced sustained eGFR improvement (p=0.0026), which persisted for up to 18 months after treatment initiation, even after the treatment cessation at month 9.  Those patients also achieved an eGFR slope of –0.25 mL/min/1.73 m[2] per year, indicating that Nefecon treatment may support them in reaching the RaDaR treatment target of an eGFR decline of <1 mL/min/1.73 m2 per year. This objective is pivotal in mitigating the risk of kidney failure in their lifetime. Poster Title: “eGFR decline in patients with IgAN treated with Nefecon or placebo: Results from the 2-year NefIgArd Phase 3 trial” During the 9-month treatment period, Nefecon showed a 30% reduction in UPCR compared to the placebo, sustained for 2 years. The percentage of patients with a confirmed 30% reduction in eGFR or kidney failure was lower in the Nefecon arm compared to placebo, and the time to such events was significantly delayed with Nefecon (hazard ratio [HR] 0.45; 95% confidence interval 0.26, 0.75]; p=0.0014 [1-sided]). Supplementary analysis with rescue medication yielded similar results, irrespective of the handling of rescue medication: Rescue medication counted as an event: HR 0.51 (95% CI 0.33, 0.79), Regardless of rescue medication: HR 0.44 (95% CI 0.27, 0.71). The treatment effect of Nefecon on the risk of kidney function decline was consistent regardless of baseline UPCR. These findings strongly suggest preserved kidney function and provide support for Nefecon as a disease-modifying therapy in patients with IgAN. Poster Title: Nefecon effect on quality of life in patients with IgAN: SF-36 results from the Phase 3 NefIgArd trial” The 2-year results of quality of life (QoL) analyses based on 36-Item Short Form Survey (SF-36) assessments at 9 and 24 months revealed no meaningful differences in any QoL domain between Nefecon and placebo groups after 9 months of treatment. These SF-36 scores remained consistent after 15 months of off-drug observational follow-up further supporting the benefit/risk profile of Nefecon. Poster Title: “Nefecon treatment response in Asian and White patient populations with immunoglobulin A nephropathy: A 2-year analysis of the Phase 3 NefIgArd trial” The responses to Nefecon treatment from the full 2-year NefIgArd trial were assessed in patients identifying as Asian (n=83) or White (n=275). Regardless of race and ethnicity, Nefecon showed a favorable change in eGFR compared to placebo of 5.5 mL/min/1.73 m[2] in Asian patients and 4.8 mL/min/1.73 m[2] in White patients. Nefecon also demonstrated greater reductions in UPCR at 9 and 24 months with notable delays in kidney function decline events. These effects were consistent across races and ethnicities. Additionally, Nefecon significantly reduced the rate of microhematuria in both Asian and White patients. Overall, these findings highlight Nefecon’s efficacy and tolerability across different racial and ethnic groups. Indication TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Important Safety Information Contraindications: TARPEYO is contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of TARPEYO. Serious hypersensitivity reactions, including anaphylaxis, have occurred with other budesonide formulations. Warnings and Precautions Hypercorticism and adrenal axis suppression: When corticosteroids are used chronically, systemic effects such as hypercorticism and adrenal suppression may occur. Corticosteroids can reduce the response of the hypothalamus-pituitary-adrenal (HPA) axis to stress. In situations where patients are subject to surgery or other stress situations, supplementation with a systemic corticosteroid is recommended. When discontinuing therapy or switching between corticosteroids, monitor for signs of adrenal axis suppression.  Patients with moderate to severe hepatic impairment (Child-Pugh Class B and C respectively) could be at an increased risk of hypercorticism and adrenal axis suppression due to an increased systemic exposure to oral budesonide. Avoid use in patients with severe hepatic impairment (Child-Pugh Class C). Monitor for increased signs and/or symptoms of hypercorticism in patients with moderate hepatic impairment (Child-Pugh Class B). Risks of immunosuppression: Patients who are on drugs that suppress the immune system are more susceptible to infection than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible patients or patients on immunosuppressive doses of corticosteroids. Avoid corticosteroid therapy in patients with active or quiescent tuberculosis infection; untreated fungal, bacterial, systemic viral, or parasitic infections, or ocular herpes simplex. Avoid exposure to active, easily transmitted infections (e.g., chicken pox, measles). Corticosteroid therapy may decrease the immune response to some vaccines.  Other corticosteroid effects: TARPEYO is a systemically available corticosteroid and is expected to cause related adverse reactions. Monitor patients with hypertension, prediabetes, diabetes mellitus, osteoporosis, peptic ulcer, glaucoma or cataracts, or with a family history of diabetes or glaucoma, or with any other condition where corticosteroids may have unwanted effects. Adverse reactions: In clinical studies, the most common adverse reactions with TARPEYO (occurring in ≥5% of TARPEYO treated patients, and ≥2% higher than placebo) were peripheral edema (17%), hypertension (12%), muscle spasms (12%), acne (11%), headache (10%), upper respiratory tract infection (8%), face edema (8%), weight increased (7%), dyspepsia (7%), dermatitis (6%), arthralgia (6%), and white blood cell count increased (6%). Drug interactions: Budesonide is a substrate for CYP3A4. Avoid use with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, and cyclosporine. Avoid ingestion of grapefruit juice with TARPEYO. Intake of grapefruit juice, which inhibits CYP3A4 activity, can increase the systemic exposure to budesonide. Use in specific populations Pregnancy: The available data from published case series, epidemiological studies, and reviews with oral budesonide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with IgAN. Infants exposed to in-utero corticosteroids, including budesonide, are at risk for hypoadrenalism.  Please see Full Prescribing Information . About TARPEYO TARPEYO is an oral 4mg delayed release formulation of budesonide, designed to remain intact until it reaches the ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum, including the Peyer’s patches, which are responsible for the production of galactose-deficient IgA1 antibodies (Gd-Ag1) causing IgA nephropathy. About the NeflgArd Study NefIgArd was a global, Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of TARPEYO 16 mg once daily vs placebo in adult patients with primary IgAN (N=364) as an addition to optimized RASi therapy. Patients were randomized 1:1 to receive 16 mg/day oral capsules of TARPEYO or matching placebo for 9 months, followed by a 15-month observational follow-up period without the study drug. The primary efficacy endpoint was time-weighted average of eGFR over 2 years. The time-weighted average of eGFR over 2 years showed a statistically significant treatment benefit with TARPEYO versus placebo (difference 5·05 mL/min per 1·73 m² [95% CI 3·24 to 7·38], p<0·0001). The favorable effect of TARPEYO on eGFR was seen by Month 3 (the earliest assessment) and did not appear to increase in magnitude over two years.  At the end of Year 2, there was a 5.9 mL/min/1.73 m2 difference in the mean change from baseline in eGFR between TARPEYO and placebo (95% CI: 3.3 to 8.5 mL/min/1.73 m2; p<0.0001). The effect on kidney function seen during the 9-month treatment period persisted following completion of treatment through the end of the study but the overall effect on the long-term rate of decline has not been established. The most common adverse reactions with TARPEYO (occurring in ≥5% of TARPEYO treated patients and ≥2% higher than placebo) were peripheral edema (17%), hypertension (12%), muscle spasms (12%), acne (11%), headache (10%), upper respiratory tract infection (8%), face edema (8%), weight increase (7%), dyspepsia (7%), dermatitis (6%), arthralgia (6%), and white blood cell count increase (6%). About Primary Immunoglobulin A Nephropathy Primary immunoglobulin A nephropathy (IgA nephropathy or IgAN or Berger’s Disease) is a rare, progressive, chronic autoimmune disease that attacks the kidneys and occurs when galactose-deficient IgA1 is recognized by autoantibodies, creating IgA1 immune complexes that become deposited in the glomerular mesangium of the kidney.This deposition in the kidney can lead to progressive kidney damage and potentially a clinical course resulting in end- stage renal disease. IgAN most often develops between late teens and late 30s.